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H E A R T  FA I L U R E  A N D  C A R D I A C  H Y P E R T R O P H Y  
Heart failure (HF) continues to be a major health problem in western 
society, being a leading cause of hospitalization and mortality (1). HF is a complex 
clinical syndrome in which myocardial pump function is insufficient to fulfill the 
body demands. It is often the final syndrome of different pathological stimuli that 
cause remodeling of the heart. Cardiac remodeling involves any structural and/or 
functional changes of the heart and plays a central role in the pathology of heart 
failure development and progression. Prominent processes that contribute to 
cardiac remodeling are cardiomyocyte hypertrophy, cell death and cardiac 
fibrosis.  
Cardiac hypertrophy is defined as an increase in heart mass with or without 
cardiac dysfunction. In response to an increased work load, cardiac hypertrophy 
develops as an adaptive response to normalize wall stress (2). This is 
characterized by thickening of the ventricular walls as a result of cardiomyocyte 
growth (3,4). At the molecular level, this is characterized by enhanced protein 
synthesis and changes in organization of force-generating units (sarcomeres), 
amongst others. Although initially, beneficial, sustained wall stress might result 
in cardiac decompensation. This is accompanied by additional changes in 
cardiomyocytes, including fetal gene expression, changes in Ca2+ handling and in 
mitochondrial function and metabolism (5,6). This cardiomyocyte hypertrophy is 
one of the main drivers of pathological cardiac remodeling and HF development.  
Despite recent advances in the prevention and treatment of cardiovascular 
diseases, the prevalence of heart failure, continues to grow. Current drug 
therapies for HF are essentially limited to unloading the heart and include 
diuretics and drugs targeting the neuro-hormonal axis (7,8). Strategies aimed to 
directly improve cardiomyocyte function need to be explored and may provide 
alternative therapeutic opportunities. Understanding the molecular mechanisms 
underlying hypertrophy development will be of pivotal importance for the 
development of new treatment modalities (9,10). 
 
M I TO C H O N D R I A  
 Alterations in cardiomyocyte energy metabolism and mitochondrial 
function are emerging as contributing factors to the pathogenesis of heart 
failure, making the mitochondria and metabolic pathways a potential target for 
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HF treatment. While mitochondria are classically viewed as the energy producing 
organelles of the cell, it has become apparent that mitochondria have numerous 
other functions. Amongst others, mitochondria play a role in calcium handling, 
reactive oxygen species (ROS) production and signaling and the integration of 
cell survival and death-promoting signals in relation to apoptosis and necrosis 
(11). All of these are altered in pathological hypertrophy and contribute to heart 
failure. Abnormal mitochondrial dynamics and the spatial distribution within the 
cell has recently gained attention, and these changes are associated with 
energetic impairment and mitochondrial dysfunction (12–14). Interestingly, 
connections between morphological regulation and the bio-energetic status of 
mitochondria are emerging as responsive processes, although the nature of 
these signaling events remain elusive.  
 
M I TO C H O N D R I A L  F U N C T I O N  A N D  H E A R T  
FA I L U R E  
Mitochondria in cardiac metabolism 
Mitochondria are double membrane organelles in eukaryotic cells. They 
have a unique evolutionary origin as they evolved from ancient protobacteria 
and contain their own mitochondrial DNA (15). Mitochondria produce over 90% 
of the energy used by mammalian cells and therefore function as the foremost 
supplier of energy to maintain systemic energy balance and homeostasis. The 
heart, as an energy demanding organ, is rich in mitochondria. The mitochondria 
host the enzymes of the tricarboxylic acid cycle (TCA) and the complexes of the 
electron transport chain (ETC), which generate the energy in the form of ATP. 
The most prominent carbon sources used for energy production in the hart are 
fatty acids (FA) (~60%) and glucose (~40%). α-oxidation in the mitochondria 
generates acetyl-CoA from FAs and via glycolysis glucose is converted into 
pyruvate and finally also converted into acetyl-CoA within the mitochondria. In 
the mitochondrial matrix, acetyl-CoA subsequently enters the TCA cycle, 
resulting in the production of NADH and FADH2. These reducing equivalents, 
enter the electron transport chain (ETC) for oxidative phosphorylation (OXPHOS), 
the final process in mitochondrial respiration (11,12). During OXPHOS, oxygen is 
reduced to water through a series of redox reactions catalyzed by mitochondrial 
protein complexes I,II,III and IV, also known as NADH-Q oxidoreductase, 
succinate-Q reductase, Q-cytochrome c oxidoreductase, and cytochrome c 
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oxidase, respectively. This generates the electrochemical gradient (∆Øm ) that is 
necessary to generate ATP from ADP, which is mediated by complex V, also 
termed ATP synthase (13).  
In the adult heart, fatty acid oxidation (FAO) is the main fuel that drives 
mitochondrial ATP production. In several models of pressure overload cardiac 
hypertrophy and heart failure, diminishment of myocardial FAO has been 
described (16–18). However, in early stages of hypertrophy these results are less 
evident and contradicting. Changes in glucose utilization are also inconsistent, 
although many studies show an increase in early stages of HF and a decline in 
severe HF (19–21). These discrepancies are most likely due to the differences in 
animal models, in experimental conditions, variable degrees of cardiac 
hypertrophy and different underlying etiologies in HF. Moreover, alterations in 
substrate metabolism can occur at different levels in the metabolic pathways, 
including substrate uptake and conversion, the TCA cycle and OXPHOS, and all 
are interdependent on each other and involve complex feedback systems. 
Together, this makes the investigation and determination of the specific 
components contributing to HF difficult to access and hence difficult to 
discriminate between cause and consequence.  
 
Ros production 
The mitochondrial ETC is a major intracellular source of superoxide 
production and the subsequent formation of other reactive oxygen species 
(ROS), like hydrogen peroxide (H2O2). Moreover, changes in ROS producing 
enzymes, such as NOX4, or downregulation of antioxidants can alter ROS levels 
(22). ROS are highly reactive with other biological molecules and have several 
functions and consequences in the heart. Under normal physiological conditions, 
ROS production is balanced by an efficient system of antioxidants, molecules that 
are capable of scavenging ROS such as superoxide dismutase (SOD), glutathione 
peroxidase (GSHPx) and catalase. In pathological conditions ROS are produced in 
excessive amounts leading to oxidative stress in the cell (23). This has several 
implications. The most widely established effect in the heart is the oxidation and 
damage of proteins, membranes and DNA, leading to cellular dysfunction and 
energetic deficits and cell death (24). Mitochondria, as the main ROS producers 
in the cell, are also a major target for oxidative stress induced damage. 
Mitochondrial DNA (mtDNA) is more vulnerable to oxidative damage, since 
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mtDNA does not have the same protection mechanisms as nuclear DNA, such as 
efficient DNA repair mechanisms and complex chromatin organization (25). 
Mitochondrial ROS are not just damaging by-products of respiration, but 
also important for cell signaling. Under normal conditions, the tightly regulated 
production of relatively low levels of ROS is involved in diverse biological 
processes by modulating the activity of intracellular molecules and signaling 
pathways by a mechanism commonly termed redox signaling (26). A link exists 
between oxidative metabolism, ROS production and contractile activity. 
Increases in contraction frequency are accompanied by enhanced oxygen 
consumption and ROS formation in isolated cardiomyocytes (27). However, the 
effect of ROS on contractile function remains controversial (22,28). 
Growing evidence supports important pathophysiological roles for redox 
signaling pathways in the processes underlying HF. ROS activates diverse 
hypertrophic signaling pathways. induces apoptosis and necrosis and interstitial 
fibrosis ultimately leading to pump dysfunction (29). Increased ROS production 
may also directly contribute to contractile dysfunction as high levels of ROS can 
alter the activity of different proteins involved in excitation–contraction coupling 
(30). Mitochondrial damage caused by pathological stress often leads to 
production of excessive ROS, which develops into a vicious cycle of oxidative 
stress and mitochondrial damage (31,32).  
 
Cell death 
Cell death can be executed by several signaling pathways, differing from 
each other in molecular constituents, morphological manifestations, biochemical 
features and immunological consequences for the organism. The best 
characterized mitochondrial cell death mechanisms are apoptosis and necrosis 
(33). Apoptosis is mediated and strictly controlled by the mitochondria, via the 
intrinsic pathway (34). Cardiac myocytes express various members of the Bcl-2 
family, several of which are transcriptionally regulated in heart disease, including 
anti- apoptotic (Bcl-2 and BclX) and pro-apoptotic (Bax and Bak) proteins (35). 
Recruitment and oligomerization of Bax and Bak to the OMM results in 
permeabilization of the OMM, leading to loss of mitochondrial ∆Øm, ATP 
depletion and the release of apoptotic proteins, including cytochrome c, Smac 
and EndoG. Cytochrome c and Smac activate caspases, both in different 
pathways (36,37). Endonuclease G (Endo G) is a nuclear-encoded endonuclease. 
In cardiac myocyte apoptosis, Endo G translocates to the nucleus, where it 
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cleaves DNA (38). The actions of these proteins leads to the death of the 
cardiomyocytes by apoptosis. 
Whereas the intrinsic pathway operates via permeabilization of the OMM, 
apoptosis can also be induced via permeabilization of the IMM. Excessive ROS 
and Ca2+ overload cause the opening of a large nonspecific channel, MPT pore, 
leading to mitochondrial permeability transition. By opening of this channel, the 
∆Øm dissipates, leading to ATP depletion, further ROS production and swelling 
and rupture of the mitochondria (36). This releases pro-apoptotic proteins, 
leading to apoptosis of the cell. 
Necrosis is marked by distinct morphological changes, including cell 
swelling, plasma membrane damage, loss of ATP and organelle swelling. This 
triggers an inflammatory response. Whereas apoptosis is regulated, necrosis is 
mainly caused by physical or chemical damage (34). However, also regulated or 
programmed necrosis exists, necroptosis, which is gaining attention in the heart 
(39). Mitochondria seem to promote necroptosis by generating ROS (40,41). 
 
A I M S  O F  T H I S  T H E S I S  
Altogether, mitochondria comprise a central platform in the execution of 
diverse cellular processes. These processes appear to become derailed under 
pathological conditions and may contribute to hypertrophy and HF 
development. Although most mitochondrial processes, like respiration, ROS 
formation and apoptosis, are well understood, the mechanisms that control 
these processes, and their dynamic behavior, remain elusive. Moreover, the 
exact sequence of events resulting in mitochondrial dysfunction in HF remains 
unclear. Difficult methodologies to study mitochondrial function in organs, and 
the different underlying etiologies of HF and HF severity have hampered these 
studies. The general aim of this thesis was to investigate the relation between 
cardiomyocyte hypertrophy and mitochondrial function and to reveal molecular 
regulatory circuitries that control mitochondrial function in normal and 
hypertrophic cardiomyocytes. An in vitro cell culture model was used, using 
isolated rat neonatal cardiomyocytes, to investigate mitochondrial function. 
Amongst others direct mitochondrial oxygen consumption measurements were 
performed in intact cells. Hypertrophy was induced by different approaches, 
including modulation of the mitochondrial localized proteins, exo/endo nuclease 
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G (EXOG) and A-kinase interacting protein 1 (AKIP1), and by hypertrophic 
stimulation with phenylephrine (PE) and Insulin-like growth factor 1 (IGF1). 
In chapter 2, we review the mitochondrial alterations in response to 
cardiomyocyte stress and the relation to hypertrophy and heart failure 
development. In chapter 3, we investigated the role of a hypertrophy inducing 
gene, AKIP1, in modulating cardiomyocyte mitochondrial function. The aim of 
chapter 4 was to investigate the role of the mitochondrial endo/exonuclease 
EXOG in mitochondrial metabolism. In chapter 5, we show the relation between 
mitochondrial reserve capacity and cardiomyocyte survival. In chapter 6, we 
describe the mitochondrial respiratory responses to physiological (IGF1) and 
pathological (PE) hypertrophic stimulation of neonatal rat cardiomyocytes. In 
this study, it is shown that the kinesin motor protein, Kif5B, is induced upon 
pathologic stimulation only, and to affect mitochondrial localization and 
function. This indicates that proper mitochondrial respiration requires precise 
spatially positioning of this important organelle . In chapter 7, I summarize my 
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I N T R O D U C T I O N  
Most energy demanding cellular processes are driven by ATP dependent 
pathways. Mitochondria, serving as the principal ATP producing organelles of 
eukaryotic cells, are therefore highly abundant in energy demanding cells. Not 
surprisingly, the heart is extremely rich in mitochondria and in an adult 
ventricular myocyte there are approximately 7000 mitochondria, which occupy 
35-40% of the total cell volume (1,2). In a day the human heart beats 
approximately 100.000 times, resulting in a total circulation of 7200L blood, 
which requires cardiac consumption of >20 g carbohydrates and >30g fatty acids 
At rest, the cardiac mitochondria consume about 10% of the body oxygen 
consumption to provide the bulk of ATP required for contraction (3–5). At 
maximal workload, about two percent of the ATP pool is consumed per 
heartbeat, resulting in a rapid turnover in the heart (4,6,7). The general 
mitochondrial ATP generating processes, including the citric acid cycle, the 
electron transfer chain (ETC) and the final oxidative phosphorylation (OXPHOS), 
are largely understood (8–11). Our knowledge on the dynamic regulation of 
mitochondrial structure, morphology and function and the dysregulation of 
these processes under pathological conditions is, however, still vague (12–15). A 
hallmark of the failing heart, is the alteration in energetic and metabolic state of 
the cardiomyocytes (16–18). Mitochondrial dysfunction in the failing heart will 
result in diminished capacity to produce ATP and enhanced production of toxic 
reactive oxygen species (ROS). Accumulating evidence shows that abnormal 
mitochondrial biogenesis, structure, dynamics and localization can drive 
mitochondrial dysfunction and energetic impairment and are associated with 
pathological cardiomyocyte hypertrophy (19). Although, we are still at the dawn 
of understanding mitochondrial dynamic behavior, numerous studies in the last 
decade have generated new insights in the processes that control mitochondrial 
behavior and function. These new insights may help to understand what goes 
wrong under pathological conditions and may elucidate the underlying purpose 
of mitochondrial dynamics and especially the translation of these morphological 
transitions into mitochondrial dysfunction. This review describes the dynamic 
behavior of mitochondria in relation to heart failure (Figure 1).  
 
 




H E A R T  FA I L U R E ,  C A R D I O M YO C Y T E  
H Y P E R T R O P H Y  A N D  M I TO C H O N D R I A L  
F U N C T I O N  
Heart failure (HF) is defined as a complex clinical syndrome, in which the 
heart is not able to support sufficient blood supply to fulfill the body demands. 
Heart failure continues to be a major health problem in western society, being a 
leading cause of hospitalization and mortality (20,21). Pathological 
cardiomyocyte growth (hypertrophy) is one of the underlying processes that 
result in structural and functional changes of the heart, termed cardiac 
remodeling, that are characteristic for the failing heart. Cardiomyocyte 
hypertrophy develops in response to increased ventricular wall stress, 
neurohormonal stimulation and increased oxidative stress, and is a major 
predictor for the development of heart failure. The therapeutic approach toward 
Figure 1 
Sustained cardiac stress result in cardiomyocyte hypertrophy together with dynamic 
alterations in mitochondria behavior and function. These mitochondrial alterations will 
generate additional stress provoking further mitochondrial and cardiac remodeling. The 
exact sequel of events remains vague and the molecular processes that drive these 
dynamic changes require further investigation. 
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HF focuses on controlling symptoms and unloading the heart by reducing preload 
and afterload by providing HF patients with beta-blockers, angiotensin 
converting enzyme inhibitors (ACE-inhibitors), diuretics and aldosterone 
receptor antagonists (22,23). These drugs have proven to relieve symptoms and 
reduce mortality (22,23), but prognosis for HF patients remains poor, with 5 year 
mortality rate of approximately 50% (24). When most patients present 
themselves at the clinic for the first time, alterations of cardiomyocytes are 
already present. Current therapies that target the initial triggers, will slow down 
further progression, but apparently do not reverse or stop the ongoing 
pathological alterations at the cellular and molecular level.  
The failing heart is often considered as an engine without fuel and 
mitochondrial dysfunction, resulting in altered energy production, is believed to 
be an important driver of heart failure progression (25). The function of 
mitochondria are not restricted to energy production, but play also important 
roles in production of reactive oxygen species (ROS), controlling cell death 
(apoptosis, necroptosis, necrosis) and calcium homeostasis. Several excellent 
reviews have discussed these topics (26–30). Here we will focus on the dynamic 
alterations in mitochondrial structure, morphology and localization, which could 
be termed mitochondrial remodeling, in analogy to cardiac remodeling. These 
alterations coincide with changes in mitochondrial function and will provoke 
additional cell stress and generate a vicious cycle of further deterioration (figure 
1).  
Given the role of mitochondria in cellular fate and energetics, tight 
regulation of mitochondrial functions is essential for normal cellular physiology 
and correcting abnormal mitochondrial behavior in heart failure may be an 
essential step in halting heart failure progression. Exploring the dynamic 
mitochondrial behavior in the heart will therefore be pivotal for our 
understanding of heart failure and to identify novel treatment possibilities. 
 
M I TO C H O N D R I A L  S T R U C T U R E  A N D  G E N E S  
Mitochondria are double membrane organelles present in the eukaryotic 
cytoplasm, which evolved from ancient alpha-protobacteria (31). Mitochondria 
consist of different compartments that carry out specialized functions (Figure 2) 
(32). The outer mitochondrial membrane (OMM) surrounds the mitochondria 
and only small molecules can pass. The intermembrane space (IMS) lies between 
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the OMM and the inner mitochondrial membrane (IMM). The IMS plays an 
important role in the detoxification of reactive oxygen species and mitochondrial 
protein sorting, amongst others (33). The IMM is highly impermeant and forms 
cristae and surrounds the interior of the mitochondria, the matrix (34). In the 
IMM the electron transport complexes are located and the matrix contains the 
enzymes of the citric acid cycle (TCA) and β-oxidation of fatty acid, as further 
discussed below.  
Mitochondria contain their own mitochondrial DNA (mtDNA), but are also 
dependent on nuclear DNA (nDNA) genes encoding mitochondrial proteins (35–
37). The maternally inherited mtDNA retains the genes for 2 ribosomal RNAs, the 
mitochondrial transfer RNAs and 13 polypeptides of the mitochondrial energy 
generating complexes, also termed the oxidative phosphorylation system 
(OXPHOS). All other genes necessary for mitochondrial function are nuclear 
encoded (8,38). Although the importance of mitochondria in the heart is 
undisputed, it is surprising that the heart is unaffected in most genetic primary 
mitochondrial diseases (39). A possible explanation would be that severe 
mutations lead to cardiac embryonic lethality and hence remain unidentified, 
whereas the heart is more flexible in coping with less severe mutations, as 
compared to other organs, in particular the brain. Moreover, within the female 
germline a mitochondrial mutant selection system is present that preferentially 
eliminates the most deleterious mtDNA gene mutations prior to ovulation 
(40,41). Nevertheless, numerous genetic mouse models in which mitochondrial 
protein encoding genes were targeted did develop cardiomyopathies including 
hypertrophy (42). This is nicely exemplified by the ANT1-/- ADP/ATP exchange 
knock-out mice that generated cardiomyopathy (43). This mouse phenotype was 
exactly similar to the human phenotype of ANT1 null human patients that were 
identified 8 years later (44). Moreover, cardiac specific targeting of otherwise 
embryonic lethal deletions of mitochondrial encoding genes often generate 
cardiomyopathies, as exemplified by the conditional Mterf3 mice that generate 
cardiac hypertrophy and gave a strongly reduced life span of 18 weeks (45,46). 
Thus genetically induced mitochondrial dysfunction negatively affects 
cardiomyocytes, resulting in cardiac hypertrophy and heart failure development. 
 
IMM cristae complex stability and heart failure 
Energy conversion occurs at the IMM which can be subdivided into: the so-
called “boundary membrane” and the cristae. Upon activation of respiration, 
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mitochondria become more condensed-like, with an expanded cristae space 
(47). Interestingly, during apoptosis, the curvature of the cristae membrane is 
inverted, allowing release of cytochrome c, which is normally confined to the 
cristae (48). The IMM protein optic atrophy 1 (OPA1) forms oligomers that keep 
the cristae junctions tight. Deletion of OPA1 leads to disorganization of the 
cristae, independent of its role of mitochondrial fusion (49,50). The pro-
apoptotic BH3-only BCL-2 family members, and BAK or BAX, can target these 
OPA1 oligomers, altering cristae shape generating an apoptosis permissive 
situation (51). Since respiratory chain complexes are mainly localized to the 
cristae it has also been suggested that cristae may promote oxidative 
phosphorylation efficiency (52). In agreement it was recently shown that acute 
ablation of Opa1, resulted in altered cristae shape, respiratory complex 
assembly, complex-I-dependent respiration, and impairment of respiratory 
growth (53). Cardiac Opa1 protein, but not mRNA, levels are decreased in human 
heart failure and in rat HF models (54). Moreover, in a mouse model with Opa1 
haplo-insufficiency age dependent cardiac dysfunction was observed 
characterized by decreased fractional shortening, altered amplitude of Ca2+ 
transients and contraction and decreased cardiac output (55). No increased 
apoptosis was observed, but the mitochondrial ultrastructure was altered with 
less cristae and a concomitant diminished complex I and IV activity was observed. 
This demonstrates the importance of mitochondrial ultrastructure in energy 
conversion and shows that alterations in the ultrastructure can induce a HF-like 
phenotype.  
Cardiolipin, is a lipid that is enriched in the IMM and is important for cristae 
formation and stabilization of the ETC. Abnormal cardiolipin metabolism, due to 
mutations in the tafazzin (TAZ) gene, are associated with cardiomyopathy, 
including hypertrophy and dilatation, and muscle weakness and is also known as 
Barth syndrome (56). Importantly, cardiolipin levels decline which age and have 
been shown to be associated with functional alterations in many components of 
the mitochondrial ETC. The synthetic Szeto-Schiller (SS)-31 peptide (also termed 
Bendavia, Elamipretide and MPT-131) was originally defined as a mitochondrial 
specific ROS scavenger, but subsequent studies have provided evidence that SS-
31 stabilizes ETC complexes (57). SS-31 binds to cardiolipin, thereby preventing 
cardiolipin oxidation by cytochrome-C, which otherwise might result in 
disturbance of cardiolipin microdomains and loss of cristae curvature and ETC 
complex stability. Numerous animal studies have shown that SS-31 shows 
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beneficial properties and protects against cardiac ischemia and pressure 
overload and AngII induced hypertrophy. Clinical trials are currently on their way 
using SS-31 to treat ischemia-reperfusion injury (58). 
Together, these data indicate that dynamic alterations in complex and 
supercomplex assembly and mitochondrial ultrastructure, contribute to reduced 
OXPHOS activity in heart failure and that pharmacological targeting may have 
therapeutic potential. 
 
Cardiac metabolism and oxidative phosphorylation (OXPHOS)  
Mitochondrial dysfunction mostly refers to diminished bioenergetic 
capabilities of mitochondria, but as discussed later may also include many other 
alterations in mitochondrial behavior (59). Fatty acids and glucose are the most 
important substrates for the heart and key mechanisms that control their 
metabolic flux are located at the level of plasma membrane uptake and their 
conversion in the mitochondria. Glucose metabolism is mainly regulated by the 
Glut1 and Glut4 plasma membrane transporters and via pyruvate 
dehydrogenase (PDH) in the mitochondria, which is regulated by 
phosphorylation and by the levels of its products and substrates (60,61). Usage 
of fatty acids is mainly regulated via plasma membrane uptake via the CDC36 
transporter (62) and via mitochondrial uptake via the CPT-I/II transport system 
(63,64). Although the heart uses both glucose and fatty acids as substrates there 
is a preferential use of fatty acids in the adult heart. In heart failure there is, 
however, a shift to glucose metabolism resembling fetal cardiac metabolism. 
These changes in metabolism are accompanied by changes in expression and 
activity of membrane transporters and main mitochondrial regulating enzymes. 
Important transcriptional regulators that control this shift are the peroxisome 
proliferator activated receptors (PPARs) and peroxisome proliferator activated 
receptor gamma coactivator 1α (PGC-1α), amongst others (1,63). Excellent 
reviews have discussed this metabolic switch (10,65–67) and it will not be further 
elaborated in this review. Importantly, PGC-1α also regulates mitochondrial 
biogenesis and appears to be an important factor in balancing metabolism and 
mitochondrial function, as discussed above. 
Acetyl-CoA formed by glucose metabolism and fatty acid β-oxidation in the 
mitochondria enters the TCA cycle to generate the substrates for the electron 
transport chain (ETC) complexes. As discovered by Mitchell, the ETC generates 
an electrochemical gradient over the inner mitochondrial membrane (IMM). The 
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ETC consists of 4 different complexes and each of these complexes is assembled 
from a large number of proteins (table 1). 
 
Table 1 
The components of the electron transport chain are organized into 4 complexes. Each 
of these complexes are large multisubunit complexes embedded in the inner 
mitochondrial membrane containing several different electron carriers. 
Protein Complexes of the Mitochondrial Transport Chain 
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Complex I (NADH dehydrogenase) is composed of about 45 proteins and 
transfers electrons from NADH (reduced nicotine adenine dinucleotide) to 
coenzyme Q10 (CoQ). Via the TCA cycle enzyme succinate dehydrogenase 
(complex II) electrons from succinate are also transferred to CoQ. On its turn CoQ 
transfers these electrons to complex III, which transfers them to Cytochrome C 
(cyt c) and then to cytochrome oxidase (complex IV). The final step is the transfer 
of electrons by complex IV to oxygen to generate H2O. The energy released by 
these electron transfer steps is used to pump protons (H+) from the 
mitochondrial matrix to the intermembrane space (IMS) to generate an 
electrochemical gradient (∆ψ). Proton transport is tightly coupled to electron 
transfer and is performed by complex I, III and IV. Together with complex V, ATP  
synthase, the ETC forms the oxidative phosphorylation system (OXPHOS). 




In the last step, protons flow back into the mitochondrial matrix via the F0 
portion of ATP synthase and this drives the synthesis of ATP from ADP. 
Dysfunction of OXPHOS may affect the electrochemical potential formation and 
ATP generation and hence cellular function. Moreover, improper action or 
coupling of the different complexes and transfer proteins may result in direct 
transfer from electrons to molecular oxygen, thereby generating toxic 
superoxide radicals and reactive oxygen species (ROS) (figure 2).  
 
OXPHOS in heart failure 
Oxidative phosphorylation (OXPHOS) in mitochondria has been reported to 
be declined in cardiac tissue of human heart failure patients (68–72). Also in 
animal models of pathological hypertrophy a decline in OXPHOS has been 
reported (68,73–77), whereas ROS is significantly enhanced in the failing 
myocardium. There, is however a broad variability in the reported mitochondrial 
defects, which most likely reflects the different heart failure etiologies, heart 
Figure 2 
Schematic depiction of the basic mitochondrial processes. The red boxes depict targeted 
therapies that have been tested in heart failure. The close connection with the 
sarcoplasmic reticulum (SR) in blue is shown. Adapted from Dai et al., Longevity and 
Healthspan2014, 3:6.(161) 
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failure severity, differences in animal cardiac stress models and severity of 
hypertrophy. Moreover it will be essential to standardize the methods used for 
investigating mitochondrial defects (78). Any subtle change in the expression, 
assembly, degradation or specific activity of any of these ETC complexes may 
have dramatic effects on ATP production and ROS generation, activating a vicious 
cycle of further deterioration. It is therefore not surprising that the decline of 
mitochondrial function correlates with heart failure severity (25). Even though 
there is consensus that mitochondrial function declines during heart failure it has 
been difficult to address the mechanisms that result in declined complex 
activities. Changes in the activities of complexes I, II, IV and V have been 
described for multiple HF models (79). Reduced complex activities do, however, 
not always coincide with changed protein levels of these particular complexes. 
Reduced assembly of specific ETC complexes, as determined using Native Blue 
(NB) gels, appears to play an important role in reduced complex activities in heart 
failure (80). Although crystallography studies have provided detailed structural 
information on all ETC complexes (81), the assembly process of the large 
complexes is still poorly understood (82). These complexes can form 
supercomplexes, mainly consisting of complex I, II and IV, commonly referred to 
as the respirasome since it can autonomously drive respiration in the presence 
of cytochrome C (83), adding further complexity to the system. More recently, 
also supercomplexes with complex II have been described (84). A decline in the 
respirasome activity and supercomplexes levels has been described in a canine 
coronary microembolization-induced HF model (80). Thus, changes in dynamics 
of mitochondrial complex and supercomplex formation may play an important 
role in decreased mitochondrial activity in heart failure. More than 10 assembly 
and stabilization factors have been described for complex I and mutations in 
some of them have been shown to be associated with human cardiomyopathies 
(82). Recently the plasma membrane Fat cadherin, large cell adhesion molecule 
was shown to be an important new factor in complex I assembly in Drosophila 
(85). Fat cadherins regulate the Hippo/Yap tumor suppressor pathway that has 
been shown to play an important role in cardiomyocyte proliferation and has 
been suggested as a potential target for adult cardiac regeneration (7). It was 
shown that an evolutionary conserved 68 kDa intracellular domain of Fat is 
cleaved and that this interacts with complex I protein Ndufv2 and is essential for 
complex I stability (85). This is the first example that a plasma membrane protein 
can directly control complex I levels and indicates that signaling pathways are 
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present that control mitochondrial complex stability. Importantly, mutations in 
human NDUFV2 have been identified in hypertrophic cardiomyopathy patients 
(86,87). It will therefore be important to investigate whether Fat cadherin could 
control complex I stability in human cardiomyocytes in response to extracellular 
signals, which would open the possibility to target assembly formation via this 
plasma membrane receptor.  
 
M I TO C H O N D R I A L  B I O G E N E S I S  
Mitochondrial biogenesis has been shown to be unaltered or even increased 
under conditions of cardiac hypertrophy (88). Upon progression towards HF 
there appears, however, to be a decreased expression of genes controlling 
mitochondrial biogenesis, leading to dysfunctional mitochondrial energy balance 
(88,89). Mitochondrial biogenesis is controlled at multiple levels of which the 
transcriptional regulation by peroxisome-proliferator-activated receptor γ 
coactivator-1α (PGC-1α ) has been studied in most detail (90,91). Cardiac specific 
overexpression of PGC-1α resulted in increased expression of hundreds of genes 
involved in mitochondrial function and major metabolic pathways. PGC-1α is a 
co-transcriptional regulation factor that activates different transcription factors, 
including nuclear respiratory factor 1 (NRF-1) and nuclear respiratory factor-2 
(NRF-2), which on their turn stimulate transcription of nuclear mitochondrial 
genes and hence induce mitochondrial biogenesis. In addition PGC-1α and NRF-
1 bind to the promoter of mitochondrial transcription factor A (TFAM) and 
stimulate the expression of TFAM (92). TFAM is a mitochondrial DNA binding 
protein and stimulates both mitochondrial transcription and DNA replication and 
its levels are strongly associated with mitochondrial copy number (93).  
Both PGC-1α overexpression and knock-out studies have been performed. 
Constitutive overexpression resulted in a strong increase in mitochondrial 
content in the heart resulting in cardiac dysfunction and hypertrophy 
development (94). Surprisingly conditional PGC-1α overexpression in the adult 
heart did not activate mitochondrial proliferation (95). It therefore appears to be 
sufficient for mitochondrial biogenesis in the perinatal period, but requires 
additional factors for induction of mitochondrial biosynthesis in the adult heart. 
PGC-1α knock-out mice are viable, and, although in some strains neurological 
disorders have been reported, no baseline cardiac abnormalities have been 
reported, but fetal program genes were activated in these mice, suggesting 
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there appears, however, to be a decreased expression of genes controlling 
mitochondrial biogenesis, leading to dysfunctional mitochondrial energy balance 
(88,89). Mitochondrial biogenesis is controlled at multiple levels of which the 
transcriptional regulation by peroxisome-proliferator-activated receptor γ 
coactivator-1α (PGC-1α ) has been studied in most detail (90,91). Cardiac specific 
overexpression of PGC-1α resulted in increased expression of hundreds of genes 
involved in mitochondrial function and major metabolic pathways. PGC-1α is a 
co-transcriptional regulation factor that activates different transcription factors, 
including nuclear respiratory factor 1 (NRF-1) and nuclear respiratory factor-2 
(NRF-2), which on their turn stimulate transcription of nuclear mitochondrial 
genes and hence induce mitochondrial biogenesis. In addition PGC-1α and NRF-
1 bind to the promoter of mitochondrial transcription factor A (TFAM) and 
stimulate the expression of TFAM (92). TFAM is a mitochondrial DNA binding 
protein and stimulates both mitochondrial transcription and DNA replication and 
its levels are strongly associated with mitochondrial copy number (93).  
Both PGC-1α overexpression and knock-out studies have been performed. 
Constitutive overexpression resulted in a strong increase in mitochondrial 
content in the heart resulting in cardiac dysfunction and hypertrophy 
development (94). Surprisingly conditional PGC-1α overexpression in the adult 
heart did not activate mitochondrial proliferation (95). It therefore appears to be 
sufficient for mitochondrial biogenesis in the perinatal period, but requires 
additional factors for induction of mitochondrial biosynthesis in the adult heart. 
PGC-1α knock-out mice are viable, and, although in some strains neurological 
disorders have been reported, no baseline cardiac abnormalities have been 
reported, but fetal program genes were activated in these mice, suggesting 
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increased cardiac stress (96,97). Induction of hypertrophy by transverse aortic 
constriction (TAC) resulted in pronounced cardiac failure in PGC-1α knockout 
mice. However, since metabolic pathways were also altered, it is unclear 
whether this is a consequence of altered mitochondrial function or changes in 
metabolism.  
Thus, PGC-1α is dispensable for cardiac function, but upon cardiac stress 
decreased levels may accelerate cardiac dysfunction and decompensation 
(98,99). Although in rodents it has been well documented that PGC-1α is down-
regulated under condition that result in cardiac hypertrophy or failure, the 
situation in humans is less clear. Both up- and down regulation of PGC-1α has 
been shown in human heart failure patients, which may underlie differences in 
etiology and treatment regimes. These results show that PGC-1α levels should 
be maintained in a narrow range to balance metabolism and mitochondrial 
function in the heart under conditions of cardiac stress.  
 
C A L C I U M  A N D  M I TO C H O N D R I A L  M O R P H O L O G Y  
A N D  A C T I V I T Y   
Ca2+ plays an important physiological role in all cells and in (cardio)myocytes 
in particular, since it is essential for excitation mediated contraction. In heart 
failure Ca2+ cycling is disturbed, which is at least a result of altered expression of 
the sarcoplasmic reticulum (SR) calcium pump, SERCA2a, resulting in increased 
cytosolic [Ca2+] and consequently in changes in contractile properties and in 
arrhythmias. Furthermore in ischemia/reperfusion calcium overload plays an 
essential role in cardiomyocyte cell death. Besides the SR, also mitochondria play 
an important role in Ca2+ sequestration and homeostasis and thereby control 
important cellular processes, including metabolism, cell survival and signaling 
pathways (100). With the discovery of the mitochondrial Ca2+ uniporter, MCU, in 
2011 the mechanism by which Ca2+ is transported over the IMM has finally been 
solved (101,102). Although this is a low affinity channel the presence of 
mitochondria in close proximity of the SR generates microdomains of high Ca2+ 
concentration upon opening of the SR RYR2 calcium channels (103,104). The 
transient nature of these Ca2+ microdomains and the low affinity of MCU 
prevents mitochondrial Ca2+ overload under normal conditions. Besides MCU, 
other channels are involved in mitochondrial Ca2+ transport, including the VDAC 
channels in the OMM (105) and the mitochondrial Na/ Ca2+ exchange protein, 
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mNCX, that drives Ca2+ efflux (106). Mitochondrial calcium activates important 
rate limiting enzymes in the Krebs cycle, including pyruvate dehydrogenase 
(PDH), α-ketoglutarate dehydrogenase and isocitrate dehydrogenase. Whereas 
the latter two are directly controlled by Ca2+ (107,108). PDH is regulated by 
reversible phosphorylation via pyruvate dehydrogenase kinase (PDK) and via Ca2+ 
sensitive PDH phosphatases (109). Dephosphorylation of the PDH complex 
increases its activity. The enzymatic conversions of these three Krebs cycle 
enzymes generate NADH and are therefore directly involved in funneling 
electrons into the ETC via NADH dehydrogenase (Complex I). The close 
connection between SR and mitochondria and the resulting Ca2+ microdomains, 
will allow rapid Ca2+ uptake by mitochondria during contraction and hence 
efficient coupling of mitochondrial energy production with contraction. In the 
heart the MCU has indeed been shown to match energetic supply with cardiac 
workload during acute stress (110). The role in chronic cardiac disease, like heart 
failure still needs to be explored. Via the MCU mitochondria will also prevent Ca2+ 
diffusion away from the area where the open SR channels are located. 
Mitochondrial localization may therefore be crucial for spatially constraining Ca2+ 
signals to defined cell domains and prevent cytosolic Ca2+ overload in large cells, 
like cardiomyocytes and to prevent Ca2+ spark formation (111). As discussed 
below, in heart failure mitochondrial morphology and localization are disturbed, 
and hence mitochondrial-SR microdomain formation will be hampered, leading 
to profound effects in Ca2+ homeostasis, energy production and cardiomyocyte 
contraction.  
 
Permeability transition pore (PTP) 
Calcium is also important for the regulation of the permeability transition 
pore (PTP) a voltage-dependent, high-conductance channel located in the (IMM). 
In the open state, the pore diameter allows passive diffusion of solutes, but not 
larger proteins (>1.5 kDa) (112). Increased Ca2+ levels due to ischemia, 
ischemia/reperfusion and heart failure will sensitize PTP opening via cyclophilin-
D. The latter can be antagonized by the drug cyclosporin-A (CsA) , which also 
inhibits the pro-hypertrophic calcineurin/NFAT pathway (Figure 2). Nevertheless, 
studies with cyclosporine have shown mixed results regarding hypertrophy 
development and cardiac function in experimental heart failure animal models 
(113). This probably reflects complexity of this clinical syndrome and it is unlikely 
that a single mechanism can halt the progression of this end-stage disease The 
2Mitochondria and heart failure 
34 
mNCX, that drives Ca2+ efflux (106). Mitochondrial calcium activates important 
rate limiting enzymes in the Krebs cycle, including pyruvate dehydrogenase 
(PDH), α-ketoglutarate dehydrogenase and isocitrate dehydrogenase. Whereas 
the latter two are directly controlled by Ca2+ (107,108). PDH is regulated by 
reversible phosphorylation via pyruvate dehydrogenase kinase (PDK) and via Ca2+ 
sensitive PDH phosphatases (109). Dephosphorylation of the PDH complex 
increases its activity. The enzymatic conversions of these three Krebs cycle 
enzymes generate NADH and are therefore directly involved in funneling 
electrons into the ETC via NADH dehydrogenase (Complex I). The close 
connection between SR and mitochondria and the resulting Ca2+ microdomains, 
will allow rapid Ca2+ uptake by mitochondria during contraction and hence 
efficient coupling of mitochondrial energy production with contraction. In the 
heart the MCU has indeed been shown to match energetic supply with cardiac 
workload during acute stress (110). The role in chronic cardiac disease, like heart 
failure still needs to be explored. Via the MCU mitochondria will also prevent Ca2+ 
diffusion away from the area where the open SR channels are located. 
Mitochondrial localization may therefore be crucial for spatially constraining Ca2+ 
signals to defined cell domains and prevent cytosolic Ca2+ overload in large cells, 
like cardiomyocytes and to prevent Ca2+ spark formation (111). As discussed 
below, in heart failure mitochondrial morphology and localization are disturbed, 
and hence mitochondrial-SR microdomain formation will be hampered, leading 
to profound effects in Ca2+ homeostasis, energy production and cardiomyocyte 
contraction.  
 
Permeability transition pore (PTP) 
Calcium is also important for the regulation of the permeability transition 
pore (PTP) a voltage-dependent, high-conductance channel located in the (IMM). 
In the open state, the pore diameter allows passive diffusion of solutes, but not 
larger proteins (>1.5 kDa) (112). Increased Ca2+ levels due to ischemia, 
ischemia/reperfusion and heart failure will sensitize PTP opening via cyclophilin-
D. The latter can be antagonized by the drug cyclosporin-A (CsA) , which also 
inhibits the pro-hypertrophic calcineurin/NFAT pathway (Figure 2). Nevertheless, 
studies with cyclosporine have shown mixed results regarding hypertrophy 
development and cardiac function in experimental heart failure animal models 
(113). This probably reflects complexity of this clinical syndrome and it is unlikely 
that a single mechanism can halt the progression of this end-stage disease The 
Chapter 2 
35 
mitochondrial MCU also modulates PTP opening (110) and PTP opening can 
result in major alterations of mitochondrial structure and function and may 
eventually cause cell death. The immediate effect of PTP opening is the collapse 
of mitochondrial membrane potential (Δψm). As a consequence glycolytic ATP 
will be hydrolyzed by the reverse operation of the ATPase resulting in ATP 
depletion. Since NAD(P)H is crucial for the maintenance of antioxidant defenses, 
oxidative stress will also increase. Moreover, PTP opening can result in matrix 
swelling, resulting in morphological changes, including alterations in cristae and 
hence ETC complex stability and possibly affecting mitochondrial-SR 
microdomains and hence Ca2+ homeostasis. In the extreme situation PTP opening 
could cause the rupture of the outer membrane (OMM) and release of 
cytochrome C and other pro-apoptotic proteins from the IMS triggering 
apoptosis. Moreover, prolonged PTP opening may lead to complete collapse of 
the membrane potential and Ca2+ discharge, resulting in the complete loss of 
mitochondrial function and necrotic cell death.  
 
M I TO C H O N D R I A L  F I S S I O N  A N D  F U S I O N  
Mitochondrial morphology is highly dynamic and mitochondrial fission and 
fusion play an important role in morphological alterations. Mitochondrial fission 
is essential during cell division and allows the tubular mitochondrial network to 
subdivide in numerous individual organelles that can be spatially distributed and 
hence faithfully segregated over both daughter cells (114). After cell division, 
these small mitochondria can fuse again to generate elongated microtubule 
network. This process of mitochondrial fission and fusion also occurs in quiescent 
cells and at steady state this process is in balance and the morphology and the 
function of mitochondria is maintained. It was long believed that mitochondria 
in adult cardiomyocytes were relatively static and that fission/fusion did not play 
a role in the adult heart . In the last decade this view has been challenged and it 
is now clear that genetic mutations in the fission/fusion machinery can generate 
cardiomyopathies, not only in experimental models, but also in patients (14,115). 
TAZ mutations for example, which affect cardiolipin metabolism, as described 
above, also affects fusion and result in many small mitochondria with abnormal 
IMM potential (116). Moreover, in patients with dilated cardiomyopathies, 
myocardial hypertrophy and end-stage heart failure disorganized and small  




mitochondria are observed (117–119). Thus, under pathological conditions a 
misbalance between fusion and fission occurs and this can result in altered 
mitochondrial dynamics and potentially promote cell death (120). 
In mammalian cells mitochondrial fission is controlled by dynamin related 
protein 1 (Drp1) and Fission 1 protein (Fis1) (Figure 3). Inhibition of Drp1 and/or 
Fis1 results in elongated mitochondria (121,122). Importantly, upon induction of 
apoptosis Drp1 translocates to mitochondrial sites of organelle division and 
inhibition of Drp1 blocks cell death, implicating mitochondrial fission as an 
potential step in cell apoptosis (121). The opposite process, mitochondrial fusion, 
is controlled by the mitofusin GTPases Mfn1, Mfn2 and optic atrophy 1 (Opa1) 
(Figure 3) (123,124). Mfn1 and Mfn2 mediate fusion of the OMM, whereas Opa1 
targets the IMM. Silencing or knockdown of these proteins results in fragmented 
smaller mitochondria (124,125) and down regulation of Opa1 results in apoptosis 
(124). Moreover, during apoptosis, mitochondrial fusion is blocked 
independently of caspase activation, indicative for the involvement of 
mitochondrial dynamics and homeostasis in apoptosis (120,126,127). Mice with 
conditional deletions in the fusion genes Mfn2 and Opa1 developed 
cardiomyopathies (55,128). Although these studies may suggest that small 
mitochondria are bad, in contrast to large mitochondria, the situation is more 
complex. Conditional removal of Drp1 in cardiomyocytes in the mouse heart 
Figure 3 
Simplified scheme of molecular pathways that control mitochondrial fission and fusion. 
For details see text. 
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resulted in large mitochondria and in the development of cardiomyopathies 
(129–131). These myopathies were linked to disturbances in mitophagy, a 
mitochondrial quality process that allows removal of dysfunctional mitochondria 
(132,133). Interestingly, it was also shown that decreased mitophagy in 
transverse aortic constricted (TAC) mice coincided with reduced Drp1 levels. 
Activation of autophagy in these mice, using Tat-Beclin1, rescued mitochondrial 
autophagy and attenuated mitochondrial dysfunction and heart failure (130). 
Importantly, in acute stress situations, like ischemia/reperfusion injury, 
inhibition of Drp1 may be beneficial (134).  
Thus, mitochondrial fission generates small mitochondria that can be 
removed by mitophagy and this mitochondrial quality control process plays an 
important role under chronic cardiac stress, in which it favors adaptation to 
stress by removing damaged mitochondria. In contrast, oxidative stress and 
apoptotic proteases may inactivate mitophagy, and hence this cardioprotective 
response, resulting in the execution of cell death (132). Mouse studies have 
indeed shown that mitochondrial fusion and fission play opposing roles in cardiac 
mitochondrial quality control (135).  
The control of fission/fusion process is even more complicated and has 
recently been shown to be strongly linked with metabolic substrate usage (136). 
Two peptidases in the IMM, OMA1 and the i-AAA protease YME1L can convert 
Opa1 into short forms of Opa1 (S-Opa1) (Figure 3) (137–140). Whereas fusion 
depends on the long form (L-Opa1), S-Opa1 is associated with fission (141–143). 
Intracellular stress can activate Oma, resulting in elevated levels of S-Opa1 and 
enhanced mitochondrial fragmentation. Moreover increased oxidative 
phosphorylation can promote cleavage of Opa1 by YME1L (144). Interestingly, 
cardiac specific deletion of Yme1l in mice activated Oma1, resulting in enhanced 
Opa1 proteolysis, mitochondrial fragmentation, altered cardiac metabolism and 
dilated cardiomyopathy (136). Concomitant deletion of Oma1 could prevent all 
these effects. Even more interesting metabolic intervention, by, feeding a high 
fat diet to cardiac ablated Yme1l prevented cardiac dysfunction despite 
mitochondrial fragmentation. These data indicate that different pathways 
control Opa1 and that there is a strong interaction with cardiac metabolism, 
which allows a balanced mitochondrial function in response to physiological 
changes. How these systems are affected in cardiac hypertrophy and heart 
failure is not yet clear, but OpaI expression is decreased in both human and rat 
heart failure and OpaI haploinsufficient mice generate age dependent 
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cardiomyopathy (55,128). This exemplifies the importance of mitochondrial 
dynamics under stress conditions and may provide interesting intervention 
options. Specific Oma1 and Yme1L protease activators and inhibitors may be 
developed that allow intervention and modulation of this process under 
pathological conditions.  
 
M I TO C H O N D R I A L  M O T I L I T Y  
In most cells mitochondria can dynamically move through the cytoplasm a 
process which is mainly driven by dynein and kinesin motor proteins that 
transport mitochondria along microtubules (145–147). This allows energy 
production at sites of high ATP need, like in axons of activated neurons. In adult 
cardiomyocytes mitochondria are relatively static and are most often depicted 
as sardines in a can (13). The sarcomeric structures around mitochondria in 
myocytes are believed to hinder dynamic movement of mitochondria. Moreover, 
in cardiomyocytes the mitochondria are in close connection to T-tubules and the 
sarcoplasmic reticulum, to allow excitation induced ATP supply for contraction, 
as described above. Dynamic movement of mitochondria is therefore not 
desirable. It should also be noted, that in adult cardiomyocytes and skeletal 
myocytes two distinct mitochondrial subpopulations were originally described, 
namely: subsarcolemmal mitochondria (SSM) and interfibrillar mitochondria 
(IFM). Recent high resolution imaging using focused ion beam scanning electron 
microscopy (FIB-SEM) revealed, however, that within skeletal muscle at least 
four subpopulations can be identified namely: paravascular mitochondria (PVM), 
I-band mitochondria (IBM), fiber parallel mitochondria (FPM) and cross fiber 
connection mitochondria (CFCM) (148). These subpopulations form a continuous 
mitochondrial reticulum that provides a conductive pathway for energy 
distribution through the muscle cell. In the cell periphery the proton motive force 
is generated and distributed to the cell interior where high levels of 
mitochondrial complex V generate ATP near the contractile apparatus (148). It is 
highly likely that a similar mitochondrial network also exists in cardiomyocytes. 
Whether these are all interconnected or function as closely connected separate 
oscillators as proposed by others may be less relevant (4). In both cases it 
requires a highly ordered network for efficient energy transfer. In heart failure 
mitochondrial fragmentation and mislocalization has been observed and 
mitochondria are often clustered together (119,149). It is easy to envision that 
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this network disruption will profoundly affect energy distribution within the 
cardiomyocytes. Whether this relocalization of mitochondria is simply a result of 
altered sarcomeric structure or a result of active transport by dynein and kinesin 
motor proteins, or both, is not known. Motor proteins also play an essential role 
in mitochondrial fission (150–152) and the observation of small and mislocalized 
mitochondria in heart failure may suggest a so far unrecognized action of 
mitochondrial motor proteins in heart failure progression. Clearly, this deserves 
further attention.  
 
R E V E R S A L  O F  M I T O C H O N D R I A L  D Y S F U N C T I O N  
One important question is whether mitochondrial dysfunction can be restored 
at stages in which mitochondrial ultrastructure and morphology have been 
altered. A situation that is typically observed in advanced heart failure. An 
interesting study, with a mouse model of Friedreich’s Ataxia has provided 
interesting insights in the reversibility of mitochondrial function and morphology 
(153). Friedreich's ataxia (FRDA) is a mitochondrial disease characterized by 
neurodegeneration, hypertrophic cardiomyopathy and diabetes (154). Cardiac 
failure is the most common cause of mortality with this syndrome (155). A 
particular genetic mutation in the frataxin (FXN) gene, which encodes an 
essential mitochondrial protein and amongst others is involved in the 
biosynthesis of iron-sulfur (Fe-S) clusters, underlies this disease (156). This 
results in energy depletion, enhanced ROS formation, mitochondrial 
morphological alterations, including hyper proliferative small mitochondria. A 
conditional mouse model with complete frataxin (FxnL3/L-) deletion in cardiac and 
skeletal muscle was used to study disease development and the possibility to 
revert disease by expressing human FXN with adeno-associated virus (AAVrh10) 
mediated gene therapy (153). Interestingly gene therapy provided to FxnL3/L- mice 
with cardiac dysfunction, fully restored cardiac function, including normalization 
of mitochondrial numbers, structure and localization and reversal of the fetal 
gene program. Only fibrotic patches, as a result of necrotic cardiomyocyte 
replacement before the start of gene therapy, were not resolved. This indicates, 
that mitochondria are highly dynamic in the diseased heart and that 
cardiomyocyte function can be restored by targeting mitochondrial dysfunction. 
Whether this is also true for all other underlying etiologies is not known and it is 
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F U T U R E  D I R E C T I O N S  A N D  T R E AT M E N T  
O P T I O N S  
 As discussed above the term mitochondrial dysfunction is poorly defined 
in heart failure Alterations in mitochondrial membrane composition, ETC 
complex assembly, ultrastructure, gene expression and dynamic behavior, may 
all contribute to mitochondrial dysfunction in heart failure and the individual 
contribution of each of these factors may be highly depended on etiology and 
other factors. Moreover, we do not know the sequel of events that result in 
progressive mitochondrial dysfunction in heart failure and again it is likely that 
this will be different between heart failure patients and be dependent on 
etiology and environmental and genetic factors, amongst others. Thus, although, 
we start to understand the mechanisms that contribute to mitochondrial 
Figure 4 
Schematic depiction of the mitochondrial changes during disease progression. In health 
all processes are in homeostasis, but upon disease progression a sequel of changes occur 
that finally result in dysfunction. The exact order of these changes is not clear and 
probably depends on the underlying etiologies. Reversal of mitochondrial form and 
function is feasible, but is not known till which disease state this restoration is still 
possible.  
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dysfunction in heart failure, we are still a long way from understanding it to the 
full extent.  
Therapeutic strategies towards mitochondrial mediated diseases have 
mostly been focused on ROS scavenging and anti-apoptotic mechanisms. These 
processes are indeed detrimental for the cell, but are most often not the primary 
cause of mitochondrial dysfunction, but rather a consequence of impaired 
mitochondrial function. These approaches do not target the underlying 
processes that culminate in mitochondrial dysfunction. This may explain why 
anti-oxidants have not provided the promised health benefits (157). Although 
more sophisticated anti-oxidant therapies with mitochondrial targeted ROS 
scavengers appear more promising (158–160), it still has to be awaited whether 
these novel strategies will have therapeutic value. In this respect the cardiolipin 
interacting peptide SS-31 may be a promising alternative approach. It does not 
only protect cardiolipin from cytochrome-C mediated oxidation, but also 
improves cristae structure and faithful mitochondrial respiration and hence 
promotes proper mitochondrial function. Other promising therapies may be 
related to the fission/fusion and mitophagy processes. Activation of mitophagy 
under chronic cardiac stress, like pressure overloaded mice, can attenuate 
mitochondrial dysfunction and heart failure in mice. Moreover, the proteases, 
Oma1 and Yme1L could constitute interesting targets to improve mitochondrial 
and hence cardiac function under sustained stress conditions. Since there are 
multiple alterations in mitochondrial behavior and function it is highly likely that 
a multi-level targeting approach will be needed to treat disease. For this, we still 
have to learn a lot about this fascinating organelle that is so central to eukaryotic 
life and its malfunctioning plays a crucial role not only in heart failure, but also in 
many other diseases. 
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A B S T R A C T  
A kinase interacting protein 1 (AKIP1) is a molecular regulator of protein kinase 
A and nuclear factor kappa B signaling. Recent evidence suggests AKIP1 is 
increased in response to cardiac stress, modulates acute ischemic stress 
response, and is localized to mitochondria in cardiomyocytes. The 
mitochondrial function of AKIP1 is, however, still elusive. Here, we investigated 
the mitochondrial function of AKIP1 in a neonatal cardiomyocyte model of 
phenylephrine (PE)-induced hypertrophy. Using a Seahorse flux analyzer we 
show that PE stimulated the mitochondrial oxygen consumption rate (OCR) in 
cardiomyocytes. This was partially dependent on PE mediated AKIP1 induction, 
since silencing of AKIP1 attenuated the increase in OCR. Interestingly, AKIP1 
overexpression alone was sufficient to stimulate mitochondrial OCR and in 
particular ATP-linked OCR. This was also true when pyruvate was used as a 
substrate, indicating that it was independent of glycolytic flux. The increase in 
OCR was independent of mitochondrial biogenesis, changes in ETC density or 
altered mitochondrial membrane potential. In fact, the respiratory flux was 
elevated per amount of ETC, possibly through enhanced ETC coupling. 
Furthermore, overexpression of AKIP1 reduced and silencing of AKIP1 increased 
mitochondrial superoxide production, suggesting that AKIP1 modulates the 
efficiency of electron flux through the ETC. Together, this suggests that AKIP1 
overexpression improves mitochondrial function to enhance respiration 
without excess superoxide generation, thereby implicating a role for AKIP1 in 
mitochondrial stress adaptation. Upregulation of AKIP1 during different forms 
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I N T R O D U C T I O N  
A kinase interacting protein 1 (AKIP1) is a small 23 kDa protein originally 
identified as a breast cancer associated gene (BCA3) (1). In humans, there are 
three splice variants, the full-length protein (AKIP1a), one that lacks the third 
exon (AKIP1b), and one that lacks the third and fifth exon (AKIP1c). In contrast, 
only the full-length protein is present in rodents (2). It has no homologies to 
other proteins, is devoid of particular catalytic domains and is therefore believed 
to have a role as an adaptor or structural intracellular protein. AKIP1 localizes to 
the cytoplasm, nucleus, and mitochondria and associations with proteins with 
different sub-cellular localizations have been reported, including PKA (3), NFκB 
(4), apoptin (5), RAC1 (6), TAP73 (7) and AIF (8). These varied sites of cellular 
localization suggest that AKIP1 may have multiple functions in the cell. In cancer 
cell lines a role for AKIP1 in nuclear-cytoplasmic shuttling of PKA and NFκB has 
been proposed (3,4,9,10), but AKIP1 may also be involved in apoptosis (5,7). 
AKIP1 has been shown to localize to mitochondria in both cancer cells and 
cardiomyocytes, but its functional role in mitochondria is still elusive (7,8). 
AKIP1 has been mainly studied in cancer cell lines, but is also expressed in 
many normal, non-tumor, cells in different organs. AKIP1 is abundantly 
expressed in cardiac tissue predominantly in cardiomyocytes (11). In a gene array 
study we identified AKIP1 as a differentially expressed gene that was significantly 
upregulated in animal models of pathological cardiac hypertrophy and heart 
failure, including pressure overload and post-myocardial infarction (MI) 
remodeling (11); however, exercise mediated “physiological hypertrophy” also 
increased AKIP1 expression (12). Cardiac hypertrophy is initially adaptive in 
cardiomyocytes to compensate for sustained wall stress, but becomes 
maladaptive during sustained pathological stress. Interestingly, mitochondrial 
function is improved during physiological hypertrophy, but diminishes upon 
sustained pathological hypertrophy (13). It is possible that AKIP1 may be 
regulating the compensation phase of pathologic hypertrophy and exercise-
induced physiologic hypertrophy through regulation of mitochondrial function. 
Mitochondria isolated from AKIP1 gene transferred hearts showed amongst 
others, enhanced calcium tolerance, and decreased mitochondrial cytochrome C 
release upon ischemic stress. Interestingly, AKIP1 overexpression could protect 
cardiac function in an ex vivo mouse ischemia/reperfusion model (8). Here we 
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test the direct effects of loss or overexpression of AKIP1 on mitochondrial 
function. 
 
M AT E R I A L S  A N D  M E T H O D S  
Ethics Statement 
Animal use for these studies was in accordance with the NIH Guide for the 
Care and Use of Laboratory Animals. The study was submitted to, and approved 
by, the Committee for Animal Experiments of the University of Groningen 
(Permit Number: DEC6002). All efforts were made to minimize suffering. 
 
Isolation and culturing of primary cardiomyocytes  
Neonatal rats of 1-3 day old were euthanized by decapitation, hearts 
excised and atria were removed. Primary neonatal rat ventricular 
cardiomyocytes (NRVCs) were isolated as previously described (14,15). 
Cardiomyocytes were grown in DMEM (Sigma D5671, Missouri, USA) 
supplemented with 5% fetal calf serum (FCS: Sigma F9665, Missouri, USA) and 
penicillin-streptomycin (100U/ml-100µg/ml; Sigma P0781, Missouri, USA). 
Adenoviral constructs were generated with the ViraPowerTM adenoviral 
expression system from Invitrogen as described previously (16). Primers used for 
cloning are listed in supplemental table S1. For adenoviral infections, 
cardiomyocytes were infected with an MOI of 25 one day after isolation, in 
medium with 5% FCS, and starved the next day for 48 hours. Similar culture 
conditions were employed for the non-infected cells or control virus infected 
cells that served as controls. For cells stimulated with phenylephrine (PE), 24 
hours after starvation PE (50 µM) was added for 24 hours after which assays were 
performed.  
 
Seahorse mitochondrial flux analyses 
To measure the rate of oxidative phosphorylation in intact cardiomyocytes, 
a Seahorse metabolic flux analyzer was used (Seahorse Biosciences, 
Massachusetts, USA). NRVCs were seeded at a density of 100,000 cells/well in 24 
well Seahorse assay plates. Cells were treated as described above. One hour 
before initiation of measurements, medium was replaced with XF medium 
supplemented with 10 mM glucose or 1 mM pyruvate and incubated for 1 hour 
in a 37°C incubator (without CO2). Three baseline oxidative consumption rate 
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(OCR) measurements were performed, followed by injection with oligomycin (1 
µM) to measure the ATP linked OCR. The uncoupler FCCP (0.5 µM) was used to 
determine maximal respiration and rotenone (1 µM) and antimycin A (1 µM) 
were injected to determine the non-mitochondrial respiration. Experimental 
treatments were performed on 3-4 wells of each plate as technical replicates and 
each experiment had at least 3 biological replicates. OCR was normalized for the 
amount of cellular protein in each well. 
 
Real time PCR 
Total RNA was isolated using a kit (Bioke, the Netherlands) and cDNA was 
synthesized using a reverse transcription kit (Qiagen, the Netherlands) following 
manufactures instructions. Total DNA was isolated using a kit (Qiagen, the 
Netherlands) following manufactures instructions. Relative gene expression was 
determined by quantitative real time PCR (RT-PCR) on a Bio-Rad CFX384 real time 
system using SYBR Green dye (Bio-Rad, California, USA). Gene expressions were 
corrected for reference gene values (cyclophilin A or GAPDH), and the calculated 
values were expressed relative to the control group per experiment. Primer 
sequences are listed in supplemental table S2.  
 
Western blot 
Protein was isolated in RIPA buffer (50 mM Tris pH 8.0, 1% nonidet P40, 
0.5% deoxycholate, 0.1% SDS, 150 mM NaCl) supplemented with 10 µl/ml 
phosphatase inhibitor cocktail 3 (Sigma p2850, Missouri, USA), protease inhibitor 
cocktail (Roche, 11873580001, Switzerland) and 1mM phenylmethylsulfonyl 
fluoride (PMSF) (Roche,10837091001, Switzerland). Protein concentration was 
determined with a DC protein assay kit (Bio-Rad, California, USA). Equal amounts 
of proteins were separated by SDS-PAGE and proteins were transferred to PVDF 
or nitrocellulose membranes. For detection of specific proteins, the following 
antibodies were used: a custom-made rabbit polyclonal anti-AKIP1 antibody, 
anti-total OXPHOS antibodies cocktail (Abcam, Cambridge, United Kingdom), and 
monoclonal anti-GAPDH antibody (Fitzgerald, Massachusetts, USA) served as a 
loading control. After incubation with secondary antibodies, signals were 
visualized with ECL and analyzed by densitometry (Syngene, Cambridge, United 
Kingdom). 
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Citrate Synthase assay 
Whole cell citrate synthase activity was measured using an enzyme assay kit 
(Sigma, Missouri, USA) according to the manufactures instructions. Cell lysates 
were prepared using the CellLytic M Cell Lysis Reagent and protein 
concentrations were measured with a DC protein assay kit (Bio-Rad, California, 
USA). 8 µg of protein was mixed with Acetyl CoenzymeA (Acetyl CoA), 5,5’-
Dithiobis-(2-nitrobenzoic acid) (DTNB), and assay buffer in a 96 well plate. The 
reaction was initiated by adding Oxaloacetate (OAA) into the mixture and total 
activity was measured. Absorbance was measured at 412 nm using a multiwall 
spectrophotometer following a kinetic program. Triplicate measurements were 
performed on each sample and 5 independent samples were measured for each 
group. 
 
Determination of mitochondrial membrane potential and ROS 
production 
Mitochondrial membrane potential (Δψm) was assessed by 
tetramethylrhodamine ethyl ester (TMRE; Life Technologies Europe BV, 
Bleiswijk, The Netherlands) following the manufacturer’s instructions. In brief, 
cells were seeded at a density of 40,000 cells/well in black 96 well plates and 
cultured as described above. TMRE was added at a final concentration of 100 nM 
with 20 min incubation at 37 °C. Cells were subsequently washed with 0.2% BSA 
in PBS, and fluorescence was measured at 575 nm with a SynergyH4 Hybrid 
Reader (BioTek, Vermont, USA). As a control, FCCP (1 µM) was added to some 
wells. ROS production was determined in a similar way using MitoSOX red 
mitochondrial superoxide indicator (Life Technologies, California, USA). Cells 
were plated in 96 well plates and treated as above. On the day of measurement, 
the cells were incubated with MitoSOX (5 µM) in KRPH buffer (20mM HEPES, 5 
mM KH2PO4, 1 mM MgSO4, 1 mM CaCL2, 136 mM NaCl, 4.7 mM KCl, pH 7.4) for 
10 min at 37 °C, and thereafter washed three times with the same buffer. 
Fluorescence was measured using excitation/emission maxima of 510/580 nm 
with a SynergyH4 Hybrid Reader (BioTek, Vermont, USA). For both assays, each 
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All values are presented as mean ± standard error of the mean (SEM). 
Independent-samples t-test was performed to compare the difference between 
both groups. One-way ANOVA with post-hoc test was used to compare the 
difference between 4 groups with homogeneity of variances. Kruskal-Wallis test 
was used to compare the difference between 4 groups with nonparametric 
variances. P<0.05 was considered to be significant. SPSS software (PASW 
Statistics 18) was used in the statistics analysis.  
 
R E S U LT S   
AKIP1 silencing attenuates PE induced OCR 
We have recently shown that AKIP1 gene expression can be induced by PE, 
a pharmacologic inducer of hypertrophy (11). We confirm this finding in the 
current data and, moreover, show that AKIP1 protein expression is induced by 
PE in NRVCs (Fig. 1A). PE has been shown to increase respiration in NRVCs (17). 
We wondered whether AKIP1 plays a role in modulating PE-induced 
mitochondrial respiration. Addition of PE to NRVCs resulted in a marked increase 
in OCR (doubling in OCR, see Fig. 1B). Addition of oligomycin (oligo), an ATP-
synthase inhibitor, reduced OCR both in control and PE treated cells. This 
difference in OCR between basal and oligomycin treated conditions, is the ATP-
linked OCR, which was higher in the PE treated cells (Fig. 1C). Subsequent 
addition of FCCP, an uncoupling agent, provided the maximal, uncoupled, OCR. 
Finally, antimycin-A and rotenone (AR) were added to the cells to block 
mitochondrial respiration (complex III and complex I inhibitors, respectively). The 
basal OCR was subsequently corrected for this non-mitochondrial OCR to obtain 
the mitochondrial specific respiration, which was significantly elevated in PE 
treated cells (Fig. 1C). To investigate whether this increase in mitochondrial 
respiration required AKIP1, we used an adenoviral small interfering RNA system 
to silence AKIP1. Silencing of AKIP1 resulted in a 90% reduction of AKIP1 protein 
levels (Fig. 1D). Interestingly, AKIP1 silencing reduced, albeit not significantly, 
mitochondrial OCR in NRVCs (Fig. 1E, F). Upon PE addition, this reduction was 
much more pronounced and mitochondrial OCR was significantly attenuated 
(Fig. 1E, F). AKIP1 silencing could also inhibit PE induced ATP-linked OCR, albeit 
just not significant (supplemental figure 1). Thus, AKIP1 silencing attenuated PE  
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Figure 1 AKIP1 silencing attenuates PE-induced OCR.  
A. A representative Western blot is shown with control and PE treated NRVCs samples. 
Blots were probed with anti-AKIP1 antibody and anti-GAPDH as a loading control. B. PE 
induced OCR in NRVCs. Metabolic flux in cardiomyocytes was determined with a 
Seahorse flux analyzer in the presence of 10 mM glucose. Addition of the ATP synthase 
inhibitor oligomycin (oligo), the uncoupler FCCP and the respiratory chain inhibitors 
antimycin A and rotenone (AR) are indicated. C. Mitochondrial OCR (difference between 
basal and AR treated levels) and ATP-linked OCR (difference between basal and 
oligomyin treated levels) are shown. OCR was corrected for total protein levels in each 
well (pmoles O2/min/mg) (*p<0.05 as compared to cont., n=4). D. A representative 
Western blot is shown of cells treated for 72 hours with control and siAKIP1 adenovirus. 
Blots were probed with anti-AKIP1 antibody and anti-GAPDH as a loading control. E. 
Silencing of AKIP1 can limit PE induced OCR. OCR was measured as above. F. 
Quantification of mitochondrial OCR showed significant lower OCR in siAKIP1+PE group 
compared to Cont+PE group (*p<0.05 as compared to cont. group, #p<0.05 compared 
to siAKIP1 group, &p<0.05 compared to cont+PE group, n=4). All values are presented 
as mean ± SEM. 
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AKIP1 induces mitochondrial OCR 
To investigate whether AKIP1 itself could induce mitochondrial OCR, we 
overexpressed AKIP1 in NRVCs (Fig. 2A). AKIP1 increased basal OCR by almost 80 
% (Fig. 2B). Blocking the mitochondrial respiratory chain with AR almost fully 
blocked this OCR, suggesting that this was specific for mitochondrial respiration. 
The calculated mitochondrial specific OCR was 4.8 pmoles O2/min/µg protein in 
control and 8.5 pmoles O2/min/µg protein in AKIP1 overexpressing cells (Fig. 2C). 
Figure 2 AKIP1 overexpression induces mitochondrial OCR.  
A. Using an adenoviral construct, rat AKIP1 was overexpressed in NRVCs. Western blots 
of control and AKIP1 overexpressing cells were probed with anti-AKIP1 antibody and 
anti-GAPDH as a loading control. Quantification of 3 blots is shown in the bar diagram 
(*P<0.05 as compared to cont. group). B. AKIP1 induced OCR in NRVCs. Metabolic flux 
in cardiomyocytes was determined in the presence of 10 mM glucose. Addition of 
different inhibitors is indicated. C. Mitochondrial OCR of control and AKIP1 
overexpressing cells is shown. D. ATP-linked OCR of control and AKIP1 overexpressing 
cells is shown. In all cases OCR was corrected for total protein levels in each well (pmoles 
O2/min/mg) (*p<0.05 as compared to cont. group, n=8). E-G. AKIP1 induced OCR in 
NRVCs in the presence of 1 mM pyruvate. The experiment was performed as above, but 
using pyruvate as substrate instead of glucose (*p<0.05 as compared to cont. group, 
n=4). All values are presented as mean ± SEM. 
3AKIP1 modulates mitochondrial function 
66 
The oligomycin effects on OCR suggested the increase was linked to ATP 
synthesis (Fig. 2D). Also, the maximal respiratory rate was increased, as 
determined by FCCP uncoupling; however, this was not significant. The reserve 
capacity, the difference between maximal and basal respiration, remained 
similar (Fig. 2B). 
To further investigate the role of AKIP1 in mitochondrial oxidation and to test 
whether this was independent of the glycolytic flux we performed a similar 
experiment with pyruvate as a substrate. Pyruvate can be converted into acetyl-
CoA in mitochondria and directly be used as a substrate in the TCA cycle. 
Interestingly, with pyruvate similar results were obtained as with glucose (Fig. 
2E-G), indicating that these changes in mitochondrial respiration were 
independent of glycolytic flux. This was further confirmed by the absence of 
changes in extracellular acidification rate in these cells.  
 
AKIP1 does not induce mitochondrial biogenesis 
AKIP has been shown to modulate SIRT1 function, and the latter has been shown 
to control the expression of PGC-1α, a master transcriptional regulator for 
mitochondrial biogenesis. Therefore, AKIP1 induced OCR could potentially be a 
result of an increase in mitochondrial biogenesis. In AKIP1 overexpressing cells 
PGC-1α was not significantly increased (Fig. 3A). Also expression of ERRα and 
NRF1, downstream targets of PGC-1α involved in the regulation for 
mitochondrial biogenesis were not altered (Fig 3B, C). To corroborate this 
finding, we also determined the ratio between mitochondrial DNA (mtDNA) 
versus nuclear DNA (nDNA), a generally accepted measurement of mitochondrial 
density. PCR analysis was performed on the nuclear gene TRPM-2 and the 
mitochondrial gene CYTB. The ratio between mtDNA and nDNA was similar in 
control and AKIP1 overexpressing cells indicating that mitochondrial biogenesis 
was not increased (Fig. 3D). To further confirm this by an independent method 
we assessed citrate synthase activity which was not affected by AKIP1 
overexpression (Fig. 3E). Multiple data support the notion that AKIP1 does not 
stimulate mitochondrial biogenesis.  
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No increase in OXPHOS levels in AKIP1 overexpressing cells 
The altered respiratory rates could also result from changes in expression of 
electron transport chain (ETC) complexes. Western blotting with an OXPHOS 
antibody cocktail, recognizing multiple subunits of the ETC, did not show an 
increase in the protein levels of ETC-complexes (Fig. 4A, B). On the contrary, a 
Figure 3 AKIP1 does not induce mitochondrial biogenesis.  
A-C. Expression of mitochondrial biogenesis controlling genes PGC-1α , ERRα and NRF1 
was determined by RT-PCR in control and AKIP1 overexpressing NRVCs. Relative 
expression levels were normalized by expression levels of the household gene, 
cyclophilin A. No significant difference was observed between groups (n=3-6). D. 
Nuclear DNA (TRPM-2) to mitochondrial DNA (CYTB) ratio was determined by RT-PCR on 
DNA isolated from control and AKIP1 overexpressing cells. No statistical significant 
difference was observed between groups (n=3). E. Citrate synthase activity was 
measured on whole cell lysates from control and AKIP1 overexpressing cardiomyocytes 
as described in method section. No statistical significant difference was observed 
between groups (n=5). All values are presented as mean ± SEM. 
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significant decrease could be observed in subunits of complex I, II, III and IV in 
AKIP1 overexpressing cells. Also complex V appeared to be somewhat reduced, 
albeit not significant. This suggests that AKIP1 overexpression enhances the 
efficiency of mitochondrial ETC. We also analyzed changes in mitochondrial 
membrane potential using the fluorophore TMRE. As shown in figure 4C, no 
significant difference between control and AKIP1 infected cells was observed in 
TMRE fluorescence. Treatment with FCCP, a depolarizing agent did strongly 
reduce TMRE signal, confirming membrane potential specificity (Fig. 4C). Thus 
despite lower OXPHOS levels, AKIP1 overexpressing did not significantly affect 
the mitochondrial membrane potential, suggesting a more efficient 
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Since OCR was elevated in AKIP1 overexpressing cells, we analyzed whether 
the potential of mitochondrial to generate reactive oxygen species would be 
altered. We assessed superoxide generation using MitoSOX, a fluorophore which 
is activated by superoxide oxidation. Interestingly, MitoSOX signal in AKIP1 
overexpressing cells was about half as compared to control cells (Fig. 5A). To 
exclude that this could be due to increased levels of oxygen radical scavenging  
Figure 4 OXPHOS levels are reduced in AKIP1 overexpressing cells.  
A. Western blot analysis was performed on proteins isolated from control and AKIP1 
overexpressing NRVCs, anti-total OXPHOS antibody cocktail was used to determine ETC 
protein levels. GAPDH was used as loading control. Representative blot is shown. B. 
Quantification of 4 independent experiments is shown in the bar diagram (*P<0.05 as 
compared to cont., n=4). C. Mitochondrial potential was measured using TMRE in 
control and AKIP1 overexpressing cells. As a control the ionophore FCCP was added to 
reduce membrane potential (*P<0.05 as compared to cont., #P<0.05 as compared to 
AKIP1 group, n=4). All values are presented as mean ± SEM. 
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systems, we also analysed the expression of manganese-superoxide dismutase 
(SOD2) and glutathione peroxidase (GPX4). Neither of these genes were 
upregulated (Fig. 5B, C), indicating that AKIP1 does not induce the anti-oxidant 
response. In contrast, AKIP1 silencing resulted in increased ROS production 
Figure 5 AKIP1 reduces superoxide formation.  
A. Mitochondrial ROS was determined using MitoSOX fluorophore in control and AKIP1 
overexpressing cells. Significant less ROS signal was observed in AKIP1 group (*P<0.05 
compared to cont., n=6). B and C. Anti-oxidant genes SOD2 and PGX4 were determined 
by RT-PCR, relative gene expression was normalized by expression levels of the 
household gene, cyclophillin A. No significant differences were observed between 
groups (n=6). D. Mitochondrial ROS was determined as above in control and AKIP1 
silenced cells. Significantly increased ROS signal was observed in the AKIP1 silenced cells 
(*P<0.05 compared to cont., n=4). All values are presented as mean ± SEM. 
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(Fig.5D). Together, this suggests that AKIP1 overexpression improves 
mitochondrial function to enhance respiration without excess generation of ROS 
implicating a role for AKIP1 in mitochondrial stress adaptation.  
 
D I S C U S S I O N  
AKIP1 protein is expressed in many organs, and in cardiac tissue a role in 
mitochondrial function has been suggested (8). Although its role at mitochondria 
is still elusive, AKIP1 localizes to and fractionates with mitochondria (7,8). Here 
we investigated the effect of AKIP1 in mitochondrial respiration in neonatal rat 
cardiomyocytes. Treatment of cells with PE induced AKIP1 expression and 
increased OCR. Interestingly, AKIP1 overexpression on its own was sufficient to 
induce mitochondrial OCR, whereas AKIP1 silencing could attenuate PE induced 
OCR. We further determined that these effects were independent of 
mitochondrial biogenesis and changes in ETC component density. The increase 
in respiratory function was not associated with increased ROS formation, 
suggesting that AKIP1 overexpression may be a means to enhance the efficiency 
of mitochondrial function in setting of cardiac stress. Having effects independent 
of structural changes to mitochondria that could take time to manifest (i.e., 
biogenesis and protein synthesis to increase ETC components) suggest that 
localization and stress induced expression and/or translocation of AKIP1 may be 
important regulatory functions of AKIP1 in the cell.  
In concordance with a previous study (17), we showed that PE induced 
mitochondrial respiration in cardiomyocytes. PE also induced AKIP1 expression 
and silencing of AKIP1 could attenuate PE induced alteration in mitochondrial 
function. Interestingly, AKIP1 overexpression was itself sufficient to increase 
OCR. Since oxygen consumption was also increased with pyruvate as a substrate, 
this was independent of potential glycolytic effects. Together these data indicate 
that AKIP1 has a contributory role in PE induced mitochondrial respiration. Since 
AKIP1 localizes to the nucleus and has been shown to modulate transcription via 
NFκB and SIRT1 in cancer cell lines (10,18), the mitochondrial changes may be a 
result of altered transcription of nuclear encoded mitochondrial genes. We 
investigated expression of numerous genes encoding mitochondrial proteins, 
but did not observe any obvious differences. SIRT1 modulation has also been 
shown to affect PGC-1α transcription, a well-known activator of mitochondrial 
biosynthesis (19). PGC-1α and other downstream mitochondrial biosynthesis 
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genes, like ERRα and NRF1, were not significantly altered. Moreover, 
mitochondrial numbers were not increased in these cells. Thus, although we 
cannot rigorously exclude the possibility that AKIP1 modulates mitochondrial 
function via transcriptional regulation, we currently find this explanation 
unlikely.  
In AKIP1 overexpressing cells lower levels of OXPHOS components were 
observed. Nevertheless, mitochondrial membrane potential was similar as 
compared to control cells and oxygen consumption rate was higher. The flux per 
ETC complex must therefore be considerably higher in AKIP1 overexpressing cells 
accounting for the higher efficiency. ROS production on the other hand was 
attenuated suggesting that the enhanced respiration was coupled and resulted 
in energy production rather than mitochondrial dysfunction. Diminished ROS 
production has recently been observed in mitochondria from AKIP expressing 
adult cardiomyocytes, further stressing that this is a mitochondrial specific effect 
(8). Within mitochondria at least ten different enzymes contribute to ROS 
formation, but ETC complexes I and III are believed to be the major sites of 
superoxide production (20–22). Moreover, as we observed changes in the levels 
of components of these complexes, it is likely that AKIP1 exerts its effects by 
modulating ETC in some way. It is possible that AKIP1 interacts with 
mitochondrial localized proteins, possibly components of the ETC, to enhance 
function and decrease ROS generation. Nevertheless, other factors like 
mitochondrial ultrastructural or morphological changes in AKIP1 overexpressing 
cells, might also contribute to changes in mitochondrial function. Cardiac 
hypertrophy and failure are also associated with changes in multiple components 
of the ETC. However, even within the same model and study, divergent 
responses in different ETC components have been observed, underscoring the 
complex regulatory networks that controls cardiac energy production (23–25). 
How AKIP1 modulates the levels and function of these complexes will therefore 
require further investigations.  
Conditions that trigger hypertrophy and heart failure formation, as well as 
ischemia/reperfusion, trigger AKIP1 expression in the heart (8,11). Increased 
AKIP1 levels result in more efficient mitochondrial respiration and reduced ROS 
formation. However, despite the presence of higher AKIP1 levels under these 
conditions, decreased mitochondrial function and increased ROS formation has 
been reported with multiple forms of cardiac stress (26–28). Also, in PE treated 
cardiomyocytes ROS production is increased (29), despite increased AKIP1 




expression. This apparent contradiction might be explained by the fact that all 
these conditions result in profound metabolic and mitochondrial changes. The 
increase in AKIP1 expression under these conditions might therefore be an 
adaptive response to limit ROS production (Fig. 6). This is comparable with genes 
like SOD and catalase, which encodes enzymes that scavenge ROS and are 
expressed only when ROS levels are high (30). It will therefore also be interesting, 
whether absence of AKIP1 makes cells more vulnerable to cardiac stress 
conditions. 
Alternatively, since increased AKIP1 expression has also been reported during 
physiological hypertrophy (exercise), AKIP1 expression may be induced to 
enhance mitochondrial performance during cardiac stress events. Many factors 
that are shown to be compensatory in heart failure (e.g., natriuretic peptides, 
caveolins, etc.) show initial patterns of upregulation that ultimately lead to heart 
failure, however, these same factors have a potential protective role in heart 
failure when they are overexpressed (31–33). Such may be the case for AKIP1 
expression. During sustained stress, other metabolic and mitochondrial 
alterations might subsequently result in deterioration of mitochondrial function 
Figure 6 Schematic model of the role of AKIP1 in modulating OCR and ROS formation.  
PE induced OCR and induced ROS formation in mitochondria. PE also induced AKIP1 
expression and AKIP1 was able to attenuate ROS formation, but stimulate OCR. AKIP1 
silencing experiments confirmed this role of AKIP1 in controlling OCR and ROS 
production. Together this indicates that AKIP1 improves mitochondrial function. 
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and increased ROS production. Obviously this still begs the question, why AKIP1 
expression is not continuously high, since improved mitochondrial respiration 
would be beneficial under all conditions. There could be multiple reasons; first 
depending on its localization AKIP1 has also different functions besides 
regulating mitochondrial respiration. Moreover, ROS is a double-edged sword. 
High levels are detrimental causing DNA and protein damage, whereas low levels 
are beneficial and are required for cell signaling (28,34). Therefore sustained high 
expression of AKIP1 under normal conditions might interfere with other cellular 
processes. 
All together, we have shed light on the role of AKIP1 in cardiomyocyte 
energy generation. In particular, we have shown that AKIP1 can improve 
mitochondrial function in cardiomyocytes resulting in increased respiration 
without enhanced ROS production. Activating AKIP1 could therefore have cell 
protective effects, whereas interfering with its function may be detrimental. 
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Supplemental table S1 Primers used for cloning 
Primers 5’-3’ 
AKIP1-foward GAAGGATCCGTCGACATGGAATACTGCCTGGCGGC 
AKIP1-reverse GAACTCGAGTCATACGGGGAACACCAAGTCCAC  
siAKIP1-forward GATCCCGTGGTTGCAGTTGACTCGTTCAAGAGAGACCGAGTCAACTGCAACCACTTTTTGGAAA  







Supplemental figure 1 AKIP1 silencing and ATP-linked OCR.  
OCR was measured as described in the materials and methods and calculation of ATP-
linked OCR was similar as described in figure 1C. (*P<0.05 as compared to cont. group, 
#P<0.05 compared to siAKIP1 group, n=4). Values are presented as mean ± SEM. 
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Supplemental table S2 Primers used for Real-Time PCR 
Genes 5’-3’ forward  5’-3’ reverse 
CyclophilinA CAGATCGAGGGATCGATTCAG  TCACCACTTGACACCCTCATTC 
AKIP1 TGGTCCAGGAAGCATCTATC  CAACCACATGCGTCTTCTTG 
PGC-1α ACCGTAAATCTGCGGGATGATG  CATTCTCAAGAGCAGCGAAAGC 
ERRa GTGGCCGACAGAAGTACAAG  GGTTCAACCACCAGCAGATG 
NRF1 TTGGAGCACTTACTGGAGTC  CTTCCGCCATAATGAATCCC 
TRPM-2 GTACAACGAGCTGCTTCATTCC  GCACCTCTAAGAGGCATCCATC 
TRPM-2 CCTCCCATTCATTATCGCCGCCCTTGC  GTCTGGGTCTCCTAGTAGGTCTGGGAA 
CYTB TGGCTTGGCTTCAATAAGGA  AAGGTAGTAAGCGTGCTCCCACAC 
SOD2 GCTGTGCGCGCTCCAT  CCATGTGCCCGTCGATGT 
GPX4 CAGATCGAGGGATCGATTCAG  TCACCACTTGACACCCTCATTC 
PGC-1α: Peroxisome proliferator-activated receptor gamma coactivator 1-alpha; 
ERRα: Estrogen related receptor alpha; NRF1: Nuclear respiratory factor 1; TRPM-2: 
Testosterone-repressed prostate message-2; CYTB: Cytochrome b, mitochondrial; 
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A B S T R A C T  
Recently, a genetic variant in the mitochondrial exo/endo nuclease EXOG, 
which has been implicated in mitochondrial DNA repair, was associated with 
cardiac function. The function of EXOG in cardiomyocytes is still elusive. Here 
we investigated the role of EXOG in mitochondrial function and hypertrophy in 
cardiomyocytes. 
Depletion of EXOG in primary neonatal rat ventricular cardiomyocytes 
(NRVCs) induced a marked increase in cardiomyocyte hypertrophy. Depletion 
of EXOG however, did not result in loss of mitochondrial DNA integrity. 
Although EXOG depletion did not induce fetal gene expression and common 
hypertrophy pathways were not activated, a clear increase in ribosomal S6 
phosphorylation was observed, which readily explains increased protein 
synthesis. Using a Seahorse flux analyzer, it was shown that mitochondrial 
oxidative consumption rate (OCR) was increased 2.4 fold in EXOG depleted 
NRVCs. Moreover, ATP-linked OCR was 5.2 fold higher. This increase was not 
explained by mitochondrial biogenesis or alterations in mitochondrial 
membrane potential. Western blotting confirmed normal levels of the oxidative 
phosphorylation (OXPHOS) complexes. The increased OCR was accompanied by 
an 5.4 fold increase in mitochondrial ROS levels. These increased ROS levels 
could be normalized with specific mitochondrial ROS scavengers (MitoTEMPO, 
mnSOD). Remarkably scavenging of excess ROS strongly attenuated the 
hypertrophic response.  
In conclusion, loss of EXOG affects normal mitochondrial function resulting 
in increased mitochondrial respiration, excess ROS production and 
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I N T R O D U C T I O N  
The heart is one of the most energy consuming organs in the human body. 
This energy, in the form of ATP, is used to maintain proper contractile function, 
and is mainly produced by cellular respiration, in particular by oxidative 
phosphorylation (OXPHOS) in the mitochondria. There is a strict correlation 
between energy production (supply) and energy utilization (demand). As the 
heart has limited energy storage capacity, ATP generating systems must respond 
proportionally to fluctuations in demand. This energetic status of the heart is a 
delicate balance and is often disturbed in cardiovascular diseases, including heart 
failure.  
As a byproduct of oxidative phosphorylation, the mitochondria produce 
reactive oxygen species (ROS). Low levels of ROS may be protective (7, 23) and 
affect signaling pathways that may stimulate growth (5). However an imbalance 
between ROS production and the normal cellular antioxidant defense system will 
lead to oxidative stress and potentially in DNA damage (10). Therefore, cells have 
developed sophisticated DNA repair mechanisms.  
EndonucleaseG-like-1 (EXOG), a nuclear encoded mitochondrial DNA/RNA 
exo/endonuclease, is one of the proteins that has been implicated in the repair 
of mtDNA damage (22) . Specifically, EXOG depletion has been reported to 
induce apoptosis due to mitochondrial dysfunction in a range of human cell lines, 
including HeLa and MCF7 cells. Also in a myoblast cell line EXOG has been shown 
important for maintaining mtDNA integrity, but, surprisingly, this was not true 
for myotubes, implicating that EXOG is not essential in all cell types (21). Probably 
other mitochondrial exo/ endonucleases, like FEN-1 and DNA2, are sufficient for 
maintaining DNA damage integrity in these cells (20).  
The function of EXOG in cardiomyocytes has not been investigated. It is 
interesting to note, however, that in a genome- wide association study EXOG was 
shown to be associated with QRS duration, which is a risk factor for mortality, 
sudden death and heart failure (19). Moreover, loss of EndoG, another 
mitochondrial endonuclease with high sequence similarity to EXOG (2), has 
recently been shown to induce cardiac hypertrophy (15). Although EndoG was 
originally believed to be a main regulator of caspase-independent regulation of 
DNA fragmentation and apoptosis (1, 17) these new results suggest additional 
functions of this enzyme. Based on the current EXOG knowledge, and in analogy 
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to EndoG, we hypothesized that EXOG would have additional functions in 
(cardio)myocytes.  
The aim of the present study was thus to investigate the function of EXOG 
in cardiomyocytes, in particular its potential role in hypertrophy next to its role 
in mtDNA repair. 
 
M E T H O D S  
Isolation and culturing of primary cardiomyocytes  
Primary neonatal rat ventricular cardiomyocytes (NRVCs) were isolated 
from neonatal rats of 1-3 days old, as previously described (12, 14). The use of 
animals for these studies was in accordance with the NIH Guide for the Care and 
Use of Laboratory Animals. The study was submitted to and approved by the 
Committee for Animal Experiments of the University of Groningen. NRVCs were 
grown in DMEM supplemented with 5% fetal calf serum (FCS) and penicillin-
streptomycin (100U/ml-100μg/ml). NRVCs were infected with recombinant 
adenovirus particles (MOI50) 24 hours after isolation and serum starved in 
DMEM with penicillin-streptomycin (100U/ml-100μg/ml) the next day. 
Stimulation of cells with 50 μM phenylephrine (PE) was done for 24 hours after 
24 hours of starvation. A schematic depiction of the culturing procedure is shown 
in Figure 1A. 
All media and supplements were purchased from Sigma-Aldrich Chemie 
B.V., Zwijndrecht, the Netherlands. 
 
Adenoviral constructs generation and infection 
Adenoviral constructs were generated with the ViraPowerTM adenoviral 
expression system from Invitrogen using specific siRNA oligo pair (forward : 
GATCCCGGGTGGAACCTGACGATTATTCAAGAGATAATCGTCAGGTTCCACCCTTTTT
GGAAA; reverse : AGCTTTTCCAAAAAGGGTGGAACCTGACGATTATCTCTTGAATAA 
TCGTCAGGTTCCACCCGG) against the rat EXOG gene. The annealed primers were 
cloned into a pENTR4 vector containing a H1-promoter and a GFP marker gene. 
Recombinant adenovirus was generated as previously described (13). For 
adenoviral infections, neonatal ventricular cardiomyocytes were infected with 
an MOI of 50.  
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Quantitative real time PCR 
Total RNA was isolated using a nucleospin RNA II kit (Bioke; Leiden, The 
Netherlands) and cDNA was synthesized using QuantiTect Reverse 
Transcriptional kit (Qiagen, Venlo, the Netherlands) following manufacturer’s 
instructions. Relative gene expression was determined by quantitative real time 
PCR (qRT-PCR) on the Bio-Rad CFX384 real time system (Bio-Rad, Veenendaal, 
the Netherlands) using ABsolute QPCR SYBR Green mix (Thermo Scientific, 
Landsmeer, the Netherlands). Gene expressions were corrected for reference 
gene values (36B4), and expressed relative to the control group. Primer 
sequences can be found in Table 1.  
 
Table 1. Primers used for real-time PCR 
Gene 5’- 3’ Forward  5’- 3’ Reverse 
EXOG  TCGGGACCTTTAACCTTACC  ACATTGTCCTCACCGATCAC 
36B4  GTTGCCTCAGTGCCTCACTC  GCAGCCGCAAATGCAGATGG 
Mt D-loop 
short  
TCGGATGCCTTCCTCAACATAG  TGCTGACCTTCATGCCTTGAC 
Mt D-loop 
long  
CTACCATCCTCCGTGAAATC  ACCAACCCTGAGAGGTATAG 
TRPM-2  GTACAACGAGCTGCTTCATTCC  GCACCTCTAAGAGGCATCCATC 
CYTB  CCTCCCATTCATTATCGCCGCCCTTGC  GTCTGGGTCTCCTAGTAGGTCTGGGAAA 
 
Western blot 
Protein was isolated with RIPA buffer (50 mM Tris pH 8.0, 1% nonidet P40, 
0.5% deoxycholate, 0.1% SDS, 150 mM NaCl) supplemented with 10 µl/ml 
phosphatase inhibitor cocktail 1 (Sigma-Aldrich Chemie B.V., Zwijndrecht, the 
Netherlands), protease inhibitor cocktail (Roche Diagnostics Corp., Indianapolis, 
IN, USA) and 1mM phenylmethylsulfonyl fluoride (PMSF) (Roche Diagnostics 
Corp., Indianapolis, IN, USA)). Protein concentrations were determined with a DC 
protein assay kit (Bio-Rad, Veenendaal, the Netherlands). Equal amounts of 
proteins were separated by SDS-PAGE and proteins were transferred onto PVDF 
membranes. The following antibodies were used : anti-OXPHOS cocktail 
(MitoSciences, Eugene, Oregon, USA), anti-EXOG, anti-pERK1/2 (Santa Cruz 
Biotechnology Dallas, Texas, USA), anti-tERK1/2 (Santa Cruz Biotechnology 
Dallas, Texas, USA), anti-pAkt (Cell Signaling Technology Danvers, MA, USA), anti-
tAkt (Cell Signaling Technology Danvers, MA, USA), anti-pS6 (Cell Signaling 
Technology Danvers, MA, USA), anti-tS6 (Cell Signaling Technology Danvers, MA, 
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USA) and anti-GAPDH (Fitzgerald Industries International, North Acton, MA, USA) 
at a dilution of 1:1000. After incubation with HRP-conjugated secondary 
antibodies, signals were visualized with ECL and analyzed with densitometry 
(ImageQuant LAS4000, GE Healthcare Europe, Diegem, Belgium). 
 
[3H]-leucine incorporation 
Cells were grown in 12-well plates and 24 hours after starvation L-[4,5-
3H]leucine (1 μCi/mL, PerkinElmer) was added in either the presence or absence 
of 50 µM PE. Cells were cultured for an additional 24 hours and L-[4,5-3H]Leucine 
incorporation was determined as previously described (12).  
 
Cell size measurement 
NRVCs were grown on coverslips coated with laminin (Millipore, 
Amsterdam, The Netherlands). After adenoviral infection and serum starvation, 
cells were washed with PBS and fixed for 10 min with paraformaldehyde buffer 
at 4 °C, followed by permeabilization with 0.5% TritonX for 5 min. Cells were 
incubated with monoclonal anti-α-actinin antibody (Sigma-Aldrich Chemie B.V., 
Zwijndrecht, the Netherlands) in 1% BSA/PBS for 1 hour at RT. Cells were washed 
and incubated for another hour with Alexa-555 secondary antibody (Invitrogen 
Life Technologies Europe BV, Bleiswijk, The Netherlands). Coverslips were 
mounted with mounting medium containing DAPI for counterstaining of the 
nuclei and slides were imaged using a TissueFAXs (AxioObserver Z1 microscope, 
Carl Zeiss, Jena, Germany) and cell size was determined by TissueQuest 
fluorescence analysis software. 
 
DNA damage and mtDNA / nDNA ratio 
Total DNA including mitochondrial DNA (mtDNA) was extracted from cells 
using the DNA Blood and tissue Kit (Qiagen, Venlo, the Netherlands) and DNA 
purity and quantity was determined by spectroscopic analysis. The isolated DNA 
showed high purity (A260/A280 > 1.8).  
A semi-long run quantitative real time qRT-PCR was performed as described 
before (18).The D-loop mitochondrial genomic region was targeted since this 
part of the mitochondrial genome is described to be the most susceptible to DNA 
damage (18). To evaluate the DNA damage lesions in this specific region, two 
mtDNA fragments of different length were used (Table 1). The PCR protocol 
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included an incubation step at 95° C for 10 min, followed by 40 cycles of 10s at 
95° C, 10s at 60° C and 10s 72° C (small fragments) or 50s 72° C (long fragments), 
respectively. DNA from untreated samples was taken as a control. For the 
quantification of damage in the mtDNA, qRT-PCR analysis for the corresponding 
long and short fragments was performed.  
To determine the ratio between mitochondrial and nuclear DNA, relative 
gene expression was determined by qRT-PCR on a Bio-Rad CFX384 real time 
system using SYBR Green dye. Mitochondrial gene expressions were corrected 
for nuclear gene expression values, and the calculated values were expressed 
relative to the control group per experiment. Primer sequences are listed in Table 
1. 
 
Lactate dehydrogenase activity 
Oxidative stress derived cytotoxicity was monitored by the lactate 
dehydrogenase (LDH) release assay. LDH activity was determined in cell culture 
medium using the Roche IFCC liquid assay on the modular analysis according to 
the manufacturer’s instructions (Roche, Mannheim, Germany). 
 
Seahorse mitochondrial flux analyses 
To determine the oxidative consumption rate (OCR) in cardiomyocytes, a 
Seahorse metabolic flux analyzer (Seahorse Biosciences, Massachusetts, USA) 
was used as previously described (24). Neonatal cardiomyocytes were seeded at 
a density of 100.000 cells/well in special Seahorse 24 well plates. Cells were 
adenoviral infected and treated as described above. One hour before initiation 
of measurements, medium was replaced with XF medium supplemented with 10 
mM glucose or 1 mM pyruvate and incubated for 1 hour in a CO2 free 37°C 
incubator. The basal respiration of the cells was measured followed by injection 
of oligomycin (ATP synthase inhibitor) (1 µM) to measure the ATP linked OCR. 
The uncoupler carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) 
(0.5 µM) was used to determine maximal respiration. Prior to the experiments a 
titration curve to determine optimal FCCP concentration was performed and 
revealed that 0.5 µM FCCP was the optimal concentration. Rotenone (1 µM) and 
antimycin A (1 µM), to inhibit complex I and III respectively, were injected to 
determine the non-mitochondrial respiration. The mitochondrial OCR was 
calculated by extracting the non-mitochondrial respiration from the basal 
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respiration. In each plate the same treatment was performed in triplicate or 
quadruple and each experiment was performed at least 3 times. OCR was 
corrected for the amount of total protein in each well. 
 
Citrate synthase assay and ATP concentration 
Whole cell citrate synthase activity was measured using an enzyme assay kit 
(Sigma-Aldrich Chemie B.V., Zwijndrecht, the Netherlands) according to the 
manufacturer’s instructions. Cell lysates were prepared using the CelLytic M Cell 
Lysis Reagent and protein concentrations were measured with a DC protein assay 
kit (Bio-Rad, Veenendaal, the Netherlands). 8 μg of protein was combined with 
Acetyl CoenzymeA , 5,5’-Dithiobis-(2-nitrobenzoic acid) (DTNB) and assay buffer 
in a 96 well plate. The reaction was initiated by adding oxaloacetate into the 
mixture and total activity was measured. Absorbance was measured at 412 nm 
using a spectrophotometer following a kinetic program. Triplicate 
measurements were performed on each sample and 5 independent samples 
were measured for each group. 
ATP concentrations were measured with bioluminescence assay kit CLS II 
(Roche, Mannheim, Germany) following manufacturer’s instructions with 
modifications. In short, cells were lysed by adding 1.5% TCA with NaF (1 mM) and 
subsequently diluted in 1M Tris buffer (pH 8.0) containing NaF (1 mM). Reaction 
was initiated by dispensing Luciferase reagent simultaneously in all wells. 
Luminescence was recorded with SynergyH4 Hybrid Reader (BioTek, Vermont, 
USA). 
 
Determination of mitochondrial membrane potential and ROS 
production 
Mitochondrial membrane potential (ΔΨm) was assessed by 
tetramethylrhodamine ethyl ester (TMRE), as described before (24). In brief, cells 
were seeded at a density of 40.000 cells/well in a black 96 well plates and 
cultured as described above. TMRE (100nM) was added and incubated for 20 
minutes at 37 °С. Cells were subsequently washed with 0.2% BSA in PBS, and 
fluorescence was measured at 575 nm with a SynergyH4 Hybrid Reader (BioTek, 
Vermont, USA). As a control, FCCP (1 μM) was used to eliminate mitochondrial 
membrane potential. 
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Mitochondrial ROS production was determined using MitoSOX red 
mitochondrial superoxide indicator (Molecular Life Technologies Europe BV, 
Bleiswijk, The Netherlands) as described before (24). Briefly, cells were plated in 
96 well plates and treated as described above. Cells were subsequently 
incubated with MitoSOX (5 μM) in KRPH buffer (20mM Hepes, 5mM KH2PO4, 
1mM MgSO4, 1mM CaCl2, 136 mM NaCl, 4.7 mM KCl pH 7.4) for 10 min at 37 °С, 
and thereafter washed three times with the same buffer. Fluorescence was 
measured using excitation/emission maxima of 510/580 nm with a SynergyH4 
Hybrid Reader (BioTek, Vermont, USA). For both assays, each experiment was 
measured in quadruplicate and five independent experiments were performed. 
 
Statistical analysis 
All values are presented as means ± standard errors of the mean (SEM). 
Independent-samples t-test was performed to compare the difference between 
both groups. One-way ANOVA with post-hoc Bonferroni test was used to 
compare the difference between multiple groups. P<0.05 was considered to be 
significant. SPSS software (PASW Statistics 18) was used for the statistical 
analyses.  
 
R E S U LT S  
Depletion of EXOG does not affect mtDNA integrity in neonatal 
cardiomyocytes 
Neonatal rat ventricular cardiomyocytes (NRVCs) were cultured and treated 
according to the scheme in Figure 1A. Using an adenoviral EXOG siRNA construct 
we tested the effect of EXOG depletion/loss of function on NRVCs. Figures 1B - D 
show that the expression of EXOG was substantially repressed both at the mRNA 
and protein level after 72 hours of adenoviral infection. Silencing of EXOG did not 
increase the level of mtDNA damage as compared to control cells (Figure 1 E), as 
determined by a previously described PCR method (18). DNA damage lesions 
were readily detected in H2O2 treated NRVCs, validating this method (Figure 1F). 
Also cell viability was not affected by silencing of EXOG, as LDH levels in cell 
culture medium were not increased in EXOG silenced cells as compared to 
control cells (Figure 1G) and cell numbers remained similar in both control and 
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Thus under these conditions, EXOG was not essential for maintaining mtDNA 
integrity. 
Figure 1 Depletion of EXOG does not affect mtDNA integrity in neonatal 
cardiomyocytes 
A. Neonatal rat cardiomyocytes were isolated and cultured according to the scheme. 
After 72 hr of adenoviral infection mRNA was isolated and protein lysates were 
prepared. B. By RT-PCR relative EXOG mRNA levels were determined and normalized to 
36B4 (n=5). C. EXOG protein levels were determined by Western blotting and corrected 
for GAPDH expression (N=5). D. A representative Western blot is shown. E. A semi-long 
run PCR was performed using primers specific for mtDNA fragments in the mitochondrial 
D-loop region in order to determine mtDNA damage (N=11). F. Different concentration 
of H2O2 were used to induce mtDNA damage, which was analysed using a semi-long run 
PCR. G. Cell death was indirectly quantified by measuring lactate dehydrogenase (LDH) 
activity in cell culture medium (N=6-8). *P < 0.05 as compared to control, N.S. = not 
significant.  
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EXOG silencing induces hypertrophy in neonatal cardiomyocytes. 
Since the EXOG locus has been linked to cardiovascular disease (19) and 
Endog has been shown to be involved in cardiomyocyte growth (15), we next 
investigated whether EXOG could induce hypertrophy in NRVCs. A significant 
Figure 2 EXOG silencing induces hypertrophy in neonatal cardiomyocytes 
A. To determine cellular protein synthesis NRVCs were incubated with 3 H-Leucine. This 
was performed for control, EXOG depleted and PE treated cells and fold changes are 
shown relative to the control (N=8-10). B. Cell size was measured to determine cellular 
hypertrophy. Cardiomyocytes were specifically stained with an á-actinin antibody and 
nuclei were counterstained with DAPI. Cell surface area of at least 1000 cells/experiment 
were determined and fold changes as compared to the control were determined ( N=6-
9). C. Representative microscopy images are shown. D. RT-PCR analysis was performed 
to determine ANP gene expression. ANP mRNA expression was normalized to 36B4 
expression and relative levels are shown (N=9). E. Western blot quantification of main 
signal transduction pathways involved in hypertrophy. Phosphorylated proteins (P-
ERK1/2, P-Akt, and P-S6) were quantified in relation to the total amounts of the 
respective proteins (T-ERK1/2, T-Akt, and T-S6). Levels in EXOG depleted cells are shown 
relative to control cells (dashed line) (N=5). F. Representative Western Blots are shown. 
*P < 0.05 as compared to control. 
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increase in both protein synthesis and cell size was observed after silencing of 
EXOG (Figure 2A-C). The increase in cell size was comparable to PE-induced 
hypertrophy. In contrast to PE-stimulated cells, the expression of the 
pathological stretch marker ANP was not increased in EXOG depleted NRVCs 
(Figure 2D). We also investigated main signaling pathways involved in 
hypertrophy, including ERK1/2 and Akt, but did not observe activation of these 
pathways after silencing of EXOG (Figure 2E,F). In contrast, we observed a strong 
increase in phosphorylation of ribosomal protein S6 (rpS6), a protein involved in 
protein elongation and synthesis (Figure 2E,F). Thus, EXOG depletion activates 
protein synthesis, resulting in hypertrophy of NRVCs, but this is not mediated via 
common pathways. 
 
EXOG depletion increases mitochondrial OCR 
Based on the mitochondrial localization of EXOG and its effect on cell 
growth we decided to investigate changes in mitochondrial function, in particular 
mitochondrial respiration. Using a seahorse metabolic flux analyzer cellular 
oxygen consumption rates (OCR) were determined.  
Total oxygen consumption rates are shown in Figure 3A. The measured 
increase in respiration was determined to be mitochondrial specific, since it was 
blocked by antimycin A/rotenone (A/R). Based on these data the mitochondrial 
specific respiration was calculated (A/R OCR levels subtracted from Total OCR 
levels). This revealed that silencing of EXOG increased mitochondrial OCR with 
2.4-fold as compared to control cells (OCR 4.8 and 11.6 pmol O2/min/µg protein, 
respectively) (Figure 3B). The OCR was corrected for protein concentration to 
correct for possible effects of hypertrophy on respiration. When corrected only 
for cell numbers the difference in mitochondrial respiration between control and 
EXOG depleted cells was even more pronounced (3.1-fold increase in EXOG 
depleted cells). By adding the ATP synthase inhibitor oligomycin to the cells, the 
ATP-linked OCR could be determined. As shown in Figure 3C, ATP-linked 
respiration was increased in EXOG depleted cells by more than 5-fold. The total 
ATP concentration in EXOG depleted cells was only marginally increased (Figure 
3D ), indicating that ATP utilization was also increased. Although not significant, 
an apparent increase in maximal respiration, induced with the uncoupler FCCP, 
and the reserve capacity, which is the difference between maximal respiration 
and basal cellular respiration, were observed (Figure3E and 3F).  
4EXOG affects mitochondrial respiration and ROS mediated cardiac hypertrophy 
92 
increase in both protein synthesis and cell size was observed after silencing of 
EXOG (Figure 2A-C). The increase in cell size was comparable to PE-induced 
hypertrophy. In contrast to PE-stimulated cells, the expression of the 
pathological stretch marker ANP was not increased in EXOG depleted NRVCs 
(Figure 2D). We also investigated main signaling pathways involved in 
hypertrophy, including ERK1/2 and Akt, but did not observe activation of these 
pathways after silencing of EXOG (Figure 2E,F). In contrast, we observed a strong 
increase in phosphorylation of ribosomal protein S6 (rpS6), a protein involved in 
protein elongation and synthesis (Figure 2E,F). Thus, EXOG depletion activates 
protein synthesis, resulting in hypertrophy of NRVCs, but this is not mediated via 
common pathways. 
 
EXOG depletion increases mitochondrial OCR 
Based on the mitochondrial localization of EXOG and its effect on cell 
growth we decided to investigate changes in mitochondrial function, in particular 
mitochondrial respiration. Using a seahorse metabolic flux analyzer cellular 
oxygen consumption rates (OCR) were determined.  
Total oxygen consumption rates are shown in Figure 3A. The measured 
increase in respiration was determined to be mitochondrial specific, since it was 
blocked by antimycin A/rotenone (A/R). Based on these data the mitochondrial 
specific respiration was calculated (A/R OCR levels subtracted from Total OCR 
levels). This revealed that silencing of EXOG increased mitochondrial OCR with 
2.4-fold as compared to control cells (OCR 4.8 and 11.6 pmol O2/min/µg protein, 
respectively) (Figure 3B). The OCR was corrected for protein concentration to 
correct for possible effects of hypertrophy on respiration. When corrected only 
for cell numbers the difference in mitochondrial respiration between control and 
EXOG depleted cells was even more pronounced (3.1-fold increase in EXOG 
depleted cells). By adding the ATP synthase inhibitor oligomycin to the cells, the 
ATP-linked OCR could be determined. As shown in Figure 3C, ATP-linked 
respiration was increased in EXOG depleted cells by more than 5-fold. The total 
ATP concentration in EXOG depleted cells was only marginally increased (Figure 
3D ), indicating that ATP utilization was also increased. Although not significant, 
an apparent increase in maximal respiration, induced with the uncoupler FCCP, 
and the reserve capacity, which is the difference between maximal respiration 





Similar results were obtained using pyruvate as a substrate, indicating that 
the findings are not explained by increased glycolysis (data not shown). In 




Figure 3 EXOG silencing increases mitochondrial metabolism 
OCR in control or EXOG silenced NRVC. Metabolic flux was measured using a Seahorse 
metabolic flux analyzer, with glucose (10mM) as a substrate. A. Representative graph 
showing the OCR in cultured NRVCs. Addition of oligomycin (oligo), FCCP and antimycin 
A and rotenone (A/R) is indicated. B. Quantification of mitochondrial OCR, which is the 
calculated difference between the basal respiration and the OCR after addition of A/R. 
C. Quantification of ATP-linked OCR which is the calculated difference between the basal 
level and the OCR after oligomycin treatment. D. Total cellular ATP concentrations were 
measured using a luminescence assay (n=4). E. Quantification of maximal respiration 
induced by the uncoupler FCCP. F. Quantification of reserve OCR capacity, calculated 
from the difference between the basal mitochondrial respiration and the maximal 
respiration. OCR was corrected for total protein levels in each well (pmoles O2/min/µg) 
(N=7).*p<0.05 as compared to control, N.S. = not significant. 
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EXOG depletion does not affect expression levels of electron transport 
chain (ETC) proteins or mitochondrial biosynthesis 
The elevated mitochondrial respiration in EXOG depleted NRVCs could be a 
result of increased mitochondrial biogenesis or the result of intrinsic changes in 
the mitochondria. The ratio between mtDNA and nDNA, an established measure 
of mitochondrial biogenesis, was similar between control and EXOG depleted 
cells (Figure 4A). In addition, citrate synthase activity an independent measure 
of mitochondrial biogenesis, was also not altered (Figure 4B).  
As shown in Figure 4C and D, no expression differences between the 
different complexes of the ETC were observed in an OXPHOS Western blot. 
Although this does not rule out that the activity of these complexes might be 
altered by posttranslational modifications, it at least shows that changes in 
expression levels cannot account for the increased OCR. 
 
Loss of EXOG induces ROS production 
Changes in mitochondrial function can result in the formation of ROS. We 
therefore analysed ROS production in mitochondria using MitoSOX. As shown in 
Figure 5A, ROS levels in mitochondria were significantly elevated in EXOG 
depleted cells. Only a limited increase in fluorescence was observed with DHE, 
which is expected since it lacks the mitochondrial localization signal which is 
present in MitoSOX (Figure 5B). Another, cytoplasmic specific, ROS sensor 
CellROX, did not show increased fluorescence in EXOG depleted cells, further 
confirming the mitochondrial specificity (data not shown). 
Because an increase in mitochondrial ROS production could be the result of 
increased membrane potential, TMRE was used to determine mitochondrial 
membrane potential. No difference in mitochondrial membrane potential 
between control and EXOG depleted cells was seen (Figure 5C). To determine 
specificity, we analysed the membrane potential in FCCP treated cells, which 
resulted as expected in a marked decrease in mitochondrial membrane 
potential. Together, this shows that EXOG depletion results in an altered 
mitochondrial flux and an increase in ROS production.  
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Figure 4 Increase in mitochondrial respiration is not a result of mitochondrial 
biogenesis 
A. Mitochondrial DNA (CYTB) to nuclear DNA (TRPM-2) ratio (mtDNA/nDNA) was 
determined by RT-PCR on DNA samples from control infected cells and EXOG depleted 
cells. No statistical significant difference was observed between the groups (N=5). B. 
Citrate synthase activity, a measure of the amount of mitochondria, was determined in 
cellular lysates. No significant differences were observed between the EXOG depleted 
cells as compared to control cells (N= 5). C-D. Western blotting using an OXPHOS 
antibody-panel, detecting components of the different electron transport chain complex 
(ETC), was used to determine ETC levels. All levels were normalized for GAPDH levels. 
No significant differences ETCs were observed between the control group and EXOG 
depleted NRVCs as shown by a representative Western Blot and quantification (N= 3). 
*p<0.05 as compared to control 
 




Scavenging ROS attenuates hypertrophy in EXOG depleted cells without 
significantly affecting mitochondrial metabolism 
Previous studies have shown that increased ROS levels could induce 
hypertrophy development (10). To investigate whether reducing ROS in EXOG 
depleted cells could attenuate hypertrophy the mitochondrial ROS scavenger 
MitoTEMPO was used.  
ROS levels were reduced to baseline levels with this scavenger ( Figure 5D). 
A similar reduction was obtained with the ROS scavenger mnSOD. In contrast, 
addition of a cellular scavenger, Catalase, did not reduce MitoSOX fluorescence, 
indicating that mitochondrial ROS is responsible for this effect (data not shown). 
Figure 5 Scavenging ROS attenuates hypertrophy in EXOG depleted cells without 
significantly affecting mitochondrial metabolism 
Figure legend on page 97. 
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Interestingly, as shown in Figure 5E, 3H-Leucine incorporation was significantly 
lower in MitoTEMPO treated EXOG depleted cells as compared to EXOG depleted 
cells without this ROS scavenger. Cell size of EXOG depleted cells treated with 
MitoTEMPO was also determined. In line with the reduction in protein synthesis 
an attenuation of cell size in MitoTEMPO treated EXOG depleted cells was 
observed, as shown in Figure 5F. This suggests that hypertrophy development in 
EXOG depleted cells is predominantly mediated by increased ROS levels, as 
schematically depicted in Figure 6.  
MitoTEMPO did not significantly affect EXOG depletion mediated OCR 
increase (Figure 5G). This indicates that the increased OCR is predominantly ROS 
and hypertrophy independent and directly a result of EXOG depletion. These 
findings are schematically depicted in Figure 6. 
 
D I S C U S S I O N  
In this study, we show that depletion of EXOG, a protein implicated in 
mitochondrial DNA repair, did not affect mtDNA integrity in neonatal 
cardiomyocytes. Surprisingly, EXOG depletion resulted in a marked induction of  
Figure 5 Scavenging ROS attenuates hypertrophy in EXOG depleted cells without 
significantly affecting mitochondrial metabolism 
A. Mitochondrial specific ROS production was measured with MitoSOX and specific 
fluorescence was determined. In EXOG depleted cells a significant increase in ROS 
production was observed as compared to control cells (N=9). B. Cellular ROS levels were 
measure using DHE. A slight, but not significant increase in fluorescence level was 
observed in EXOG silenced cells (N=4). C. Mitochondrial membrane potential, measured 
by cellular labelling with TMRE, was not different between groups. As a control, the 
depolarizing compound FCCP was added, which resulted in a significant reduction of 
TMRE fluorescence (N=5). D. The increase in EXOG depletion induced mitochondrial ROS 
levels could be effectively scavenged with the exogenous added mitochondrial specific 
scavenger MitoTEMPO. ROS was measured with MitoSOX, as in panel A (N=6-8). E. 3 H-
Leucine incorporation in EXOG silenced cells with and without MitoTEMPO. The increase 
in EXOG mediated hypertrophy could be attenuated with MitoTEMPO (N=6). F. 
Cardiomyocytes treated with or without MitoTEMPO were specifically stained with an 
α-actinin antibody, nuclei were counterstained with DAPI and cell surface area was 
measured (N=6). G. Mitochondrial OCR was measured in control and EXOG depleted 
cells, with or without treatment with MitoTEMPO (N=5).*p<0.05 as compared to 
control; #p<0.05 compared with EXOG silenced NRVCs control. 




hypertrophy in these cells. EXOG depletion is not associated with increased 
activity of hypertrophic common signaling pathways or mitochondrial 
biogenesis. Instead, EXOG depletion markedly increased mitochondrial 
respiration, which was accompanied by an increase in mitochondrial ROS 
emissions. Scavenging of mitochondrial ROS attenuated hypertrophy 
development in EXOG depleted cells, suggesting that hypertrophy induced by 
diminished EXOG levels is dependent on mitochondrial ROS. Together these 
findings indicate that EXOG has a pivotal role in the control of mitochondrial 
respiration and ROS emissions and has functions beyond mtDNA repair. In 
Figure 6 Schematic depiction of different roles of EXOG 
In proliferating tumor cells a function of EXOG in maintaining mtDNA integrity has been 
proposed (left part). Here we showed that EXOG function is also involved in maintaining 
normal mitochondrial flux in cardiomyocytes (middle part). Moreover, increased ROS 
production in EXOG depleted cells can stimulate cardiomyocyte hypertrophy (right 
part).  
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addition, the current study provides a clear precedent for the role of reverse 
mitochondrial signaling in the control of critical cellular responses such as 
hypertrophy. 
Depletion of EXOG did not result in mtDNA damage in neonatal 
cardiomyocytes. This does not exclude that under specific stress conditions or 
upon prolonged depletion DNA damage might increase in EXOG depleted NRVCs. 
In Hela cells, a similar time period of EXOG depletion was sufficient to cause 
extensive damage. This indicates that cardiomyocytes are either more resistant 
to ROS mediated mtDNA damage or that other pathways operate to maintain 
proper mtDNA integrity. This is in line with Szczesny et al. (21) who showed that 
mtDNA of proliferating myoblasts was more sensitive to ROS induced damage as 
compared to non proliferating myotubes. Thus, the importance of EXOG in 
mtDNA repair appears to be cell type specific. Perhaps that other mitochondrial 
exo/ endonucleases, like FEN-1 and DNA2, can take over EXOG function or are 
sufficient for maintaining mtDNA integrity in these cells (20).Alternatively, EXOG 
might be more important in maintaining mtDNA integrity during DNA replication 
in proliferating cells, rather than damage repair per se. Such a function has 
recently been shown for another mitochondrial exonuclease MGME1 (9) and 
may explain why proliferating cells are more prone to EXOG depletion.  
Even though EXOG does not appear to be essential for maintaining mtDNA 
integrity in cardiomyocytes , it is highly expressed in these cells. This begs the 
question why EXOG is present in these cells, and in analogy to Endog, whether 
this exonuclease has additional functions beyond DNA cleavage. Interestingly, 
mitochondrial OCR was strongly increased in EXOG depleted cardiomyocytes. 
This was independent of mitochondrial biogenesis and mitochondrial membrane 
potential and suggests an intrinsic change in mitochondrial function. So far we 
did not observe changes in ETC complex levels or ATP synthase, but we cannot 
exclude that post-translational modifications or stability of particular sub-units 
of the ETC have been altered. This would require more in depth proteomic 
investigations.  
Increased mitochondrial flux could both be beneficial and detrimental, 
depending on cellular needs and substrate supply. ATP levels remained normal 
in EXOG depleted cells, and hence no detrimental imbalance between ATP 
production and requirement was observed. Increased metabolic flux is also 
strongly linked to increased ROS production, which is one of the main 
mechanisms behind cellular ageing (4, 7). Indeed, we did observe increased 
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mitochondrial ROS production in EXOG depleted cells. Although MitoSOX and 
other DHE based fluorescent dyes are sensitive sensors for superoxide also other 
oxidants can affect their fluorescent properties (25). An increase in MitoSOX 
fluorescence could also indicate an impairment in the mitochondrial antioxidant 
system. Although we cannot fully exclude this possibility, no changes in mRNA 
levels of components of the antioxidant systems (MnSOD, Catalase) were 
observed (data not shown). Mitochondrial ROS production has been linked to 
hypertrophy development (6, 11) and interestingly we observed hypertrophy in 
EXOG depleted NRVCs as determined by increased protein synthesis and cell size 
surface area. We checked the main hypertrophic signaling pathways, including 
activation of the pathological ERK signaling pathway and the physiological AKT 
signaling pathway, but, interestingly did not observe activation of these 
pathways. Thus hypertrophy stimulation was not mediated via these canonical 
pathways. rpS6 phosphorylation was, however, strongly enhanced in EXOG 
depleted cells. rpS6 directly controls protein translation and cellular growth and 
is a key cell size determination and hence would readily explain the observed 
hypertrophic effects (16). Interestingly, we did not observe an increase in the 
pathological stress marker, ANP, suggesting that these levels of ROS did not 
provoke a general stress response in these cells. This is in contrast to ENDOG 
depletion that resulted in ANP induction (15), which was confirmed by us (our 
unpublished results) and shows that ENDOG and EXOG function are distinct. 
Moreover, although increased ROS production and consequent hypertrophy 
development was observed in both EXOG and ENDOG depleted cells, the 
underlying mechanisms appear to be different. In ENDOG depleted cells 
mitochondrial function and levels were impaired (15), whereas in EXOG depleted 
cells mitochondrial respiration was increased. At least for the latter case, we 
have shown here that scavenging of mitochondrial ROS attenuated hypertrophy 
development, indicating that ROS is an important driver of hypertrophy in EXOG 
depleted cells. This may also be true for other mitochondrial proteins that can 
stimulate hypertrophy and supports the idea that mitochondrial ROS scavenging 
may have clinical applications to attenuate cardiac hypertrophy development (3, 
4).  
This study was conducted with neonatal rat cardiomyocytes in vitro and 
these results cannot be directly extrapolated to cardiomyocytes in the adult 
heart. Moreover, energy demand in these cells is limited, because these 
cardiomyocytes do not perform load dependent contractions. Despite these 
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limitations, neonatal rat cardiomyocytes are an established model to investigate 
cellular hypertrophy and these results clearly show that EXOG has mitochondrial 
functions beyond mtDNA repair in cardiomyocytes. 
In conclusion, this study shows that EXOG depletion does not affect mtDNA 
integrity in neonatal cardiomyocytes. It does, however, affect mitochondrial OCR 
implicating that EXOG has additional mitochondrial functions. Interestingly, this 
resulted in increased ROS production and consequent hypertrophy development 
in neonatal cardiomyocytes.  
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A B S T R A C T  
Depletion of mitochondrial endo/exonuclease G-like (EXOG) in cultured 
neonatal cardiomyocytes stimulates mitochondrial oxygen consumption rate 
(OCR) and induces hypertrophy via reactive oxygen species (ROS). Here, we 
show that neurohormonal stress triggers cell death in endo/exonuclease G-like-
depleted cells, and this is marked by a decrease in mitochondrial reserve 
capacity. Neurohormonal stimulation with phenylephrine (PE) did not have an 
additive effect on the hypertrophic response induced by endo/exonuclease G-
like depletion. Interestingly, PE-induced atrial natriuretic peptide (ANP) gene 
expression was completely abolished in endo/exonuclease G-like-depleted 
cells, suggesting a reverse signalling function of endo/exonuclease G-like. 
Endo/exonuclease G-like depletion initially resulted in increased mitochondrial 
OCR, but this declined upon PE stimulation. In particular, the reserve capacity 
of the mitochondrial respiratory chain and maximal respiration were the first 
indicators of perturbations in mitochondrial respiration, and these marked the 
subsequent decline in mitochondrial function. Although pathological 
stimulation accelerated these processes, prolonged EXOG depletion also 
resulted in a decline in mitochondrial function. At early stages of 
endo/exonuclease G-like depletion, mitochondrial ROS production was 
increased, but this did not affect mitochondrial DNA (mtDNA) integrity. After 
prolonged depletion, ROS levels returned to control values, despite 
hyperpolarization of the mitochondrial membrane. The mitochondrial 
dysfunction finally resulted in cell death, which appears to be mainly a form of 
necrosis. In conclusion, endo/exonuclease G-like plays an essential role in 
cardiomyocyte physiology. Loss of endo/exonuclease G-like results in 
diminished adaptation to pathological stress. The decline in maximal 
respiration and reserve capacity is the first sign of mitochondrial dysfunction 
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I N T R O D U C T I O N  
Cardiac hypertrophy is the cellular response to increased ventricular wall 
stress and can be induced by a variety of pathological stimuli like hypertension, 
valvular disease and myocardial infarction, and also by physiological stimuli 
including endurance exercise and pregnancy (1–3). Hypertrophy is deﬁned by an 
increase in cardiomyocyte size and is accompanied by enhanced protein 
synthesis and changes in sarcomere organization (4). This response is initially an 
adaptive mechanism of the heart to cope with this increased wall stress. 
However, hypertrophy induced by sustained pathological stimulation, like 
neurohormonal stimulation, is not reversible and may become maladaptive. 
Under these conditions, the initially adaptive response of compensated 
hypertrophy may advance into decompensated hypertrophy and subsequently 
result in heart failure (5). 
Hypertrophy is also accompanied by metabolic alterations and changes in 
mitochondrial energy production in the muscle cells, including altered substrate 
utilization (6,7). It is more and more recognized that mitochondrial dysfunction 
is an important event in the development of heart failure (8). This is plausible, as 
the heart is the most energy-consuming organ in the body and is largely 
dependent on mitochondrial metabolism to generate energy in the form of ATP 
to sustain proper cardiac function (9). Although the basic aspects of 
mitochondrial metabolism and energetics, including electron transfer and ATP 
production, are well established, relatively little is known about the mechanisms 
and pathways leading to mitochondrial energetic dysfunction in hypertrophy 
(10). In heart failure, the mitochondria in cardiomyocytes appear to be intact but 
functionally impaired (8). This provides opportunities for therapeutic 
interventions, but it will require a better understanding of genes and processes 
that affect mitochondrial function. 
Besides the role of mitochondria in providing energy, they also generate 
reactive oxygen species (ROS). Under physiological conditions, minor amounts of 
ROS are produced that can be detoxiﬁed or act as signaling molecules (11). 
Changes in mitochondrial function can result in increased production of ROS, 
triggering signal transduction pathways and/or resulting in cellular damage (11). 
In addition, mitochondria play a central role in cell death mechanisms, including 
apoptosis and regulated necrosis (12,13). Thus, mitochondria have a key position 
in regulating and maintaining cellular functions. 
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Recently, we demonstrated that mitochondrial endo/ exonuclease G-like 
(EXOG) modulates mitochondrial respiration and hypertrophy in cardiomyocytes 
(14). Interestingly, the EXOG-containing locus was previously identiﬁed in a 
genome-wide association study on QRS duration, which is a risk factor for heart 
failure (15). Hence, we hypothesized that perturbed EXOG function may affect 
human heart function. We reported that in EXOG-depleted cardiomyocytes, 
mitochondrial respiration is strongly enhanced and a concomitant increase in 
ROS has been observed. These increased ROS levels triggered cell growth, 
resulting in a hypertrophic phenotype (14). In clear contrast, in EXOG-depleted 
cancer cell lines, mitochondrial DNA (mtDNA) damage was reported, resulting in 
diminished mitochondrial respiration (16). More- over, in myoblasts, but not in 
myotubes, increased EXOG levels were protective against oxidative stress (17). 
Thus, it appears that EXOG affects mitochondrial function in different ways 
depending on the cell type and the cellular environment, including cellular stress. 
The role of EXOG under cardiac stress and whether EXOG function is essential 
under these conditions are not known. Cultured neonatal rat ventricular 
cardiomyocytes (NRVCs) are an excellent in vitro model to study cardiac stress 
conditions that mimic pathological hypertrophy, like adrenergic stimulation. So, 
in this study, we investigated the role of EXOG under conditions of pathological 
cardiac stress in these non-proliferative cardiomyocytes. To this aim, we 
stimulated EXOG-depleted cardiomyocytes with phenylephrine (PE) and 
evaluated mitochondrial function, including mitochondrial respiration and cell 
death. 
 
M E T H O D S  
Isolation and culturing of primary cardiomyocytes  
The use of animals for this study was in accordance with the National 
Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals. The 
study was submitted to and approved by the Committee for Animal Experiments 
of the University of Groningen. Primary NRVCs were isolated from neonatal rats 
of 1–3 days old, as previously described (18,19). NRVCs were grown in Dulbecco’s 
modiﬁed Eagle’s medium (DMEM) supplemented with 5% fetal calf serum (FCS) 
and penicillin / streptomycin (100 U/mL to 100 μg/mL), and during the ﬁrst day, 
0.1 mM BrdU was included to prevent proliferation of ﬁbroblasts. NRVCs were 
infected with recombinant adenoviral particles [multiplicity of infection (MOI) 
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50] 24 hours after isolation and serum starved in DMEM with penicillin-
streptomycin (100 U/mL to 100 μg/mL) the next day. At this MOI, nearly all 
cardiomyocytes become infected and express green ﬂuorescent protein (GFP), 
which is co-expressed with the short hairpin RNAs (shRNA). Recombinant 
adenovirus expressing shRNAs targeting EXOG or control shRNA virus (with a 
non-speciﬁc sequence) have been described before (14). Cells were infected with 
virus for 72 or 144 hours. Stimulation of cells with 50 μM PE was carried out after 
24 hours of starvation, resulting in 24 or 96 hours of stimulation. Inhibitors Z-
VAD fmk (carbobenzoxy- valyl-alanyl-aspartyl-[O-methyl]-ﬂuoromethyl ketone) 
(20 μM) and MitoTEMPO (1 μM) were added at the same time of infection. All 
media and supplements were purchased from Sigma-Aldrich Chemie B.V., 
Zwijndrecht, the Netherlands. 
 
Hypertrophy measurements 
Protein synthesis was measured via the incorporation of radioactive labeled 
3H-leucine, as described before (20). 
For cell size measurements, NRVCs were grown on cover slips coated with 
laminin (Millipore, Amsterdam, the Netherlands) and cultured as described 
earlier. After ﬁxation for 10 minutes with paraformaldehyde, cells were 
permeabilized with 0.5% Triton X. Cells were incubated with monoclonal anti-α-
actinin antibody (Sigma-Aldrich Chemie B.V.) in 1% bovine serum albumin 
(BSA)/phosphate-buffered saline (PBS) for 1 hour at room temperature (RT). 
Cells were washed and incubated for another hour with Alexa-555 secondary 
antibody (Invitrogen Life Technologies Europe B.V., Bleiswijk, the Netherlands). 
Cover slips were mounted with mounting medium containing DAPI for 
counterstaining of the nuclei, and slides were imaged using a TissueFAXS (Axio 
Observer Z1 microscope, Carl Zeiss, Jena, Germany), and cell size was determined 
by TISSUEQUEST ﬂuorescence analysis software. 
 
Quantitative real-time polymerase chain reaction 
Total RNA was isolated using a NucleoSpin RNA II kit (Bioké, Leiden, the 
Netherlands), and cDNA was synthesized using QuantiTect Reverse Transcription 
Kit (Qiagen, Venlo, the Netherlands) following manufacturer’s instructions. 
Relative gene expression was determined by quantitative real-time polymerase 
chain reaction (qRT-PCR) on the Bio-Rad CFX384 real-time system (Bio-Rad, 
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Veenendaal, the Netherlands) using ABsolute qPCR SYBR Green Mix (Thermo 
Scientiﬁc, Landsmeer, the Netherlands). NPPA [atrial natriuretic peptide (ANP)] 
gene expression was corrected for reference gene values (36B4) and expressed 
relative to the control group. Primer sequences included ANP forward 
atgggctccttctccatcac, ANP reverse tctaccggcatcttctcctc, 36B4 forward 
gttgcctcagtgcctcactc and 36B4 reverse gcagccgcaaatgcagatgg. 
 
Seahorse mitochondrial flux analyses 
To determine oxygen consumption rate (OCR) in cardiomyocytes, a 
Seahorse metabolic ﬂux analyzer (Seahorse Bioscience, North Billerica, MA, USA) 
was used as previously described (21). 
Neonatal cardiomyocytes were seeded at a density of 100,000 cells per well 
in special Seahorse 24-well plates. Cells were adenoviral infected and treated as 
described earlier. One hour before initiation of the Seahorse measurements, 
medium was replaced with XF medium supplemented with 10 mM glucose and 
incubated for 1 hour in a CO2-free 37 °C incubator. Basal respiration of cells was 
measured, followed by injection of oligomycin (ATP synthase inhibitor) (1 μM) to 
measure ATP-linked OCR. The uncoupler carbonyl cyanide 4-
(triﬂuoromethoxy)phenylhydrazone (FCCP) (0.5 μM) was used to determine 
maximal respiration. Finally, rotenone (1 μM) and antimycin A (1 μM), inhibiting 
complexes I and III, respectively, were injected to determine the non-
mitochondrial respiration. In each plate, the same treatment was performed in 




Total DNA including mtDNA was extracted from cells using the DNeasy 
Blood & Tissue Kit (Qiagen), and DNA purity and quantity were determined by 
spectroscopic analysis. The isolated DNA showed high purity (A260/A280 > 1.8). 
The D-loop mitochondrial genomic region was ampliﬁed by PCR because this part 
of the mitochondrial genome is described to be the most susceptible to DNA 
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Seahorse mitochondrial flux analyses 
To determine oxygen consumption rate (OCR) in cardiomyocytes, a 
Seahorse metabolic ﬂux analyzer (Seahorse Bioscience, North Billerica, MA, USA) 
was used as previously described (21). 
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in special Seahorse 24-well plates. Cells were adenoviral infected and treated as 
described earlier. One hour before initiation of the Seahorse measurements, 
medium was replaced with XF medium supplemented with 10 mM glucose and 
incubated for 1 hour in a CO2-free 37 °C incubator. Basal respiration of cells was 
measured, followed by injection of oligomycin (ATP synthase inhibitor) (1 μM) to 
measure ATP-linked OCR. The uncoupler carbonyl cyanide 4-
(triﬂuoromethoxy)phenylhydrazone (FCCP) (0.5 μM) was used to determine 
maximal respiration. Finally, rotenone (1 μM) and antimycin A (1 μM), inhibiting 
complexes I and III, respectively, were injected to determine the non-
mitochondrial respiration. In each plate, the same treatment was performed in 




Total DNA including mtDNA was extracted from cells using the DNeasy 
Blood & Tissue Kit (Qiagen), and DNA purity and quantity were determined by 
spectroscopic analysis. The isolated DNA showed high purity (A260/A280 > 1.8). 
The D-loop mitochondrial genomic region was ampliﬁed by PCR because this part 
of the mitochondrial genome is described to be the most susceptible to DNA 






Determination of mitochondrial membrane potential 
Mitochondrial membrane potential (ΔΨm) was assessed by 
tetramethylrhodamine ethyl ester (TMRE), as described before (21). In brief, cells 
were seeded at a density of 40,000 cells per well in a black 96-well plate and 
cultured as described earlier. TMRE (100 nM) was added and incubated for 20 
minutes at 37 °C. Cells were subsequently washed with 0.2% BSA in PBS, and 
ﬂuorescence was measured at an excitation of 549 nm and emission of 575 nm 
with a SynergyH4 Hybrid Reader (BioTek, Winooski, VT, USA). As a control, FCCP 
(1 μM) was used to eliminate mitochondrial membrane potential. Each 
experiment was measured in quadruplicate. 
 
Mitochondrial ROS 
Mitochondrial ROS production was determined using MitoSOX red 
mitochondrial superoxide indicator (Molecular Life Technologies Europe B.V., 
Bleiswijk, the Netherlands) as described before [21]. Brieﬂy, cells were plated in 
96-well plates and cultured as described earlier. Cells were subsequently 
incubated with MitoSOX (2.5 μM) in Krebs-Ringer-Phosphate-HEPES (KRPH) 
buffer (20 mM HEPES, 5 mM KH2PO4, 1 mM MgSO4, 1 mM CaCl2, 136 mM NaCl, 
4.7 mM KCl pH 7.4) for 10 minutes at 37 °C and thereafter washed three times 
with the same buffer. Fluorescence was measured using excitation/emission 
maxima of 510/580 nm with a SynergyH4 Hybrid Reader (BioTek). 
 
Microscopic analysis of cell death 
For counting dead cells, NRVCs were grown and treated as described earlier. 
Cells were incubated with Hoechst 33342 (2 μg/μL) and propidium iodide (PI; 3 
μg/μL) and imaged using Leica DM6000. PI-positive dead cells relative to total 
cells (Hoechst positive) were determined per ﬁeld. For counting apoptotic cells, 
NRVCs were ﬁxed for 10 minutes with 4% paraformaldehyde at 4 °C, followed by 
permeabilization with 0.5% Triton X for 5 minutes. Cells were incubated with 
monoclonal anti-cleaved caspase 3 antibody (Sigma-Aldrich Chemie B.V.) in 1% 
BSA, 2% normal goat serum and 0.1% Tween in PBS for 1 hour at RT. Cells were 
washed with PBS and incubated for another hour with a goat anti-mouse 
Fluorescein isothiocyanate (FITC) secondary antibody (Santa-Cruz 
Biotechnology, Heidelberg, Germany). Cover slips were mounted with mounting 
medium containing DAPI (Vector Laboratories, Burlingame, CA, USA) for 
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counterstaining of the nuclei. Slides were imaged using Leica DM6000, and 
cleaved caspase-positive cells were counted, relative to the total amount of cells 
per ﬁeld. 
 
Lactate dehydrogenase activity 
Lactate dehydrogenase (LDH) is a cytosolic enzyme that is an indicator of 
cellular toxicity and was monitored by the LDH release assay. LDH activity was 
determined in cell culture medium using the Roche International Federation of 
Clinical Chemistry (IFCC) liquid assay on the modular analysis according to the 
manufacturer’s instructions (Roche, Mannheim, Germany). 
 
Statistical analysis 
All values are presented as means ± standard errors of the mean (SEM). 
Independent-samples t-test was performed to compare the difference between 
two groups. One-way analysis of variance (ANOVA) with post hoc Bonferroni test 
was used to compare the difference between multiple groups. p < 0.05 was 
considered to be signiﬁcant. SPSS software (PASW Statistics 22, IBM Corporation, 
Armonk, NY, USA) was used for the statistical analyses. 
 
R E S U LT S  
EXOG depletion and PE induce hypertrophy in neonatal cardiomyocytes 
We have recently shown that EXOG depletion stimulates mitochondrial 
respiration and causes ROS-mediated cardiomyocyte hypertrophy (14). This is  
surprising because EXOG is known as an mtDNA repair enzyme and protects the 
mitochondrial genome from oxidative stress in a proliferating myoblast cell line 
(16,17). We therefore decided to investigate whether EXOG would have more 
critical effects in cardiomyocytes under stress conditions by neurohormonal 
stimulation with PE. We ﬁrst assessed hypertrophy development in EXOG-
depleted NRVCs in the presence and absence of PE. As shown in Fig. 1, both EXOG 
depletion and PE stimulation generated a hypertrophic response indicated by 
increased protein synthesis (Fig. 1A) and cell size (Fig. 1B). Although in PE the 
stimulated EXOG- depleted cells protein synthesis appeared somewhat higher 
than in PE-stimulated control cells, this difference was not signiﬁcant (Fig. 1A). 
The increase in cell size in EXOG-depleted cells, as determined using microscopy, 
was similar to that of PE stimulation in control cells (Fig. 1B). EXOG depletion 
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 did not signiﬁcantly augment the PE-induced hypertrophic response. The mRNA 
expression of the established pathological hypertrophic marker ANP was also 
determined. Stimulation of NRVC with PE signiﬁcantly induced ANP expression, 
whereas EXOG depletion had no effect on ANP expression. Surprisingly, EXOG 
depletion fully prevented PE-mediated ANP expression (Fig. 1C). Thus, EXOG 
appears to be modulating pathological ANP gene expression under these 
conditions. 
 
EXOG depletion reduces maximal respiration and reserve capacity in PE-
stimulated cells 
Stimulation of NRVC with PE and depletion of EXOG both stimulate mitochondrial 
respiration in NRVCs (14,21), but whether these effects are interdependent is not 
known. Here, we investigated the combined response on metabolic respiration 
of NRVCs to stimulation with PE and 72 hours of EXOG depletion. EXOG depletion 
increased mitochondrial respiration and ATP-linked respiration (Fig. 2A, B). 
Although not signiﬁcant, an increase in maximal respiration, induced with the 
uncoupler FCCP, and the reserve capacity, which is the difference between 
maximal respiration and mitochondrial respiration, was observed (Fig. 2A, B). 
Also, PE stimulation resulted in an increase in respiration as compared with 
Figure 1 Effects of EXOG depletion on PE induced hypertrophic responses.  
Neonatal rat ventricular cardiomyocytes were infected with control or EXOG specific 
shRNA expresseng adenovirus for 72 hr and stimulated with or without PE for 24 hr. 
EXOG silencing is indicated as siEXOG. A. Protein synthesis was determined by leucine 
incorporation (N=12). B. Cell surface area was measured using a Tissuefaxs (N=9-6). C. 
Gene expression of the hypertrophic marker ANP was determined by Rt-PCR (N=7-11). 
All graphs depict means and SEM, one-way ANOVA with post-hoc Bonferroni test was 
used to compare the difference between multiple groups.* .*p<0.05 as compared to 
control, #p<0.05 as compared to control with PE, $p<0.05 as compared to siEXOG. 




Figure 2 Effect of EXOG depletion on cellular oxygen consumption rate. 
Oxygen consumption rate (OCR) was measured in a Seahorse XF24 extracellular flux 
analyzer in NRVC. Glucose (10mM) was used as a substrate. A. Total OCR was measured 
in cells infected for 72 hr with control or siEXOG adenovirus, addition of oligomycin (ATP 
synthase inhibitor), FCCP and antimycin A and rotenone (respiration inhibitor) is 
indicated. B. Quantification of mitochondrial OCR (Mito), maximal OCR (Max.), reserve 
capacity (Res.Cap.) and ATP-linked OCR (ATP) of the conditions shown in (A) relative to 
mitochondrial OCR of control cells. Mitochondrial OCR is the difference between the 
basal respiration and the OCR after addition of respiration inhibitor, maximal respiration 
is defined as the OCR induced after FCCP injection, reserve capacity is calculated as the 
difference between maximal respiration basal respiration and the ATP-linked OCR is 
defined as oligomycin sensitive OCR (N=6-9). C. Total OCR measurements, comparable 
as is shown in A, except that cells were also stimulated with PE for 24 hr. D. 
Quantification of the graph shown in C, relative to mitochondrial OCR of control cells. 
OCR was corrected for total protein levels in each well and all measurements were 
performed at least in triplicates. All graphs depict means and SEM, independent-
samples t-test was performed to compare the difference between both groups. *p<0.05 
as compared to control, #p<0.05 as compared to control with PE. EXOG silencing is 
indicated as siEXOG 
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control cells (Fig. 2C). EXOG depletion did not show an additive effect on 
mitochondrial respiration in the presence of PE. In contrast, EXOG depletion 
resulted in a strong attenuation of PE-induced maximal respiration and reserve 
capacity (Fig. 2C, D). Despite this attenuation, ATP-linked respiration was 
maintained (Fig. 2D), and these cells still showed a normal hypertrophic response 
(Fig. 1A and B), indicating viable cells. Thus, stimulation with PE of EXOG-
depleted cells does not have additive effects on mitochondrial respiration, and 
the diminished increase in maximal respiration and reserve capacity may suggest 
detrimental rather than positive effects of EXOG depletion under these 
pathological conditions. 
 
Mitochondrial respiration is decreased upon prolonged PE stimulation 
of depleted cells 
The reserve capacity is believed to be an important determinant in coping with 
cellular stress (23,24). Because EXOG- depleted cells showed a decreased reserve 
capacity after stimulation with PE, this may provide a ﬁrst indication that EXOG-
depleted cells are unable to adapt properly to changes induced by this 
pathological stress factor. As shown in Supporting Information Figure 1, EXOG 
depletion remained constant for at least 144 hours, and we therefore decided to 
investigate mitochondrial function at later time points after EXOG depletion. In 
Fig. 3A and B, it is shown that mitochondrial OCR is strongly declined in cells that 
are EXOG depleted for 144 hours and stimulated with PE, as compared with 
control PE-stimulated cells. Also, maximal respiration, reserve capacity and ATP-
linked OCR were strongly declined, indicating that mitochondrial respiration was 
strongly hampered at this time point. To exclude the effect of differences in cell 
number and cell size, the OCR values were corrected for amount of protein per 
well. To investigate whether this was not solely an effect of EXOG depletion, OCR 
of EXOG-depleted cells at the same moment was measured. Although these cells 
also showed a decline in cellular respiration, mitochondrial-speciﬁc OCR and 
ATP-linked OCR were still comparable with the control cells, but reserve capacity 
and maximal respiration were lower, albeit not signiﬁcantly (Fig. 3C and D). Thus, 
prolonged EXOG depletion resulted in mitochondrial dysfunction, and this was 
strongly exacerbated by stimulation with PE. 
 
 








Figure 3 Effect of prolonged EXOG depletion on cellular oxygen consumption rate 
Oxygen consumption rate was measured using the same protocol as used in Figure 2.  
A. Total OCR was measured in cells infected for 144 hr, with control or siEXOG virus 
stimulated with PE for 96 hr (N=6). B. Quantification of mitochondrial OCR (Mito), 
maximal OCR (Max.), reserve capacity (Res.Cap.) and ATP-linked OCR (ATP) of the 
conditions shown in (A), relative to mitochondrial OCR of control cells (N=6). 
C. Total OCR was measured in cells infected for 144 hr with control or siEXOG adenovirus 
(N=6). D. Quantification of mitochondrial OCR (Mito), maximal OCR (Max.), reserve 
capacity (Res.Cap.) and ATP-linked OCR (ATP) of the conditions shown in (C), relative to 
mitochondrial OCR of control cells (N=6). OCR was corrected for total protein levels in 
each well and all measurements were performed at least in triplicates. All graphs depict 
means and SEM, independent-samples t-test was performed to compare the difference 
between both groups. #p<0.05 as compared to control with PE. EXOG silencing is 
indicated as siEXOG 
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Depletion of EXOG did not result in mtDNA damage but increased 
mitochondrial membrane potential 
As the function of EXOG has been linked to DNA repair mechanisms (16), we 
investigated whether the decline in OCR after PE stimulation of prolonged EXOG-
depleted NRVCs could be explained by an increase in mtDNA damage. We 
performed a semi-long-run PCR to detect mtDNA damage lesion. mtDNA damage 
was not increased between the different conditions, indicating that the decline 
in mitochondrial function was not a result of mtDNA damage (Fig. 4A and B). As 
shown, before, EXOG depletion did not also affect the mtDNA/nDNA ratio 
(Supporting Information Figure 2). 
Figure 4 Effect of EXOG depletion on mtDNA damage, mitochondrial membrane 
potential and ROS production 
Cells were stimulated with or without PE and infected with control or EXOG silencing 
adenovirus (siEXOG) for the indicated time. A and B. Mitochondrial DNA damage was 
measured using RT-PCR after 72 hr silencing (A) or 144 hr (B) (N=5-11). C and D. 
Mitochondrial membrane potential was measured using TMRE after 72 hr silencing (C) 
or 144 hr (D) (N=4-6). E and F. Mitochondrial superoxide production was measured using 
mitoSOX after 72 hr silencing (E) or 144 hr (F) (N=10-14). Fluorescence was measured in 
quadruplicates per experiment. All graphs depict means and SEM, one-way ANOVA with 
post-hoc Bonferroni test was used to compare the difference between multiple 
groups.*p<0.05 as compared to control, #p<0.05 as compared to control with PE, 
$p<0.05 as compared to siEXOG. 
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Loss of the proton motive force, the pH gradient and mem- brane potential 
will result in the loss of ATP synthesis via oxidative phosphorylation and result in 
cell death. Therefore, we investigated this potential using TMRE ﬂuorescence. 
After 72 hours of EXOG depletion, we did not observe any signiﬁcant changes in 
membrane potential between EXOG-depleted cells, PE-stimulated cells and the 
combination of both (Fig. 4C). After prolonged depletion of EXOG, the membrane 
potential was even increased both in the presence and in the absence of PE (Fig. 
4D). We wondered whether this increase in mitochondrial mem- brane potential 
was associated with increased ROS production. As shown in Fig. 4E, EXOG 
depletion increased ROS production, and this response was exacerbated after 
stimulation with PE. However, after 144 hours of EXOG depletion, this increased 
ROS production was diminished (Fig. 4F). Thus, although initially an increased 
ROS production is observed, most likely as a result of increased ﬂux, this high 
ROS production is not maintained. 
 
Prolonged depletion of EXOG causes cell death, which is enhanced by 
pathological stimulation 
As mitochondrial dysfunction is apparent, we next investigated if prolonged 
EXOG depletion induced cell death. We microscopically determined cell numbers 
and observed no obvious change within the ﬁrst 72 hours of depletion, also not 
in the presence of PE (Fig. 5A and B). However, prolonged depletion of EXOG 
signiﬁcantly decreased cell numbers. Again, this effect was strongly exacerbated 
in PE-stimulated EXOG-depleted cells (Fig. 5A and C). Under these conditions, we 
observed a higher number of ﬁbroblasts, which was merely a result of decreased 
numbers of cardiomyocytes. 
To corroborate this ﬁnding, we also stained the cells with PI, which stains 
nuclei of dead cells. Hoechst was used as a counterstain, which stains nuclei of 
all cells. As expected, no increase in PI-positive cells was observed after 72 hours 
of EXOG depletion, with or without stimulation with PE (Fig. 5D). An increase in 
PI-positive cells was observed after 144 hours of EXOG depletion and was more 
elevated with PE (Fig. 5E). 
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Figure 5 Effect of EXOG depletion on cell death 
Cells were stimulated with or without PE and infected with control or EXOG silencing 
adenovirus (siEXOG) for the indicated time. A. Representative images of control and 
EXOG depleted cells with and without PE. B and C. Cells were stained with Hoechst and 
total cells per field were counted after 72 hr (B) or 144 hr (C) silencing. For quantification 
at least 150 cells were counted per experiment (N=6-8) D and E. Cells were stained with 
propidium iodide (PI) and counterstained with Hoechst. PI positive cells were counted 
and corrected for total cells per field after 72 hr silencing (D) or 144 hr (E) (N=6). All 
graphs depict means and SEM, one-way ANOVA with post-hoc Bonferroni test was used 
to compare the difference between multiple groups.*p<0.05 as compared to control, 
#p<0.05 as compared to control with PE, $p<0.05 as compared to siEXOG 
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Prolonged depletion of EXOG results in cell death with features of 
necrosis 
As PI can stain the nuclei of both late apoptotic and necrotic cells, we next 
investigated whether programmed cell death via apoptosis occurred. NRVCs 
were stained with an antibody against cleaved caspase 3, which is the activated 
form of caspase 3, and this is a well-known marker for apoptosis. This did not 
show an increase in apoptotic cells under the different conditions (Fig. 6A and 
B). Western blotting revealed, however, a faint cleaved caspase 3 band after 
overexposure of the blot, but this was not different between control and EXOG-
depleted cells (Supporting Information Figure 3). No speciﬁc increase of cleaved 
caspase 3 in EXOG-depleted cells was observed. 
Also, Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
staining was performed, and positive nuclei could be detected in the NRVC 
cultures, but these were always devoid of cytoplasmic staining (Supporting 
Information Figure 4). This is suggestive of nuclear remnants of dead cells and 
not of early apoptotic cells. Also, late necrotic cells become TUNEL 
cardiomyocytes and become TUNEL positive (25). NRVCs could be detected in 
the EXOG PE-treated cultures that showed abnormal shrinkage and are probably 
dying cells, but these were always TUNEL negative (Supporting Information 
Figure 4A). Cells were also treated with the pan caspase inhibitor Z-VAD fmk (20 
μM). Treatment of the cells with this inhibitor did not affect the cells after 72 
hours of EXOG depletion. Moreover, Z-VAD fmk did not inhibit EXOG depletion-
induced cell death after 144 hours (Fig. 6C and D). All together, these data 
suggest that apoptosis is not a major driver of cell death in EXOG-depleted cells. 
 
Figure 6 EXOG depletion results in cell death via necrosis 
A and B. Cells were stained with specific cleaved caspase 3 antibody and positive cells 
were counted after 72 hr silencing (A) or 144 hr (B) (N=6-8). C and D. Cells were treated 
with the pan caspase inhibitor Z-VAD fmk and cells were stained with Hoechst and total 
cells per field were counted after 72 hr silencing (C) or 144 hr (D) (N=4-8). E and F. Cells 
were treated with the ROS scavenger MitoTEMPO and cells were stained with Hoechst 
and total cells per field were counted after 72 hr silencing (E) or 144 hr (F) (N=4-8). G 
and H. LDH activity was measured in cell culture medium after 72 hr silencing (G) or 144 
hr (H) (N=4-6). All graphs depict means and SEM, one-way ANOVA with post-hoc 
Bonferroni test was used to compare the difference between multiple groups.*p<0.05 
as compared to control, #p<0.05 as compared to control with PE, $p<0.05 as compared 
to siEXOG. EXOG silencing is indicated as siEXOG. 
5Decreased reserve capacity precedes EXOG induced cell death 
122 
Prolonged depletion of EXOG results in cell death with features of 
necrosis 
As PI can stain the nuclei of both late apoptotic and necrotic cells, we next 
investigated whether programmed cell death via apoptosis occurred. NRVCs 
were stained with an antibody against cleaved caspase 3, which is the activated 
form of caspase 3, and this is a well-known marker for apoptosis. This did not 
show an increase in apoptotic cells under the different conditions (Fig. 6A and 
B). Western blotting revealed, however, a faint cleaved caspase 3 band after 
overexposure of the blot, but this was not different between control and EXOG-
depleted cells (Supporting Information Figure 3). No speciﬁc increase of cleaved 
caspase 3 in EXOG-depleted cells was observed. 
Also, Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
staining was performed, and positive nuclei could be detected in the NRVC 
cultures, but these were always devoid of cytoplasmic staining (Supporting 
Information Figure 4). This is suggestive of nuclear remnants of dead cells and 
not of early apoptotic cells. Also, late necrotic cells become TUNEL 
cardiomyocytes and become TUNEL positive (25). NRVCs could be detected in 
the EXOG PE-treated cultures that showed abnormal shrinkage and are probably 
dying cells, but these were always TUNEL negative (Supporting Information 
Figure 4A). Cells were also treated with the pan caspase inhibitor Z-VAD fmk (20 
μM). Treatment of the cells with this inhibitor did not affect the cells after 72 
hours of EXOG depletion. Moreover, Z-VAD fmk did not inhibit EXOG depletion-
induced cell death after 144 hours (Fig. 6C and D). All together, these data 
suggest that apoptosis is not a major driver of cell death in EXOG-depleted cells. 
 
Figure 6 EXOG depletion results in cell death via necrosis 
A and B. Cells were stained with specific cleaved caspase 3 antibody and positive cells 
were counted after 72 hr silencing (A) or 144 hr (B) (N=6-8). C and D. Cells were treated 
with the pan caspase inhibitor Z-VAD fmk and cells were stained with Hoechst and total 
cells per field were counted after 72 hr silencing (C) or 144 hr (D) (N=4-8). E and F. Cells 
were treated with the ROS scavenger MitoTEMPO and cells were stained with Hoechst 
and total cells per field were counted after 72 hr silencing (E) or 144 hr (F) (N=4-8). G 
and H. LDH activity was measured in cell culture medium after 72 hr silencing (G) or 144 
hr (H) (N=4-6). All graphs depict means and SEM, one-way ANOVA with post-hoc 
Bonferroni test was used to compare the difference between multiple groups.*p<0.05 
as compared to control, #p<0.05 as compared to control with PE, $p<0.05 as compared 





Figure 6 EXOG depletion results in cell death via necrosis 
Figure legend on page 122. 
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As ROS production was increased in EXOG-depleted cells, we treated the 
cells with the ROS scavenger MitoTEMPO as high ROS levels also might induce 
cell death. As shown in Fig. 6E and F, MitoTEMPO had no effect on the EXOG-
depleted cells after 72 hours of silencing and also did not prevent prolonged 
EXOG depletion-induced cell death. 
Another major cell death mechanism in cardiomyocytes is necrosis. Necrotic 
cell death is characterized by loss of cytoplasmic content, and the presence of 
extracellular LDH activity is a clear sign of necrosis (26). LDH activity signiﬁcantly 
increased after prolonged depletion of EXOG, and the activity was further 
increased in combination with PE (Fig. 6G and H). This suggests that prolonged 
EXOG depletion caused necrosis, and, again, this was strongly augmented by PE. 
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In this study, we show that EXOG is an important gene in cardiomyocytes 
and that cell death is enhanced in EXOG- depleted cells treated with the 
pathological stress factor PE. We have recently shown that EXOG depletion 
activated mitochondrial respiration and induced ROS-mediated hypertrophy 
(14). We conﬁrmed these ﬁndings here but now also investigated the effects of 
prolonged EXOG depletion and the effects of EXOG depletion under pathological 
stress conditions. These results show that EXOG is important to maintain 
homeostasis in cardiomyocytes, but this is not related to its purported function 
in maintaining mtDNA integrity. EXOG depletion ﬁrst resulted in improved 
mitochondrial respiration, but in time, and particularly after PE stimulation, 
mitochondrial respiration declined. Interestingly, diminished maximal 
respiration and reserve capacity were the ﬁrst signs of mitochondrial dysfunction 
in these cells resulting in cellular death. Although we do not know the 
mechanisms underlying these changes, it is highly interesting that depletion of 
EXOG ﬁrst stimulates mitochondrial function and cell growth but, in the long run, 
results in mitochondrial dysfunction and cell death. 
Initially, mitochondrial respiration in EXOG-depleted cells was increased, 
but prolonged depletion resulted in a decrease in respiration, and this is more 
pronounced in the presence of PE. The decline in maximal respiration and 
reserve capacity was the ﬁrst sign that mitochondrial respiration was hampered 
in EXOG-depleted cells stimulated with PE, which ultimately resulted in cell 
death. Previously, the metabolic reserve capacity was shown to be important for 
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maintaining cellular function during acute and chronic stress (23). In endothelial 
cells, the exhaustion of the reserve capacity by ROS leads to mitochondrial 
protein modiﬁcations, ultimately resulting in cell death (27,28). As the ROS 
scavenger MitoTEMPO did not prevent cell death in EXOG-depleted 
cardiomyocytes, it appears unlikely that the initial higher levels of ROS are 
responsible for cell death under these conditions. As EXOG depletion-induced 
ROS production could not be decreased by treatment with MitoTEMPO, we 
suggest that increased ROS levels are implicated in several other effects on the 
cell, including cardiac hypertrophy (14). Apparently, this is a more direct effect 
of EXOG on mitochondrial function and maintaining reserve capacity. Although 
reserve capacity is still a vague term and its exact role is not clear, it probably 
provides cells with the ﬂexibility to adapt to changing conditions. Our result that 
diminishment of reserve capacity in EXOG-depleted cells is the ﬁrst sign in a 
process leading to cell death underscores the importance of the reserve capacity. 
It will therefore be very interesting to investigate whether a decline in reserve 
capacity is in general a ﬁrst sign that marks subsequent cell death. 
Cell death in EXOG-depleted cells did not appear to be an effect of enhanced 
stress levels. On the contrary, expression of the cardiac stress marker ANP did 
not signiﬁcantly change in EXOG- depleted cells and was even diminished in 
EXOG-depleted cells in the presence of PE as compared with control PE-treated 
cells. Also oxidative stress markers (catalase and MnSOD) were not increased in 
EXOG-depleted cells (14). Although we cannot rigorously exclude activation of 
other stress markers, it may indicate that there is no increased stress level in 
these cells. However, as an alternative hypothesis, EXOG depletion may also 
prevent activation of protective stress responsive pathways and consequently 
drives cells into cell death under stress conditions. ANP has cardiomyocyte 
protective actions via cGMP-mediated signalling (29), but its expression is 
repressed in EXOG-depleted cells. Although it will be difﬁcult to discriminate 
between these two possibilities, further investigation of how EXOG may affect 
stress levels or stress protection will be highly relevant. 
A multitude of mitochondrial alterations is observed in a temporal manner 
in EXOG-depleted cells, and these can be enhanced by PE stimulation. Whereas 
depletion of EXOG ﬁrst stimulates mitochondrial OCR, in time, a decline is 
observed. ROS production is ﬁrst increased but normalizes later, whereas 
mitochondrial potential is ﬁrst comparable with control cells but increases at 
later stages. These pleiotropic responses make it very difﬁcult to determine the 
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direct effects of EXOG, and most mitochondrial processes are strongly 
interlinked. The mitochondrial membrane potential (Δψ), for example, controls 
ATP synthesis, neration of ROS, mitochondrial calcium sequestration, import of 
proteins into the mitochondrion and mitochondrial membrane dynamics (30,31). 
Conversely, Δψ is controlled by ATP utilization, mitochondrial proton 
conductance, respiratory chain capacity and mitochondrial calcium (31,32). So, 
it is difﬁcult to interpret the single events, and the increased Δψ observed at later 
time points could be a result of many different factors. This high Δψ is, however, 
in agreement with the absence of apoptosis, which is accompanied by MPTP 
opening and consequently a decreased Δψ. Altogether, our results show that in 
neonatal cardiomyocytes, loss of EXOG initially enhances mitochondrial function 
and induces cell growth, but in time, mitochondrial function declines. This is not 
a result of mtDNA damage or induction of apoptosis but a result of mitochondrial 
dysfunction resulting in cell death, which can be enhanced by pathological 
stimulation. Most interestingly, a decline in mitochondrial reserve capacity is the 
ﬁrst sign of mitochondrial dysfunction under these conditions. 
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mtDNA/nDNA ratios in EXOG silenced (siEXOG, using shRNA) NRVCs at 72 and 144 h. N= 
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Supplemental figure 4.  
TUNEL staining of EXOG silenced and control NRVCs treated with PE or H2O2. On the right, 
in red, the TUNEL staining and at the left merged with DAPI (blue) and GFP (green) 
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A B S T R A C T  
Cardiac hypertrophy is associated with growth and functional changes of 
cardiomyocytes, including mitochondrial alterations, but the latter are still 
poorly understood. Here we investigated mitochondrial function and dynamic 
localization in neonatal rat ventricular cardiomyocytes (NRVCs) stimulated with 
insulin like growth factor 1 (IGF1) or phenylephrine (PE), mimicking 
physiological and pathological hypertrophic responses, respectively.  
A decreased activity of the mitochondrial electron transport chain (ETC) 
(state 3) was observed in permeabilized NRVCs stimulated with PE, whereas this 
was improved in IGF1 stimulated NRVCs. In contrast, in intact NRVCs, 
mitochondrial oxygen consumption rate (OCR) was increased in PE stimulated 
NRVCs, but remained constant in IGF1 stimulated NRVCs. After stimulation with 
PE, mitochondria localized to the periphery of the cell. To study the differences 
in more detail, we performed gene array studies. IGF1 and PE stimulated NRVCs 
did not reveal major differences in gene expression of mitochondrial encoding 
proteins, but we identified a gene encoding amotor protein implicated in 
mitochondrial localization, kinesin family member 5b (Kif5b ), which was clearly 
elevated in PE stimulated NRVCs but not in IGF1 stimulated NRVCs. We 
confirmed that Kif5b gene and protein expression was elevated in animal 
models with pathological cardiac hypertrophy. Silencing of Kif5b reverted the 
peripheral mitochondrial localization in PE stimulated NRVCs and diminished PE 
induced increases in mitochondrial OCR, indicating that KIF5B dependent 
localization affects cellular responses to PE stimulated NRVCs.  
These results indicate that KIF5B contributes to mitochondrial localization 
and function in cardiomyocytes and may play a role in pathological 
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I N T R O D U C T I O N  
Cardiac hypertrophy is believed to be an adaptive response of the heart 
aimed at reducing wall stress and maintaining cardiac function. Cardiac 
hypertrophy can be broadly divided into pathological and physiological 
hypertrophy. Both types of hypertrophy are associated with growth and 
functional changes of cardiomyocytes, but pathological hypertrophy may result 
in cardiac decompensation and heart failure (1,2).  
Physiological hypertrophy can be induced by growth factors, like insulin-like 
growth factor (IGF1), whereas adrenergic signaling and angiotensin II can 
stimulate pathological hypertrophy. Although the common outcome of these 
hypertrophic signals is cardiomyocyte growth (hypertrophy), these responses 
are associated with distinct intracellular signaling pathways and different 
structural and functional consequences (3). Amongst different events, like 
fibrosis and microvascular abnormalities (3,4), energy metabolic reprogramming 
also appears to be disparate between the two hypertrophic conditions (5). This 
includes alterations in substrate usage and mitochondrial function (3). The 
metabolic switch from fatty acids to glucose usage, which is observed in 
pathological hypertrophy, has been investigated in great detail (6–8). The 
changes in mitochondrial dynamics and function on the other hand are still 
vague. The general view is that physiological factors stimulate mitochondrial 
biogenesis and hence mitochondrial capacity (9), whereas pathological 
stimulation results in altered mitochondrial dynamics and activity (10). These 
changes are still far from understood and differences in etiology, hypertrophic 
state (compensated/decompensated) and methodology have probably 
contributed to different results (11). Moreover, the complexity of the 
cardiovascular system in which (neuro)hormonal signals, biomechanical 
changes, hemodynamic effects and altered substrate availability all have an 
impact on hypertrophy development and mitochondrial function most likely 
hamper these studies.  
In this study we aimed to investigate mitochondrial function in a simplified 
system using cultured neonatal rat cardiomyocytes (NRVCs) and mimicked 
physiological and pathological hypertrophy with IGF1 and phenylephrine (PE), 
respectively. We show that a pathological stimulus (PE) can induce changes in 
mitochondrial function and dynamic localization within 24 hours of stimulation. 
In contrast to IGF1 stimulated NRVCs, in PE stimulated NRVCs the kinesin motor 
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protein KIF5B was upregulated. This results in abnormal and more peripheral 
localization of mitochondria. Depletion of KIF5B prevented this mitochondrial 
redistribution and also partially inhibits the mitochondrial respiratory increase 
and hypertrophic response observed after stimulation with PE. This indicates 
that KIF5B is involved in PE induced changes in mitochondrial localization and 
function and suggests that KIF5B could play a role in energetic changes in 
pathological hypertrophic responses. 
 
M AT E R I A L S  A N D  M E T H O D S  
Ethics statement 
All experiments were approved by the Committee on Animal 
Experimentation of the University of Groningen and were conducted under 
international guidelines on animal experimentation conform the Guide for the 
Care and Use of Laboratory Animals published by the Directive 2010/63/EU of 
the European Parliament. 
 
Isolation and culturing of primary cardiomyocytes 
Primary neonatal rat ventricular cardiomyocytes (NRVCs) were isolated 
from Sprague Dawley neonatal rats of 1-3 days old, as previously described 
(12,13). NRVCs were grown in Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with 5% fetal calf serum (FCS) and penicillin-streptomycin (100 
U/ml-100 μg/ml). NRVCs were serum starved in DMEM with penicillin-
streptomycin (100 U/ml-100 μg/ml) 48 hours after isolation. After 24 hours of 
starvation NRVCs were stimulated with 50 μM phenylephrine (PE) or 10 nM 
insulin-like growth factor 1 (IGF1) (Life Technologies) for 24 hours. All media and 
supplements were purchased from Sigma-Aldrich Chemie B.V., Zwijndrecht, the 




NRVCs were grown on coverslips coated with laminin (Millipore, 
Amsterdam, The Netherlands) and treated as described above. NRVCs were fixed 
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protein KIF5B was upregulated. This results in abnormal and more peripheral 
localization of mitochondria. Depletion of KIF5B prevented this mitochondrial 
redistribution and also partially inhibits the mitochondrial respiratory increase 
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that KIF5B is involved in PE induced changes in mitochondrial localization and 
function and suggests that KIF5B could play a role in energetic changes in 
pathological hypertrophic responses. 
 
M AT E R I A L S  A N D  M E T H O D S  
Ethics statement 
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Zwijndrecht, the Netherlands) in 3% BSA, 2% normal goat serum, 0.1% tween in 
PBS for 1 hour at RT. NRVCs were washed with PBS and incubated for another 
hour with a goat anti-mouse fluorescein isothiocyanate (FITC) secondary 
antibody (Santa-Cruz Biotechnology, Heidelberg, Germany). Coverslips were 
mounted with mounting medium containing 4,6-Diamidine-2-phenylindole 
dihydrochloride (DAPI) (Vector laboratories, Burlingame, CA, USA) for 
counterstaining of the nuclei. Slides were imaged using a Leica DMI6000B 
inverted immunofluorescence microscope and cell size was determined using 
Image J analysis software. To determine mitochondrial localization the same 
staining protocol was followed as described above, but next to alpha-actinin 
staining, anti-TOM20 antibody staining was performed (Santa Cruz, Heidelberg, 
Germany). To obtain a quantitative measure of mitochondrial distribution in the 
cytosol, the intensity of TOM20 staining was determined in a circular area at the 
nuclear periphery (perinuclear) and an identical sized area at the cell membrane 
(cellular periphery) using Image J software. These regions were never 
overlapping. The intensity ratio for perinuclear versus peripheral TOM20 staining 
was determined and at least 25 NRVCs/condition were analyzed in at least three 
independent experiments. The percentage of NRVCs with a perinuclear to 
peripheral ratio above 3.0 was determined. Detailed microscopy images were 
generated using a Delta Vision Elite system using a 60x objective at the UMCG 
imaging center. Z-stacks were generated and images were deconvolved by 5 
iterations and subsequently a Z-projection was generated.  
 
[3H]-Leucine incorporation 
NRVCs were grown in 12-well plates and L-[4,5-3H]leucine (1 μCi/mL, 
PerkinElmer) was added to the medium right after stimulation with PE or IGF1. 
NRVCs were cultured for an additional 24 hours and L-[4,5-3H]Leucine 
incorporation was determined as previously described (12). 
 
Quantitative real time PCR 
Total RNA was isolated using a nucleospin RNA II kit (Bioke; Leiden, The 
Netherlands) and cDNA was synthesized using QuantiTect Reverse 
Transcriptional kit (Qiagen, Venlo, the Netherlands) according to the 
manufacturer’s instructions. Relative gene expression was determined by 
quantitative real time PCR (qRT-PCR) on the Bio-Rad CFX384 real time system 
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(Bio-Rad, Veenendaal, the Netherlands) using ABsolute QPCR SYBR Green mix 
(Thermo Scientific, Landsmeer, the Netherlands). Gene expressions were 
corrected for reference gene values (Rplp0), and expressed relative to the 
control group. Primer sequences used are depicted in supplemental table 1.  
 
Western blot 
Western blotting was performed as described previously (14). In brief, 
protein was isolated with Radio-Immunoprecipitation Assay (RIPA) buffer (50 
mM Tris pH 8.0, 1% nonidet P40, 0.5% deoxycholate, 0.1% SDS, 150 mM NaCl) 
supplemented with 40 μl/ml phosphatase inhibitor cocktail 1 (Sigma-Aldrich 
Chemie B.V., Zwijndrecht, the Netherlands), 10 μl/ml protease inhibitor cocktail 
(Roche Diagnostics Corp., Indianapolis, IN, USA) and 1 mM phenylmethylsulfonyl 
fluoride (PMSF) (Roche Diagnostics Corp., Indianapolis, IN, USA). Protein 
concentrations were determined with a DC protein assay kit (Bio-Rad, 
Veenendaal, the Netherlands). Equal amounts of proteins were separated by 
SDS-PAGE and proteins were transferred onto Polyvinylidene Difluoride (PVDF) 
membranes.. (The following antibodies were used: anti-OXPHOS cocktail 
(MitoSciences, Eugene, Oregon, USA), anti-pAKT (Cell Signaling Technology 
Danvers, MA, USA), anti-total AKT (Cell Signaling Technology Danvers, MA, USA), 
anti-beta-actin (Sigma-Aldrich Chemie B.V., Zwijndrecht, the Netherlands) and 
anti-Kif5b anti-Mitofusin-1 (Abcam Cambridge, UK), anti-Drp1 (Becton Dickinson, 
Breda, The Netherlands) and anti-TOM20 (Santa Cruz, Heidelberg, Germany). 
After incubation with HRP-conjugated secondary antibodies, signals were 
visualized with ECL and analyzed with densitometry (ImageQuant LAS4000, GE 
Healthcare Europe, Diegem, Belgium). Cardiac troponin T (cTnT) was used as a 
loading control as described before (15).  
 
Seahorse mitochondrial flux analyses 
To determine the mitochondrial oxygen consumption rate (OCR) a Seahorse 
metabolic flux analyzer (Seahorse Biosciences, Massachusetts, USA) was used. A 
standardized protocol (16) was used to determine specific mitochondrial 
complex activities in permeabilized cells. To measure complex I and complex II 
mediated respiratory activity, cardiomyocytes were permeabilized using 
recombinant perfringolysin O (rPFO) (XF-plasma membrane permeabilizer (PMP) 
reagent) (Seahorse Biosciences, Massachusetts, USA). NRVCs were cultured as 
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described above. On the day of analysis, NRVCs were washed twice with ASBSA 
(70 mM sucrose, 220 mM mannitol, 10mM KH2PO4, 5 mM KOH, 0.4% BSA). The 
XFPMP reagent (1 nM) was added together with the appropriate substrates and 
inhibitors and the assay was started immediately. To measure complex I activity, 
pyruvate (5 mM) and malate (2.5 mM) were added to the MAS-BSA solution. For 
complex II mediated respiration rotenone (1 μM) and succinate (10 mM) were 
used. The OCR was measured by adding subsequently ADP (1 mM), oligomycin 
(1 μg/μl) and FCCP (1 μM). Non-mitochondrial OCR was measured after addition 
of antimycin/rotenone (1 μM/1 μM). This non mitochondrial respiration was 
subtracted from the total OCR values resulting in ADP induced state 3 
mitochondrial OCR, ATP-linked state 4 mOCR and FCCP induced uncoupled 
mOCR (state3u). 
Determination of the OCR in intact cardiomyocytes with the Seahorse 
metabolic flux analyzer was performed as previously described (17). Neonatal 
cardiomyocytes were seeded at a density of 100.000 NRVCs/well in special 
Seahorse 24-well plates. One hour before initiation of measurements, medium 
was replaced with XF medium supplemented with 10 mM glucose or 1 mM 
pyruvate and incubated for 1 hour in a CO2 free 37˚C incubator. The basal 
respiration of the NRVCs was measured, followed by injection of oligomycin (ATP 
synthase inhibitor) (1 µM) to measure the ATP linked OCR. The uncoupler 
carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) (0.5 µM) was 
used to determine maximal respiration. Finally, rotenone (1 µM) and antimycin 
A (AR) (1 µM) were injected to determine the non-mitochondrial respiration via 
inhibition of complex I and III, respectively. Mitochondrial specific OCR (mOCR) 
was calculated by subtracting the non-mitochondrial respiration AR of the total 
OCR values. ATP-linked OCR is the calculated difference between basal mOCR 
and mOCR after addition of oligomycin. In each plate the same treatment was 
performed in triplicate or quadruple. The OCR was corrected for the amount of 
total protein per well as determined using the Biorad DC Protein Assay (Biorad). 
 
mtDNA / nDNA ratio 
Total DNA, including mitochondrial DNA (mtDNA), was extracted from 
NRVCs using the DNA Blood and tissue Kit (Qiagen, Venlo, the Netherlands). The 
isolated DNA showed high purity (A260/A280 > 1.8), as determined by 
spectroscopic analysis. To determine the ratio between mitochondrial and 
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nuclear DNA, relative gene expression was determined by qRTPCR on a Bio-Rad 
CFX384 real time system using SYBR Green dye. The expression of the 
mitochondrial gene Cytochrome b (CytB) was corrected for the expression of the 
nuclear gene Trpm2. Primers and procedure have been described before (17).  
 
Citrate synthase activity 
Whole cell citrate synthase activity was measured using an enzyme assay kit 
(Sigma-Aldrich Chemie B.V., Zwijndrecht, the Netherlands) according to the 
manufacturer’s instructions and as previously described by us (17). In short, cell 
lysates were prepared using the CelLytic M Cell Lysis Reagent and protein 
concentrations were measured. 3 μg of protein was combined with Acetyl 
Coenzyme A, 5,5’-Dithiobis-(2-nitrobenzoic acid) (DTNB) and assay buffer in a 96 
well plate. The reaction was initiated by adding oxaloacetate into the mixture 
and total activity was measured. Absorbance was measured at 412 nm using a 
spectrophotometer following a kinetic program. Triplicate measurements were 
performed on each sample. 
 
Gene Array 
RNA was isolated as described above and 4 independent biological samples 
per condition were used for whole genome expression analysis. Biotin-labeling, 
hybridization, washing and scanning of GeneChip Rat Gene 1.1 ST arrays 
(Affymetrics) were performed in expert labs (Nutrigenomics Consortium, 
Wageningen, The Netherlands) according to Affymetrix’s protocols. Processing 
of the data occurred using the MADMAX pipeline (18). Array data have been 
deposited at the Gene Expression Omnibus (GEO) database (GSE73896). 
Differentially expressed gene sets were identified with the IBMT regularized t-
test (19). Corrections for multiple testing were done using the false discovery 
rate method (20). A false discovery rate (FDR) of <10% was considered 
significantly changed. Genes related to mitochondria were selected from the 
gene list with significantly regulated genes (FDR < 10%). These genes were 
annotated in biological processes using Database for Annotation, Visualization 
and Integrated Discovery (DAVID) software (21). Biological processes shown are 
based on Gene Ontology, GOTERM_BP4. Gene set enrichment analysis (22) was 
performed to be able to detect significant pathway regulation of gene sets, 
thereby not only focusing on significantly regulated genes, but taking into 
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account all expressed genes. A heat map was generated using statistical and 
graphical computer software “R”. For the heat map only motor protein encoding 
genes were selected that we identified in the FDR<10% gene lists. 
 
Animal experiments 
Expression of Kif5b was analyzed in multiple hypertrophy animal models. In 
all animal experiments, animals were kept on a 12 hr light:12 hr dark cycle with 
ad libitum access to food and water. Pressure overload in male C57BL/6J mice 
(Harlan, The Netherlands) was induced at the age of 8–10 weeks by transverse 
aortic constriction (TAC). Mice were terminated at 4 or 8 weeks post-TAC and 
sham operated animals were used as controls, as described previously (23). 
Homozygous transgenic TGR (mREN2)27 rats overexpress mouse renin resulting 
in hypertension and consequently develop cardiac hypertrophy were used as 
described before (13,14,24). Age- and gender-matched Sprague Dawley (SD) 
animals (genetic background strain) served as controls. For induction of 
physiological hypertrophy, male C57BL/6J mice were allowed voluntary wheel 
running for 10 weeks. Sedentary animals were used as controls. 
 
Gene silencing 
Silencing of gene expression was performed with oligofectamine 
(Dharmacon) according to the manufacturers instruction. Silencing was 
performed with AccuTarget predesigned siRNA 1664194 and 1664195 from 
Bioneer targeting rat Kif5b. Control Accutarget siRNA sequences were also from 
Bioneer and have been described before (17). 
 
Statistical analysis 
All values are presented as means ± standard deviation (SD). Comparison of 
two groups was done using a two-tailed Student's t-test. One-way ANOVA with 
posthoc Bonferroni correction was used to compare the difference between 
multiple groups. . When data were not normally distributed, a Kruskall Wallis test 
was performed, followed by a Mann-Whitney U test for individual comparison of 
means. SPSS software (PASW Statistics 22) was used for the statistical analyses. 
P <0.05 was considered to be significant.  
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R E S U LT S  
PE and IGF1 induce different pathways, resulting in similar hypertrophic 
responses in NRVCs. 
Stimulation of NRVCs with IGF1 and PE resulted in a similar increase in cell 
size as is shown in Figure 1A and B. Also protein synthesis was significantly 
increased upon stimulation with PE and IGF1, albeit somewhat stronger with 
IGF1 (Figure 1C). The pathological stress markers Nppa (Anp) and Nppb (Bnp) 
were significantly up-regulated in PE stimulated NRVCs (Figure 1D), but 
expression did not change upon IGF1 treatment. Acta1 was up-regulated upon 
stimulation with both stimuli and probably indicates a general response of the  
 
 
Figure 1 Stimulation of NRVCs with PE or IGF1 induced hypertrophy.  
NRVCs were stimulated with PE or IGF1 for 24 hr and hypertrophic responses were 
measured. Cell size was determined by staining with the sarcomeric cardiomyocyte 
specific marker á-actinin (green) and nuclei were counterstained with DAPI (blue). 
Representative images are shown. (A). Quantification of cell surface area of PE or IGF1 
stimulated NRVCs relative to control NRVCs (N=3). (B). Protein synthesis was determined 
using 3H-Leucine incorporation (N=11) (C). mRNA expression levels of the hypertrophic 
markers Nppa, Nppb, Rcan1 and Acta1 were determined using qRT-PCR (N=6-8) (D). 
Protein expression levels of phosphorylated Akt and total Akt were determined by 
Western Blot (N=7) (E). Representative Western Blot images are shown (F). All graphs 
depict means and SD, *P < 0.05 compared to control; #P<0.05 compared to PE 
stimulated NRVCs. Nppa, Atrial Natriuretic Peptide; Nppb, Brain Natriuretic Peptide; 
Rcan1, Regulator Of Calcineurin; Acta1, Actin Alpha1 Skeletal Muscle 
6Hypertrophy induced KIF5B controls mitochondrial localization and function 
144 
R E S U LT S  
PE and IGF1 induce different pathways, resulting in similar hypertrophic 
responses in NRVCs. 
Stimulation of NRVCs with IGF1 and PE resulted in a similar increase in cell 
size as is shown in Figure 1A and B. Also protein synthesis was significantly 
increased upon stimulation with PE and IGF1, albeit somewhat stronger with 
IGF1 (Figure 1C). The pathological stress markers Nppa (Anp) and Nppb (Bnp) 
were significantly up-regulated in PE stimulated NRVCs (Figure 1D), but 
expression did not change upon IGF1 treatment. Acta1 was up-regulated upon 
stimulation with both stimuli and probably indicates a general response of the  
 
 
Figure 1 Stimulation of NRVCs with PE or IGF1 induced hypertrophy.  
NRVCs were stimulated with PE or IGF1 for 24 hr and hypertrophic responses were 
measured. Cell size was determined by staining with the sarcomeric cardiomyocyte 
specific marker á-actinin (green) and nuclei were counterstained with DAPI (blue). 
Representative images are shown. (A). Quantification of cell surface area of PE or IGF1 
stimulated NRVCs relative to control NRVCs (N=3). (B). Protein synthesis was determined 
using 3H-Leucine incorporation (N=11) (C). mRNA expression levels of the hypertrophic 
markers Nppa, Nppb, Rcan1 and Acta1 were determined using qRT-PCR (N=6-8) (D). 
Protein expression levels of phosphorylated Akt and total Akt were determined by 
Western Blot (N=7) (E). Representative Western Blot images are shown (F). All graphs 
depict means and SD, *P < 0.05 compared to control; #P<0.05 compared to PE 
stimulated NRVCs. Nppa, Atrial Natriuretic Peptide; Nppb, Brain Natriuretic Peptide; 
Rcan1, Regulator Of Calcineurin; Acta1, Actin Alpha1 Skeletal Muscle 
Chapter 6 
145 
cardiomyocytes to hypertrophic stimulation (Figure 1D). Whereas IGF1 strongly 
stimulated AKT phosphorylation, (Figure 1E and 1F), PE stimulated Rcan1 
expression, a marker for calcineurin activation. These results demonstrate that 
NRVCs show similar growth response upon PE and IGF1 stimulation, but that the 
underlying hypertrophic pathways are not identical, reflecting the in vivo 
pathological and physiological differences.  
 
PE stimulation decreased complex II activity, whereas IGF1 increased 
complex I activity. 
The general perception is that mitochondrial function declines in 
pathological cardiac hypertrophy, whereas it improves in physiological 
hypertrophy (10,11,25,26). To investigate whether this could also be observed in 
NRVCs in vitro, the mitochondrial complex I and II dependent respiration in 
permeabilized NRVCs was determined using the Seahorse flux analyser. Either 
malate/pyruvate was used as a substrate for complex I or succinate/rotenone for 
complex II. As shown in Figure 2A and B, an increase in complex I dependent 
oxygen consumption rate (OCR) was observed after stimulation with IGF1, 
although only state 3 was significantly increased. No increase in complex I 
dependent OCR was observed after PE stimulation, rather a trend of lower 
complex I dependent OCR was shown. No differences in complex II dependent 
OCR were observed after stimulation with IGF1. Stimulation with PE resulted, 
however, in a significant diminishment of state 3 activity. Also state 4 and state 
3u activity appeared lower after PE stimulation, albeit not significant (Figure 2C 
and D). Thus, a specific pathological or physiological stimulus can, respectively, 
decrease and enhance specific mitochondrial complex activities in vitro. 
 
NRVCs stimulated with PE, but not IGF1, have increased cellular 
mitochondrial respiration. 
The seahorse flux analyser provides the unique opportunity to measure 
mitochondrial OCR also in intact NRVCs. Figure 3A and B show the cellular OCR 
in control, PE and IGF1 stimulated NRVCs as determined in intact NRVCs using 
glucose as a substrate. Interestingly,cellular OCR was significantly higher in PE 
stimulated NRVCs, as compared to control and IGF1 stimulated NRVCs (Figure 
3A). Also after correction for non-mitochondrial OCR (total cellular OCR – A/R 
insensitive OCR), the mitochondrial specific OCR after stimulation with PE 




showed a significant increase of 2 fold as compared with control NRVCs (Figure 
3B). Addition of the ATP synthase inhibitor oligomycin revealed that the ATP-
linked (oligomycin dependent) OCR was 3.5 fold higher in PE stimulated NRVCs. 
Figure 2 Complex II dependent OCR is decreased after PE stimulation whereas IGF1 
stimulation increased complex I dependent OCR 
Total mitochondrial complex specific OCR was analyzed by permeabilizing NRVCs before 
measuring the OCR using a Seahorse XF24 Extracellular Flux Analyzer. Substrates were 
included in the buffer and basal respiration was measured. Sequential addition of ADP, 
oligomycin, FCCP and antimycin/rotenone (AR) is indicated in the graph. Parameters of 
complex specific mitochondrial respiration were calculated, after subtraction of OCR 
measured after A/R resulting in mitochondrial specific OCR. State 3 is the OCR after 
addition of ADP indicating the maximal coupled respiration. State 4 is the OCR after 
addition of oligomycin, indicating the ATP –independent respiration. State 4u is induced 
after addition of FCCP. Complex I dependent OCR was measured using pyruvate and 
malate as substrates (N=6) (A)(B). Complex II dependent OCR was measured using 
succinate as substrates and rotenone to inhibit complex I (N=6) (C)(D). All graphs depict 
means and SD, *P < 0.05 compared to control; #P<0.05 compared to PE stimulated 
NRVCs. 




showed a significant increase of 2 fold as compared with control NRVCs (Figure 
3B). Addition of the ATP synthase inhibitor oligomycin revealed that the ATP-
linked (oligomycin dependent) OCR was 3.5 fold higher in PE stimulated NRVCs. 
Figure 2 Complex II dependent OCR is decreased after PE stimulation whereas IGF1 
stimulation increased complex I dependent OCR 
Total mitochondrial complex specific OCR was analyzed by permeabilizing NRVCs before 
measuring the OCR using a Seahorse XF24 Extracellular Flux Analyzer. Substrates were 
included in the buffer and basal respiration was measured. Sequential addition of ADP, 
oligomycin, FCCP and antimycin/rotenone (AR) is indicated in the graph. Parameters of 
complex specific mitochondrial respiration were calculated, after subtraction of OCR 
measured after A/R resulting in mitochondrial specific OCR. State 3 is the OCR after 
addition of ADP indicating the maximal coupled respiration. State 4 is the OCR after 
addition of oligomycin, indicating the ATP –independent respiration. State 4u is induced 
after addition of FCCP. Complex I dependent OCR was measured using pyruvate and 
malate as substrates (N=6) (A)(B). Complex II dependent OCR was measured using 
succinate as substrates and rotenone to inhibit complex I (N=6) (C)(D). All graphs depict 




Maximal respiration induced by the addition of the uncoupler FCCP was also 
clearly increased and this trend was observed in all our experiments (Figure 3, 8, 
supplemental Figure 1, 5), albeit not always significant. The latter is probably a 
power issue. No differences in mitochondrial respiration were observed in IGF1 
stimulated NRVCs, indicating that increased OCR is not a prerequisite for 
hypertrophy development (Figure 3B). Similar results were obtained using 
pyruvate as a substrate, indicating that these findings are not a result of changes 
in glycolysis (supplemental Figure 1). These data show that changes in complex 




Changes in mitochondrial respiration are not due to mitochondrial 
biogenesis. 
Altered mitochondrial biogenesis could explain the observed differences in 
the cellular mitochondrial respiration. To exclude mitochondrial biogenesis as a 
Figure 3 Mitochondrial respiration in intact NRVCs is increased after stimulation with 
PE. 
Total cellular OCR was measured using a Seahorse XF24 Extracellular Flux Analyzer, with 
sequential addition of the ATP synthase inhibitor oligomycin, the uncoupling agent FCCP 
and mitochondrial respiration inhibitors antimycin A/rotenone (AR) as depicted in the 
graph (A). Mitochondrial specific OCR values were obtained by subtracting OCR values 
after addition of AR from total OCR resulting in mitochondrial respiration, maximal and 
ATP-linked OCR. Corrected oxygen consumption data of the first 3 measurements were 
averaged to yield the mitochondrial respiration. The ATP-linked OCR, defined as 
oligomycin- sensitive OCR, was calculated. Maximal respiration was induced by FCCP 
(N=5) (B). All graphs depict means and SD, *P < 0.05 as compared to control. 
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causal factor underlying these observed mitochondrial effects several 
parameters were investigated. Protein expression of the different complexes of 
the ETC was not altered in PE and IGF1 stimulated NRVCs, as shown with an 
OXPHOS Western blot (Figure 4A and B). Also the ratio between mtDNA and 
nDNA, an established measurement of mitochondrial biogenesis, was similar 
between control, PE and IGF1 stimulated NRVCs (Figure 4C). In addition, citrate 
synthase activity as an independent measurement of mitochondrial biogenesis, 
was unaltered (Figure 4D). This indicates that the observed changes in 
mitochondrial respiration were not mediated by increased mitochondrial 




Figure 4 Increased mitochondrial respiration is not due to mitochondrial biogenesis. 
Several independent measurements of mitochondrial biogenesis were assessed in PE 
and IGF1 stimulated NRVCs. Total cellular protein was blotted and incubated with 
specific OXPHOS antibody to assess protein expression levels of the different complexes 
of the ETC. A representative Western blot is shown (A) and the expression of the 
separate complexes was quantified (N=11) (B). RT-PCR analysis was used to compare the 
amount of mtDNA with nDNA (N=5) (C). Whole cell citrate synthase activity was 
measured using an enzyme assay kit (N=5) (D). All graphs depict means and SD. 
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Figure 4 Increased mitochondrial respiration is not due to mitochondrial biogenesis. 
Several independent measurements of mitochondrial biogenesis were assessed in PE 
and IGF1 stimulated NRVCs. Total cellular protein was blotted and incubated with 
specific OXPHOS antibody to assess protein expression levels of the different complexes 
of the ETC. A representative Western blot is shown (A) and the expression of the 
separate complexes was quantified (N=11) (B). RT-PCR analysis was used to compare the 
amount of mtDNA with nDNA (N=5) (C). Whole cell citrate synthase activity was 





Changed mitochondrial localization in PE treated NRVCs. 
Although mitochondrial activity has been the main focus in cardiac 
energetics for many years, also mitochondrial dynamics and localization have 
increasingly gained interest in the cardiac field. Abnormalities have been 
described to affect mitochondrial function (27,28). We stained NRVCs with an 
antibody against the mitochondrial outer membrane protein TOM20 (29). 
Microscopic inspection revealed a strong perinuclear staining in control and IGF1 
stimulated NRVCs, whereas PE stimulated NRVCs showed a more dispersed and 
cytoplasmic mitochondrial staining (Figure 5A). This effect in PE treated cells was 
not simply a reflection of increased cell size, since both PE and IGF1 stimulated 
cells increased equally in size. Quantification of the ratio of perinuclear versus 
Figure 5 Mitochondria in PE stimulated NRVCs are dispersed throughout the cytosol. 
Mitochondrial localization was visualized by staining NRVCs with anti-TOM20 antibody 
(green). NRVCs were stained with specific sarcomeric á-actinin (red) and nuclei were 
counterstained with DAPI (blue). Representative pictures are shown (A). Quantification 
of the intensity of perinuclear localized mitochondrial staining as compared to 
peripheral cytoplasmic mitochondrial staining (N=6) (B). Quantification of the 
percentage of NRVCs with a perinuclear versus peripheral mitochondrial fluorescence 
intensity ratio lower than 3 (N=6). (C) All graphs depict means and SD, *P < 0.05 as 
compared to control. #P<0.05 compared to IGF1 stimulated NRVCs. 
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peripheral staining intensity confirmed a high intensity around the nucleus in 
control and even more in IGF1 stimulated NRVCs. This ratio was significantly 
lower in PE stimulated cells (Figure 5B). Furthermore, counting the number of 
NRVCs with a low perinuclear/peripheral staining ratio (<3.0) confirmed this 
peripheral localization in PE stimulated NRVCs (Figure 5C). Thus, PE, but not IGF1, 
stimulates peripheral mitochondrial localization in NRVCs. 
 
Gene array analysis reveals upregulation of Kif5b in PE treated NRVCs. 
Gene expression changes could potentially reveal targets that explain the 
observed differences. A gene array analysis was therefore performed with RNA 
from control, PE and IGF1 stimulated NRVCs. Using a FDR of 10%, we 
identified >300 genes that were differentially expressed in PE stimulated NRVCs, 
compared to almost 1200 genes in IGF1 stimulated NRVCs. Of these genes at 
least 4,9% of both the PE and IGF1 group translated into proteins that are 
localized to mitochondria , based on available proteomic data (Figure 6A) (30). 
This mitochondrial set was further explored using DAVID to categorize genes into 
biological processes (Figure 6B). No specific functionally related groups of genes 
were found in the PE stimulated NRVCs (Figure 6B) but within the 9 specific PE 
controlled genes, we identified upregulation of Bcl2 (anti-apoptotic) and 
downregulation of Htra2 (apoptotic), which is in line with a previously described 
 
Figure 6 Analysis of gene expression arrays of control versus PE and IGF1 stimulated 
NRVCs 
 
Gene expression was analysed using Affymetrics gene expression arrays. RNA of control, 
PE and IGF1 stimulated cells was isolated and used for expression analysis (A). 
Expression of genes encoding mitochondrial proteins was analysed. Using an FDR <10% 
revealed a number of genes that were differentially expressed in NRVCs upon 
stimulation with PE or IGF1 (A). Analysis of the significantly regulated genes related to 
the mitochondria. The number of differentially expressed genes related to the 
mitochondria compared to Control in PE-treated NRVCs (blue) and IGF1-treated NRVCs 
(yellow) are depicted in circles, common genes are shown in green. The biological 
processes (DAVID) to which these genes are related are shown in respective boxes (B). 
A simplified scheme of Gene Sets that were significantly regulated upon stimulation with 
PE or IGF1 (C). 
6Hypertrophy induced KIF5B controls mitochondrial localization and function 
150 
peripheral staining intensity confirmed a high intensity around the nucleus in 
control and even more in IGF1 stimulated NRVCs. This ratio was significantly 
lower in PE stimulated cells (Figure 5B). Furthermore, counting the number of 
NRVCs with a low perinuclear/peripheral staining ratio (<3.0) confirmed this 
peripheral localization in PE stimulated NRVCs (Figure 5C). Thus, PE, but not IGF1, 
stimulates peripheral mitochondrial localization in NRVCs. 
 
Gene array analysis reveals upregulation of Kif5b in PE treated NRVCs. 
Gene expression changes could potentially reveal targets that explain the 
observed differences. A gene array analysis was therefore performed with RNA 
from control, PE and IGF1 stimulated NRVCs. Using a FDR of 10%, we 
identified >300 genes that were differentially expressed in PE stimulated NRVCs, 
compared to almost 1200 genes in IGF1 stimulated NRVCs. Of these genes at 
least 4,9% of both the PE and IGF1 group translated into proteins that are 
localized to mitochondria , based on available proteomic data (Figure 6A) (30). 
This mitochondrial set was further explored using DAVID to categorize genes into 
biological processes (Figure 6B). No specific functionally related groups of genes 
were found in the PE stimulated NRVCs (Figure 6B) but within the 9 specific PE 
controlled genes, we identified upregulation of Bcl2 (anti-apoptotic) and 
downregulation of Htra2 (apoptotic), which is in line with a previously described 
 
Figure 6 Analysis of gene expression arrays of control versus PE and IGF1 stimulated 
NRVCs 
 
Gene expression was analysed using Affymetrics gene expression arrays. RNA of control, 
PE and IGF1 stimulated cells was isolated and used for expression analysis (A). 
Expression of genes encoding mitochondrial proteins was analysed. Using an FDR <10% 
revealed a number of genes that were differentially expressed in NRVCs upon 
stimulation with PE or IGF1 (A). Analysis of the significantly regulated genes related to 
the mitochondria. The number of differentially expressed genes related to the 
mitochondria compared to Control in PE-treated NRVCs (blue) and IGF1-treated NRVCs 
(yellow) are depicted in circles, common genes are shown in green. The biological 
processes (DAVID) to which these genes are related are shown in respective boxes (B). 
A simplified scheme of Gene Sets that were significantly regulated upon stimulation with 




Figure 6 Analysis of gene expression arrays of control versus PE and IGF1 stimulated 
NRVCs 
Figure legend on page 150. 
6Hypertrophy induced KIF5B controls mitochondrial localization and function 
152 
link between PE and protection against cardiomyocyte apoptosis (31,32). Only 6 
genes were shared between PE and IGF1 stimulated NRVCs, identifying enriched 
biological pathways in isoprenoid, sterol and cholesterol biosynthetic and 
metabolic processes (Figure 6B). In IGF1 stimulated NRVCs more mitochondrial 
related genes were differentially expressed. For the IGF1 gene set functional 
annotation revealed enrichment in several metabolic and biosynthetic processes  
including oxoacid, coenzyme, cofactor, organic acid, heterocycle, nucleotide and 
fatty acid metabolic and biosynthetic processes. No major changes in specific ETC 
related gene expression were observed (Figure 6B and supplemental data set). 
Whole Gene Set Enrichment Analysis, which allows detection of changes in 
gene sets not depending on significant changed expression of individual genes, 
did however, show significant differences. A schematic and simplified overview 
of gene sets related to metabolism is shown in Figure 6C. A number of changes 
related to metabolism in IGF1 stimulated NRVCs was observed, including the TCA 
cycle, the ETC and OXPHOS pathways. In PE stimulated NRVCs less changes in 
specific gene sets were found, including fatty acid metabolism (Figure 6C). Thus, 
changes in expression of genes encoding mitochondrial localized proteins are 
small in these 24 hours PE and IGF1 stimulated NRVCs. 
 
 
Figure 7 Increased KIF5B expression in animal models of pathological hypertrophy 
Based on gene expression array data described in Figure 6, differentially expressed 
genes encoding motor proteins (FDR<10%) were identified in the PE stimulated or IGF1 
stimulated NRVCs. A heat-map of these genes is shown (A). To confirm expression in 
animal models of hypertrophy Kif5b gene expression were measured by quantitative RT-
PCR in cardiac tissue. Kif5b expression in mice after 4 and 8 weeks TAC surgery (N=7-12) 
Expression of Kif5b protein levels after 36 hours PE stimulation was evaluated by 
Western blotting and a representative blot from three independent experiments is 
shown (B). To confirm expression in animal cardiac hypertrophy models, Kif5b gene and 
protein expression were determined by quantitative RT-PCR and Western blotting, 
respectively. Cardiac Kif5b gene expression in mice after 4 and 8 weeks TAC surgery 
(N=7-12) (C). Quantification of KIF5B protein expression in mice after 8 weeks TAC 
surgery (N=6) (D) and representative Western blot (E). Kif5b gene expression in 
transgenic Ren2 rats (N=8-9)(F). KIF5B protein expression in transgenic Ren2 rats 
(N=6)(G) and representative Western blot (H). All graphs depict means and SD, *P < 0.05 
as compared to control. 
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The kinesin motor protein KIF5B is specifically upregulated in PE treated 
cells 
Based on our localization data, we also investigated genes potentially involved in 
mitochondrial dynamics and localization. We did not observe gene expression 
differences in genes involved in mitochondrial fission/fusion and also protein 
levels and dynamic localization of two of these proteins, dynamin-like protein 
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6Hypertrophy induced KIF5B controls mitochondrial localization and function 
154 
(Drp1) and mitofusin (Mfn1/2) were not altered (supplemental figure 2). We did, 
however, identify several kinesin and dynein motor proteins in our gene array 
that were differentially expressed between the different conditions (Figure 7A). 
Most interestingly, Kif5b showed the highest expression and was upregulated 
under PE stimulatory conditions only (1.6 fold increase). Moreover, we could 
confirm that KIF5B protein levels were similarly increased in PE stimulated cells 
only (Figure 7B). KIF5B has previously been shown to affect localization of 
mitochondria in tumour cell lines (33). Also in in vivo hypertrophic conditions 
disturbed morphology and mitochondrial localization has been reported (28,34–
38). We therefore analyzed whether Kif5b gene expression was altered in mice 
with cardiac hypertrophy generated by transverse aortic constriction (TAC) and 
in hypertensive transgenic Ren2 rats. Kif5b gene expression was indeed elevated 
in the animal models with pathological hypertrophy (Figure 7C and D). Also in 
this case KIF5B protein levels paralleled the gene expression increases (Figure 7C 
and D). We also like to note that we did not observe an increase in Kif5b gene 
expression in a physiological mouse hypertrophy model (Supplemental Figure 3). 
Together these data suggests that KIF5B could control mitochondrial dynamic 
localization in cardiac tissue in response to pathological hypertrophic stimuli.  
 
Depletion of KIF5B prevented mitochondrial dispersion and limited the 
respiratory increase 
Silencing of Kif5b was performed to investigate whether KIF5B could be 
responsible for the changed mitochondrial localization in PE treated NRVCs. 
Transfection of specific siRNA’s targeting Kif5b resulted approximately in a 75% 
decrease in Kif5b mRNA levels (Figure 8A) and around 70% decrease in KIF5B 
protein levels (Figure 8B). Interestingly, this fully prevented PE induced 
dispersion of mitochondria as is shown by the intensity of TOM20 staining (Figure 
8C and 8D). Thus, also in cardiomyocytes, Kif5b is involved in mitochondrial 
transport. We also investigated whether this changed localization would affect 
cellular respiration and hypertrophy. Silencing of Kif5b attenuated PE induced 
3H-leucine incorporation, but did not prevent it (figure 9A) and a similar effect 
was observed on cell size (1.34±0.15 versus 1.21±0.12 fold increase for PE and 
siKif5B+PE, respectively). Pathological gene expression was, however, not 
attenuated by KIF5B silencing (Figure 9B and supplemental figure 4). Also  
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Figure 8 Kif5b silencing in NRVCs affects mitochondrial localization  
Kif5b was silenced in NRVCs for 72hr. Kif5b mRNA levels were measured by quantitative 
RT-PCR in control cells and PE stimulated NRVCs (N=6)(A). Protein expression levels were 
measured by Western blot in control and PE stimulated NRVCs and a representative blot 
from three independent experiments is shown (B). Mitochondrial localization is 
visualized by staining mitochondria with anti-TOM20 antibody (green). Cardiomyocytes 
were stained with cardiac specific sarcomeric α-actinin (red) and nuclei were 
counterstained with DAPI (blue). Representative images are shown (B). Quantification 
of the ratio in intensity of perinuclear and peripheral cytoplasmic TOM20 signal (N=4) 
(D).  
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respiration was investigated, and, since it has been reported that the scaffold 
protein Daxx together with KIF5B controls insulin mediated translocation of the 
glucose transporter Glut4 in adipose cells (39), we performed these experiments 
with pyruvate as a carbon source. In control cells Kif5b silencing did not show a 
significant effect on respiration, but in PE treated NRVCs silencing of Kif5b 
showed a partial diminishment (Figure 9C and 9D). Similar results were observed 
when glucose was used as a substrate instead of pyruvate, indicating that the 
observed effects were carbon source and hence transporter independent 
(supplemental Figure 5). Thus, mitochondrial relocalization by KIF5B affects 
mitochondrial dependent cellular respiration and attenuates phenylephrine 
induced hypertrophy. 
 
D I S C U S S I O N  
Hypertrophic stimuli induce cardiomyocyte growth, but the biochemical and 
molecular alterations are clearly different between various hypertrophic stimuli. 
Here we show that this is also true for mitochondrial localization and function in 
vitro. Using neonatal cardiomyocyte cultures, we were able to determine effects 
of specific hypertrophic stimuli on mitochondrial localization. Interestingly, 
stimulation of NRVCs with PE resulted in an altered mitochondrial OCR and 
mitochondrial localization within 24 hours. Kif5b was identified as a pathological 
hypertrophy specific gene and was responsible for the changes in mitochondrial 
localization. Altered mitochondrial morphology and distribution are hallmarks of 
heart failure (37,38) and we could show that also in pathological hypertrophy 
animal models, KIF5B expression was upregulated.  
Hypertrophic stimulation with PE or IGF1 resulted in the activation of different 
signal transduction pathways. Moreover, in agreement with others, only PE 
stimulation resulted in expression of the fetal gene program, a pathological 
hypertrophy characteristic. Here we showed that these different stimuli also 
have direct, but distinct effects on mitochondrial function and localization. 
Measurements of the activities of mitochondrial complex I and II revealed 
opposite effect in PE and IGF1 stimulated NRVCs. Whereas complex II and to a 
lesser extend complex I dependent activity (state 3) were declined in PE 
stimulated NRVCs, complex I dependent activity (state 3) was increased in IGF1 
treated NRVCs. Also in hypertrophic HF samples a decline in activities of different 
complexes have been observed, but there is limited consensus which complex 
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activities are altered (40–42). This is probably related to the differences in the 
etiology and severity of disease and it has been proven difficult to uncover the 
Figure 9 Kif5b silencing partially reverses PE induced effects on mitochondrial 
dependent cellular respiration and hypertrophy. 
Effects of silencing of Kif5b on PE induced cellular hypertrophy was measured using 3H-
Leucine incorporation (N=3) (A). mRNA expression levels of the hypertrophic markers 
Nppa, was determined using qRT-PCR (N=3) (B). Total cellular OCR using pyruvate as a 
substrate was measured with sequential additions of the ATP synthase inhibitor 
oligomycin, the uncoupling agent FCCP and mitochondrial respiration inhibitors 
antimycin A/rotenone (AR) as depicted in the graph (C). Mitochondrial specific OCR 
values, mitochondrial respiration, ATP-linked OCR and maximal respiration, were 
determined by correcting total OCR values for OCR values after addition of AR. Corrected 
oxygen consumption data of the first 3 measurements were averaged to yield the 
mitochondrial respiration. The ATP-linked OCR, defined as oligomycin- sensitive OCR, 
was calculated. Maximal respiration was induced by FCCP (N=4)(D). All graphs depict 
means and SD, *P < 0.05 as compared to control. 
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processes that underlie these changed activities. To our knowledge, we now 
show for the first time that complex I and II dependent activities can be 
modulated by specific hypertrophic stimuli in vitro and this may provide an 
opportunity to study these processes in more detail in an isolated cellular 
system. This also suggests that changes in mitochondrial function can already 
arise early during hypertrophy development and are not necessarily a late stage 
HF phenomenon, which is in agreement with others (43).  
Despite decreased complex activities, mitochondrial respiration was 
strongly increased in PE stimulated NRVCs. In contrast no changes in 
mitochondrial respiration were observed in IGF1 stimulated NRVCs. Thus, 
changes in mitochondrial complex activities do not necessarily reflect 
mitochondrial fluxes in intact NRVCs and caution is required when results from 
isolated mitochondria are extrapolated to the whole cell or organ. It has been 
proposed that in the compensated stage of hypertrophy, respiratory flux may 
first increase resulting in a gradual decline at later stages (11). Our increase in 
flux in PE stimulated NRVCs may support this idea and suggest that the PE 
condition with increased OCR is more comparable to early stages of cardiac 
pathological hypertrophy. These results show that no simple relation exist 
between mitochondrial function and hypertrophy development.  
Within the investigated time frame (24 hours) no significant changes in 
mitochondrial biogenesis or levels of OXPHOS proteins were observed with the 
two different hypertrophic stimuli. Also no significant changes in expression of 
genes of the ETC and OXPHOS were identified. However, we do like to note that 
when whole gene set analysis was performed, ETC complex expression was 
significantly upregulated in IGF1 stimulated NRVCs. These minor differences 
could, however, not be identified at the protein level, and probably the 24 hours 
stimulation is too short to induce IGF1 mediated mitochondrial biogenesis in 
NRVCs. The changes in complex activities are therefore likely mediated by 
posttranslational processes, like phosphorylation, succinylation and acetylation 
(44,45) and complex or supercomplex assembly (46). In contrast to our in vitro 
data, a number of studies have shown that mitochondrial gene expression is 
altered in cardiac HF samples. These studies have, however, predominantly been 
performed on end-stage HF cardiac tissue (47,48). A recent study, with a focus 
on earlier stages of HF, with less severe cardiac remodeling showed absence of 
transcriptional changes in OXPHOS and ETC genes (5), which is in line with our in 
vitro data.  
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IGF1 signaling is essential for mitochondrial biogenesis during physiological 
hypertrophy stimulation in mice (49). In a transgenic IGF1 overexpressing mouse 
model PGC-1 α expression and mitochondrial protein levels were, however, not 
increased, but high fat diet induced repression of mitochondrial biogenesis was 
prevented (50). Thus, IGF1 alone appears not sufficient for induction of 
mitochondrial biogenesis. Also in this study no mitochondrial biogenesis was 
observed upon IGF1 stimulation and gene expression of mitochondrial gene sets 
was only slightly elevated. Mitochondrial biogenesis is thus not required for 
development of physiological hypertrophy.  
Mitochondria in PE treated NRVCs showed a different localization pattern 
and we identified KIF5B, a motor protein of the kinesin family reported to control 
mitochondrial localization and function, to be upregulated under pathological 
hypertrophy. Moreover, depletion of KIF5B, confirmed that this protein is 
required for the changed localization in PE treated NRVCs. Depletion of KIF5B 
also resulted in diminished hypertrophy development after PE stimulation, but 
could not prevent pathological gene expression. Thus, KIF5B contributes to 
pathological growth, but is not essential for the pathological response. Although 
we focused here on dynamic mitochondrial localization, also effects on other 
mitochondrial dynamics, namely fission and fusion have been reported. Whereas 
Javadov et al., (51) reported altered expression of dynamin-like protein (Drp1) 
and mitofusin (Mfn1/2), Pennanen et al. (35) did not observe differences in the 
expression of these proteins after hypertrophic stimulation of neonatal 
cardiomyocytes. Nevertheless they reported that norepinephrine (NE) can 
stimulated mitochondrial fission by increasing the localization of Drp1 to 
mitochondria (35). In our PE stimulated we did not observe changes in Drp1 and 
Mfn1 gene and protein expression in agreement with Pennanen et al. (35), but 
did also not observe mitochondrial redistribution of Drp1 or Mfn1. The use of PE 
instead of NE could potentially explain this difference, and we do not like to 
exclude potential alterations in mitochondrial morphology, but the altered 
localization makes this difficult to analyze. Together these results show that 
pathological conditions, can alter mitochondrial localization and potentially 
morphology and thereby affecting mitochondrial function. Also in heart failure 
patients and in animal heart failure models changed morphology and localization 
of mitochondria have been reported (28,37,38) and with the identification of a 
potential molecular mechanism this now warrants further investigations. In the 
adult cardiomyocyte the situation is, however, more complex with two different 
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types of mitochondria, subsarcolemmal (SS) and intermyofibrillar (IFM) (52). It is 
likely that other factors next to KIF5B play a role in the proper localization of 
these distinct mitochondrial populations.  
Some study limitations have to be taken into account. Although neonatal 
rat cardiomyocytes are an established in vitro hypertrophy model, these results 
cannot be directly translated to the adult heart. The model has, however, a major 
advantage in that it allows to investigate single stimuli independent of other 
contributing factors and that it is feasible to perform mitochondrial OCR 
measurements in intact NRVCs. Although we have investigated the levels of 
some mitochondrial complex proteins, to exclude changes in biogenesis, we have 
not investigated complex formation or post-translational modifications. 
Considering our results elaborate mass spectrometry analysis might be an 
interesting next step.  
In conclusion, we provide for the first time an in vitro model of 
mitochondrial dysfunction and changed dynamic localization in pathological and 
physiological cardiac hypertrophy. We identify KIF5B as a gene that is 
upregulated exclusively in pathological hypertrophy with a role in mitochondrial 
localization and function. 
 
A C K N O W L E D G E M E N T S  
We like to thank Sarah Meijer, Reinier Bron and Louise van Wijk for help 
with Western blotting, microscopy, cell counting and RNA analysis. We like to 
thank Moshin Kahn for help with generating heat-maps in “R”. We like to thank 
Laura Meems for supplying us with RNA of animal experiments. R.A de Boer is 
supported by the Innovational Research Incentives Scheme program of the 
Netherlands Organization for Scientific Research [Vidi grant 917.13.350]. 
 






6Hypertrophy induced KIF5B controls mitochondrial localization and function 
160 
types of mitochondria, subsarcolemmal (SS) and intermyofibrillar (IFM) (52). It is 
likely that other factors next to KIF5B play a role in the proper localization of 
these distinct mitochondrial populations.  
Some study limitations have to be taken into account. Although neonatal 
rat cardiomyocytes are an established in vitro hypertrophy model, these results 
cannot be directly translated to the adult heart. The model has, however, a major 
advantage in that it allows to investigate single stimuli independent of other 
contributing factors and that it is feasible to perform mitochondrial OCR 
measurements in intact NRVCs. Although we have investigated the levels of 
some mitochondrial complex proteins, to exclude changes in biogenesis, we have 
not investigated complex formation or post-translational modifications. 
Considering our results elaborate mass spectrometry analysis might be an 
interesting next step.  
In conclusion, we provide for the first time an in vitro model of 
mitochondrial dysfunction and changed dynamic localization in pathological and 
physiological cardiac hypertrophy. We identify KIF5B as a gene that is 
upregulated exclusively in pathological hypertrophy with a role in mitochondrial 
localization and function. 
 
A C K N O W L E D G E M E N T S  
We like to thank Sarah Meijer, Reinier Bron and Louise van Wijk for help 
with Western blotting, microscopy, cell counting and RNA analysis. We like to 
thank Moshin Kahn for help with generating heat-maps in “R”. We like to thank 
Laura Meems for supplying us with RNA of animal experiments. R.A de Boer is 
supported by the Innovational Research Incentives Scheme program of the 
Netherlands Organization for Scientific Research [Vidi grant 917.13.350]. 
 















R E F E R E N C E S  
1.  Barry SP, Davidson SM, Townsend 
PA. Molecular regulation of cardiac 
hypertrophy. Int J Biochem Cell 
Biol. 2008 Jan;40(10):2023–39.  
2.  Frey N, Katus HA, Olson EN, Hill JA. 
Hypertrophy of the heart: a new 
therapeutic target? Circulation. 
2004 Apr 6;109(13):1580–9.  
3.  Bernardo BC, Weeks KL, Pretorius 
L, McMullen JR. Molecular 
distinction between physiological 
and pathological cardiac 
hypertrophy: experimental 
findings and therapeutic 
strategies. Pharmacol Ther. 2010 
Oct;128(1):191–227.  
4.  De Boer RA, Pinto YM, Van 
Veldhuisen DJ. The Imbalance 
Between Oxygen Demand and 
Supply as a Potential Mechanism 
in the Pathophysiology of Heart 
Failure: The Role of Microvascular 
Growth and Abnormalities. 
Microcirculation. 2003 
Apr;10(2):113–26.  
5.  Lai L, Leone TC, Keller MP, Martin 
OJ, Broman AT, Nigro J, et al. 
Energy Metabolic Reprogramming 
in the Hypertrophied and Early 
Stage Failing Heart: A 
Multisystems Approach. Circ Hear 
Fail. 2014 Sep 18;7(6):1022–31.  
6.  Kienesberger PC, Pulinilkunnil T, 
Nagendran J, Dyck JRB. Myocardial 
triacylglycerol metabolism. J Mol 
Cell Cardiol. 2013 Feb;55:101–10.  
7.  Kolwicz SC, Tian R. Glucose 
metabolism and cardiac 
hypertrophy. Cardiovasc Res. 2011 
May 1;90(2):194–201.  
8.  Lehman JJ, Kelly DP. Gene 
regulatory mechanisms governing 
energy metabolism during cardiac 
hypertrophic growth. Heart Fail 
Rev. 2002 Apr;7(2):175–85.  
9.  Neill BTO, Kim J, Wende AR, 
Theobald HA, Tuinei J, Buchanan J, 
et al. A conserved role for 
phosphatidylinositol 3-kinase but 
not Akt signaling in mitochondrial 
adaptations that accompany 
physiological cardiac hypertrophy. 
Cell Metab. 2007;6(4):294–306.  
10.  Abel ED, Doenst T. Mitochondrial 
adaptations to physiological vs. 
pathological cardiac hypertrophy. 
Cardiovasc Res. 2011 May 
1;90(2):234–42.  
11.  Rosca MG, Tandler B, Hoppel CL. 
Mitochondria in cardiac 
hypertrophy and heart failure. J 
Mol Cell Cardiol. 2013 
Feb;55(1):31–41.  
12.  Lu B, Mahmud H, Maass AH, Yu B, 
van Gilst WH, de Boer RA, et al. 
The Plk1 inhibitor BI 2536 
temporarily arrests primary 
cardiac fibroblasts in mitosis and 
generates aneuploidy in vitro. PLoS 
One. 2010 Jan;5(9):e12963.  
13.  Lu B, Yu H, Zwartbol M, Ruifrok 
WP, van Gilst WH, de Boer RA, et 
al. Identification of hypertrophy- 
and heart failure-associated genes 
by combining in vitro and in vivo 
models. Physiol Genomics. 2012 
Apr 15;44(8):443–54.  
6 
 
R E F E R E N C E S  
1.  Barry SP, Davidson SM, Townsend 
PA. Molecular regulation of cardiac 
hypertrophy. Int J Biochem Cell 
Biol. 2008 Jan;40(10):2023–39.  
2.  Frey N, Katus HA, Olson EN, Hill JA. 
Hypertrophy of the heart: a new 
therapeutic target? Circulation. 
2004 Apr 6;109(13):1580–9.  
3.  Bernardo BC, Weeks KL, Pretorius 
L, McMullen JR. Molecular 
distinction between physiological 
and pathological cardiac 
hypertrophy: experimental 
findings and therapeutic 
strategies. Pharmacol Ther. 2010 
Oct;128(1):191–227.  
4.  De Boer RA, Pinto YM, Van 
Veldhuisen DJ. The Imbalance 
Between Oxygen Demand and 
Supply as a Potential Mechanism 
in the Pathophysiology of Heart 
Failure: The Role of Microvascular 
Growth and Abnormalities. 
Microcirculation. 2003 
Apr;10(2):113–26.  
5.  Lai L, Leone TC, Keller MP, Martin 
OJ, Broman AT, Nigro J, et al. 
Energy Metabolic Reprogramming 
in the Hypertrophied and Early 
Stage Failing Heart: A 
Multisystems Approach. Circ Hear 
Fail. 2014 Sep 18;7(6):1022–31.  
6.  Kienesberger PC, Pulinilkunnil T, 
Nagendran J, Dyck JRB. Myocardial 
triacylglycerol metabolism. J Mol 
Cell Cardiol. 2013 Feb;55:101–10.  
7.  Kolwicz SC, Tian R. Glucose 
metabolism and cardiac 
hypertrophy. Cardiovasc Res. 2011 
May 1;90(2):194–201.  
8.  Lehman JJ, Kelly DP. Gene 
regulatory mechanisms governing 
energy metabolism during cardiac 
hypertrophic growth. Heart Fail 
Rev. 2002 Apr;7(2):175–85.  
9.  Neill BTO, Kim J, Wende AR, 
Theobald HA, Tuinei J, Buchanan J, 
et al. A conserved role for 
phosphatidylinositol 3-kinase but 
not Akt signaling in mitochondrial 
adaptations that accompany 
physiological cardiac hypertrophy. 
Cell Metab. 2007;6(4):294–306.  
10.  Abel ED, Doenst T. Mitochondrial 
adaptations to physiological vs. 
pathological cardiac hypertrophy. 
Cardiovasc Res. 2011 May 
1;90(2):234–42.  
11.  Rosca MG, Tandler B, Hoppel CL. 
Mitochondria in cardiac 
hypertrophy and heart failure. J 
Mol Cell Cardiol. 2013 
Feb;55(1):31–41.  
12.  Lu B, Mahmud H, Maass AH, Yu B, 
van Gilst WH, de Boer RA, et al. 
The Plk1 inhibitor BI 2536 
temporarily arrests primary 
cardiac fibroblasts in mitosis and 
generates aneuploidy in vitro. PLoS 
One. 2010 Jan;5(9):e12963.  
13.  Lu B, Yu H, Zwartbol M, Ruifrok 
WP, van Gilst WH, de Boer RA, et 
al. Identification of hypertrophy- 
and heart failure-associated genes 
by combining in vitro and in vivo 
models. Physiol Genomics. 2012 
Apr 15;44(8):443–54.  
Chapter 6 
163 
14.  de Boer RA, Pokharel S, Flesch M, 
van Kampen DA, Suurmeijer AJH, 
Boomsma F, et al. Extracellular 
signal regulated kinase and SMAD 
signaling both mediate the 
angiotensin II driven progression 
towards overt heart failure in 
homozygous TGR(mRen2)27. J Mol 
Med (Berl). 2004 Oct;82(10):678–
87.  
15.  Muller O, Lange M, Rattunde H, 
Lorenzen H, Muller M, Frey N, et 
al. Transgenic rat hearts 
overexpressing SERCA2a show 
improved contractility under 
baseline conditions and pressure 
overload. Cardiovasc Res. 2003 
Aug 1;59(2):380–9.  
16.  Salabei JK, Gibb A a, Hill BG. 
Comprehensive measurement of 
respiratory activity in 
permeabilized cells using 
extracellular flux analysis. Nat 
Protoc. 2014 Feb;9(2):421–38.  
17.  Tigchelaar W, Yu H, De Jong AM, 
van Gilst WH, van der Harst P, 
Westenbrink BD, et al. Loss of 
mitochondrial exo/endonuclease 
EXOG affects mitochondrial 
respiration and induces ROS 
mediated cardiomyocyte 
hypertrophy. Am J Physiol Cell 
Physiol. 2014 Nov 
5;ajpcell.00227.2014.  
18.  Lin K, Kools H, de Groot PJ, Gavai 
AK, Basnet RK, Cheng F, et al. 
MADMAX - Management and 
analysis database for multiple 
~omics experiments. J Integr 
Bioinform. 2011;8(2):160.  
19.  Sartor MA, Tomlinson CR, 
Wesselkamper SC, Sivaganesan S, 
Leikauf GD, Medvedovic M. 
Intensity-based hierarchical Bayes 
method improves testing for 
differentially expressed genes in 
microarray experiments. BMC 
Bioinformatics. 2006;7(1):538.  
20.  Storey JD, Tibshirani R. Statistical 
significance for genomewide 
studies. Proc Natl Acad Sci. 2003 
Aug 5;100(16):9440–5.  
21.  Huang DW, Sherman BT, Lempicki 
RA. Systematic and integrative 
analysis of large gene lists using 
DAVID bioinformatics resources. 
Nat Protoc. 2008 Dec;4(1):44–57.  
22.  Subramanian A, Tamayo P, 
Mootha VK, Mukherjee S, Ebert BL, 
Gillette MA, et al. Gene set 
enrichment analysis: A knowledge-
based approach for interpreting 
genome-wide expression profiles. 
Proc Natl Acad Sci. 2005 Oct 
25;102(43):15545–50.  
23.  De Jong AM, Van Gelder IC, 
Vreeswijk-Baudoin I, Cannon M V., 
Van Gilst WH, Maass AH. Atrial 
Remodeling Is Directly Related to 
End-Diastolic Left Ventricular 
Pressure in a Mouse Model of 
Ventricular Pressure Overload. 
Lionetti V, editor. PLoS One. 2013 
Sep 6;8(9):e72651.  
24.  Lee MA, Böhm M, Paul M, Bader 
M, Ganten U, Ganten D. 
Physiological characterization of 
the hypertensive transgenic rat 
TGR(mREN2)27. Am J Physiol. 
1996;270(6 Pt 1):E919–29.  
6Hypertrophy induced KIF5B controls mitochondrial localization and function 
164 
25.  Sharov VG, Todor A V, Silverman 
N, Goldstein S, Sabbah HN. 
Abnormal mitochondrial 
respiration in failed human 
myocardium. J Mol Cell Cardiol. 
2000 Dec;32(12):2361–7.  
26.  Strom CC, Aplin M, Ploug T, 
Christoffersen TEH, Langfort J, 
Viese M, et al. Expression profiling 
reveals differences in metabolic 
gene expression between exercise-
induced cardiac effects and 
maladaptive cardiac hypertrophy. 
FEBS J. 2005 Jun;272(11):2684–95.  
27.  Dorn GW. Mitochondrial dynamics 
in heart disease. Biochim Biophys 
Acta - Mol Cell Res. 
2013;1833(1):233–41.  
28.  Dorn GW. Mitochondrial 
dynamism and heart disease: 
changing shape and shaping 
change. EMBO Mol Med. 2015 Jul 
1;7(7):865–77.  
29.  Yano M, Kanazawa M, Terada K, 
Takeya M, Hoogenraad N, Mori M. 
Functional Analysis of Human 
Mitochondrial Receptor Tom20 for 
Protein Import into Mitochondria. 
J Biol Chem. 1998 Oct 
9;273(41):26844–51.  
30.  Pagliarini DJ, Calvo SE, Chang B, 
Sheth SA, Vafai SB, Ong SE, et al. A 
Mitochondrial Protein 
Compendium Elucidates Complex I 
Disease Biology. Cell. 
2008;134(1):112–23.  
31.  Yao L-L, Wang Y-G, Liu X-J, Zhou Y, 
Li N, Liu J, et al. Phenylephrine 
protects cardiomyocytes from 
starvation-induced apoptosis by 
increasing glyceraldehyde-3-
phosphate dehydrogenase 
(GAPDH) activity. J Cell Physiol. 
2012 Oct;227(10):3518–27.  
32.  Zhu H, McElwee-Witmer S, 
Perrone M, Clark KL, Zilberstein a. 
Phenylephrine protects neonatal 
rat cardiomyocytes from hypoxia 
and serum deprivation-induced 
apoptosis. Cell Death Differ. 2000 
Sep;7(9):773–84.  
33.  Tanaka Y, Kanai Y, Okada Y, 
Nonaka S, Takeda S, Harada a, et 
al. Targeted disruption of mouse 
conventional kinesin heavy chain, 
kif5B, results in abnormal 
perinuclear clustering of 
mitochondria. Cell. 1998 Jun 
26;93(7):1147–58.  
34.  Fang L, Moore XL, Gao XM, Dart 
AM, Lim YL, Du XJ. Down-
regulation of mitofusin-2 
expression in cardiac hypertrophy 
in vitro and in vivo. Life Sci. 
2007;80(23):2154–60.  
35.  Pennanen C, Parra V, López-
Crisosto C, Morales PE, Del Campo 
A, Gutierrez T, et al. Mitochondrial 
fission is required for 
cardiomyocyte hypertrophy 
mediated by a Ca2+-calcineurin 
signaling pathway. J Cell Sci. 2014 
Jun 15;127(Pt 12):2659–71. 
 36.  Tang Y, Mi C, Liu J, Gao F, Long J. 
Compromised mitochondrial 
remodeling in compensatory 
hypertrophied myocardium of 
spontaneously hypertensive rat. 
Cardiovasc Pathol. 2014 
Mar;23(2):101–6.  
6Hypertrophy induced KIF5B controls mitochondrial localization and function 
164 
25.  Sharov VG, Todor A V, Silverman 
N, Goldstein S, Sabbah HN. 
Abnormal mitochondrial 
respiration in failed human 
myocardium. J Mol Cell Cardiol. 
2000 Dec;32(12):2361–7.  
26.  Strom CC, Aplin M, Ploug T, 
Christoffersen TEH, Langfort J, 
Viese M, et al. Expression profiling 
reveals differences in metabolic 
gene expression between exercise-
induced cardiac effects and 
maladaptive cardiac hypertrophy. 
FEBS J. 2005 Jun;272(11):2684–95.  
27.  Dorn GW. Mitochondrial dynamics 
in heart disease. Biochim Biophys 
Acta - Mol Cell Res. 
2013;1833(1):233–41.  
28.  Dorn GW. Mitochondrial 
dynamism and heart disease: 
changing shape and shaping 
change. EMBO Mol Med. 2015 Jul 
1;7(7):865–77.  
29.  Yano M, Kanazawa M, Terada K, 
Takeya M, Hoogenraad N, Mori M. 
Functional Analysis of Human 
Mitochondrial Receptor Tom20 for 
Protein Import into Mitochondria. 
J Biol Chem. 1998 Oct 
9;273(41):26844–51.  
30.  Pagliarini DJ, Calvo SE, Chang B, 
Sheth SA, Vafai SB, Ong SE, et al. A 
Mitochondrial Protein 
Compendium Elucidates Complex I 
Disease Biology. Cell. 
2008;134(1):112–23.  
31.  Yao L-L, Wang Y-G, Liu X-J, Zhou Y, 
Li N, Liu J, et al. Phenylephrine 
protects cardiomyocytes from 
starvation-induced apoptosis by 
increasing glyceraldehyde-3-
phosphate dehydrogenase 
(GAPDH) activity. J Cell Physiol. 
2012 Oct;227(10):3518–27.  
32.  Zhu H, McElwee-Witmer S, 
Perrone M, Clark KL, Zilberstein a. 
Phenylephrine protects neonatal 
rat cardiomyocytes from hypoxia 
and serum deprivation-induced 
apoptosis. Cell Death Differ. 2000 
Sep;7(9):773–84.  
33.  Tanaka Y, Kanai Y, Okada Y, 
Nonaka S, Takeda S, Harada a, et 
al. Targeted disruption of mouse 
conventional kinesin heavy chain, 
kif5B, results in abnormal 
perinuclear clustering of 
mitochondria. Cell. 1998 Jun 
26;93(7):1147–58.  
34.  Fang L, Moore XL, Gao XM, Dart 
AM, Lim YL, Du XJ. Down-
regulation of mitofusin-2 
expression in cardiac hypertrophy 
in vitro and in vivo. Life Sci. 
2007;80(23):2154–60.  
35.  Pennanen C, Parra V, López-
Crisosto C, Morales PE, Del Campo 
A, Gutierrez T, et al. Mitochondrial 
fission is required for 
cardiomyocyte hypertrophy 
mediated by a Ca2+-calcineurin 
signaling pathway. J Cell Sci. 2014 
Jun 15;127(Pt 12):2659–71. 
 36.  Tang Y, Mi C, Liu J, Gao F, Long J. 
Compromised mitochondrial 
remodeling in compensatory 
hypertrophied myocardium of 
spontaneously hypertensive rat. 




37.  Chen L, Gong Q, Stice JP, Knowlton 
AA. Mitochondrial OPA1, 
apoptosis, and heart failure. 
Cardiovasc Res. 2009 Oct 
1;84(1):91–9.  
38.  Schaper J, Froede R, Hein S, Buck 
a, Hashizume H, Speiser B, et al. 
Impairment of the myocardial 
ultrastructure and changes of the 
cytoskeleton in dilated 
cardiomyopathy. Circulation. 
1991;83(2):504–14.  
39.  Lalioti VS, Vergarajauregui S, 
Tsuchiya Y, Hernandez-Tiedra S, 
Sandoval I V. Daxx functions as a 
scaffold of a protein assembly 
constituted by GLUT4, JNK1 and 
KIF5B. J Cell Physiol. 2009 
Feb;218(2):416–26.  
40.  Cordero-Reyes AM, Gupte AA, 
Youker KA, Loebe M, Hsueh WA, 
Torre-Amione G, et al. Freshly 
isolated mitochondria from failing 
human hearts exhibit preserved 
respiratory function. J Mol Cell 
Cardiol. 2014 Mar;68:98–105.  
41.  Marín-García J, Goldenthal MJ, 
Moe GW. Abnormal cardiac and 
skeletal muscle mitochondrial 
function in pacing-induced cardiac 
failure. Cardiovasc Res. 
2001;52:103–10.  
42.  Schoepe M, Schrepper A, 
Schwarzer M, Osterholt M, Doenst 
T. Exercise can induce temporary 
mitochondrial and contractile 
dysfunction linked to impaired 
respiratory chain complex activity. 
Metabolism. 2012 Jan;61(1):117–
26.  
43.  Lemieux H, Semsroth S, Antretter 
H, Höfer D, Gnaiger E. 
Mitochondrial respiratory control 
and early defects of oxidative 
phosphorylation in the failing 
human heart. Int J Biochem Cell 
Biol. 2011 Dec;43(12):1729–38.  
44.  Hofer A, Wenz T. Post-translational 
modification of mitochondria as a 
novel mode of regulation. Exp 
Gerontol. 2014;56:202–20.  
45.  Shinmura K. Post-Translational 
Modification of Mitochondrial 
Proteins by Caloric Restriction: 
Possible Involvement in Caloric 
Restriction-Induced 
Cardioprotection. Trends 
Cardiovasc Med. 2013;23(1):25.  
46.  Dudkina N V., Kouřil R, Peters K, 
Braun H-P, Boekema EJ. Structure 
and function of mitochondrial 
supercomplexes. Biochim Biophys 
Acta - Bioenerg. 
2010;1797(6):664–70.  
47.  Beisvag V, Kemi OJ, Arbo I, 
Loennechen JP, Wisloff U, Langaas 
M, et al. Pathological and 
physiological hypertrophies are 
regulated by distinct gene 
programs. Eur J Cardiovasc Prev 
Rehabil. 2009 Dec;16(6):690–7.  
48.  Drozdov I, Didangelos A, Yin X, 
Zampetaki A, Abonnenc M, 
Murdoch C, et al. Gene network 
and proteomic analyses of cardiac 
responses to pathological and 
physiological stress. Circ 
Cardiovasc Genet. 2013 
Dec;6(6):588–97.  
49.  Riehle C, Wende AR, Zhu Y, 
6Hypertrophy induced KIF5B controls mitochondrial localization and function 
166 
Oliveira KJ, Pereira RO, Jaishy BP, 
et al. Insulin receptor substrates 
are essential for the bioenergetic 
and hypertrophic response of the 
heart to exercise training. Mol Cell 
Biol. 2014 Sep 15;34(18):3450–60.  
50.  Zhang Y, Yuan M, Bradley KM, 
Dong F, Anversa P, Ren J. Insulin-
like growth factor 1 alleviates high-
fat diet-induced myocardial 
contractile dysfunction: role of 
insulin signaling and mitochondrial 
function. Hypertension. 2012 
Mar;59(3):680–93.  
51.  Javadov S, Rajapurohitam V, Kilić 
A, Hunter JC, Zeidan A, Said Faruq 
N, et al. Expression of 
mitochondrial fusion–fission 
proteins during post-infarction 
remodeling: the effect of NHE-1 
inhibition. Basic Res Cardiol. 2011 
Jan 1;106(1):99–109. 
 52.  Hollander JM, Thapa D, Shepherd 
DL. Physiological and structural 
differences in spatially distinct 
subpopulations of cardiac 
mitochondria: influence of cardiac 
pathologies. Am J Physiol Heart 




















6Hypertrophy induced KIF5B controls mitochondrial localization and function 
166 
Oliveira KJ, Pereira RO, Jaishy BP, 
et al. Insulin receptor substrates 
are essential for the bioenergetic 
and hypertrophic response of the 
heart to exercise training. Mol Cell 
Biol. 2014 Sep 15;34(18):3450–60.  
50.  Zhang Y, Yuan M, Bradley KM, 
Dong F, Anversa P, Ren J. Insulin-
like growth factor 1 alleviates high-
fat diet-induced myocardial 
contractile dysfunction: role of 
insulin signaling and mitochondrial 
function. Hypertension. 2012 
Mar;59(3):680–93.  
51.  Javadov S, Rajapurohitam V, Kilić 
A, Hunter JC, Zeidan A, Said Faruq 
N, et al. Expression of 
mitochondrial fusion–fission 
proteins during post-infarction 
remodeling: the effect of NHE-1 
inhibition. Basic Res Cardiol. 2011 
Jan 1;106(1):99–109. 
 52.  Hollander JM, Thapa D, Shepherd 
DL. Physiological and structural 
differences in spatially distinct 
subpopulations of cardiac 
mitochondria: influence of cardiac 
pathologies. Am J Physiol Heart 






















D ATA  S U P P L E M E N T  
 
Supplemental Figure 1 
Mitochondrial respiration in intact NRVCs is increased after stimulation with PE. 
Total cellular OCR was measured using a Seahorse XF24 Extracellular Flux Analyzer, using 
pyruvate as a substrate. The ATP synthase inhibitor oligomycin, the uncoupling agent 
FCCP and mitochondrial respiration inhibitors antimycin A/rotenone (AR) were 
sequentially added as depicted in the graph (A). Mitochondrial specific OCR values were 
obtained by subtracting OCR values after addition of AR from total OCR resulting in 
mitochondrial respiration, maximal and ATP-linked OCR. Corrected oxygen consumption 
data of the first 3 measurements were averaged to yield the mitochondrial respiration. 
The ATP-linked OCR, defined as oligomycin-sensitive OCR, was calculated. Maximal 
respiration was induced by FCCP (N=7)(B). All graphs depict means and SD, *P < 0.05 as 
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Supplemental Figure 2 
No changes in mitochondrial fission/fusion gene and protein expression and 
subcellular distribution. 
NRVCs were stimulated with PE or IGF1 for 24 hr. mRNA expression levels of the fission 
and fusion markers drp1, mfn1, fis1 and opa1 were determined using qRT-PCR (N=5). 
Mitochondrial and cytoplasmic fraction of control and PE and IGF1 stimulated 
cardiomyocytes were isolated. Western blots with these lysates were probed with anti-
TOM20, a mitochondrial marker anti-actin, a cytoplasmic marker and with anti-Drp1 and 
anti-Mfn1, as indicated (B). Similar results were obtained in three independent 
experiments and representative Western blots of one experiment are shown.  
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Supplemental Figure 3 
Gene expression of Kif5b in a mouse model of physiological hypertrophy 
Kif5b expression in sedentary and voluntary wheel running mice (N=5-7). Graph depicts 
means and SD, *P < 0.05 as compared to control. 
 
 
Supplemental Figure 4 
Pathological gene expression after PE stimulation of KIF5B silenced NRVCs 
Control and Kif5b silenced NRVCs (72hr) were treated for 24 hours with PE. mRNA 
expression levels of the hypertrophic markers Nppb, Rcan1 and Acta1 were determined 
using qRT-PCR (N=3). 




Supplemental Figure 5 
Kif5b silencing in NRVCs affects mitochondrial respiration 
Kif5b was silenced in NRVCs for 72hr. Total cellular OCR, using glucose as a substrate, was 
measured with sequential additions of the ATP synthase inhibitor oligomycin, the 
uncoupling agent FCCP and mitochondrial respiration inhibitors antimycin A/rotenone 
(AR) as depicted in the graph (A). Mitochondrial specific OCR values; mitochondrial 
respiration, ATP-linked OCR and maximal respiration are shown. Corrected oxygen 
consumption data of the first 3 measurements were averaged to yield the mitochondrial 
respiration. The ATP-linked OCR, defined as oligomycin-sensitive OCR, was calculated. 
Maximal respiration was induced by FCCP (N=3)(B). All graphs depict means and SD, *P 
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consumption data of the first 3 measurements were averaged to yield the mitochondrial 
respiration. The ATP-linked OCR, defined as oligomycin-sensitive OCR, was calculated. 
Maximal respiration was induced by FCCP (N=3)(B). All graphs depict means and SD, *P 























































































Heart failure is a major problem in the Western world and despite significant 
progress in heart failure management, prognosis remains poor with high 
rehospitalization and mortality rates (1,2). Currently, therapy is aimed to relieve 
symptoms, by unloading the heart using diuretics and drugs targeting the neuro-
hormonal axis (1,2). Additional treatment options will be needed, including those 
that directly target the pathological processes in the heart, resulting in 
restoration of cardiac function. Mitochondria play a pivotal role in cardiac 
function and their structure, morphology and activity are altered during heart 
failure. These alterations are believed to generate additional cardiac stress and 
to induce a vicious cycle of further deterioration. The exact sequence of events, 
resulting in mitochondrial dysfunction in HF remains unclear. Targeting 
mitochondria and restoring their normal function could be essential for the 
proper treatment of heart failure. To allow this, detailed knowledge on the 
processes that control mitochondrial behavior and function will be necessary. 
Although basic mitochondrial processes are well understood, the underlying 
mechanisms controlling the activity and behavior of these interesting organelles, 
which are central to eukaryotic live, remains a daunting task. Modifying 
molecular regulatory circuitries that control mitochondria in a simplified 
cardiomyocyte model may provide a better understanding of mitochondrial 
regulation and reveal connections to cardiomyocyte hypertrophy. The overall 
aim of this thesis was to investigate mitochondrial function under stress 
conditions and to investigate the relation between cardiomyocyte hypertrophy 
and mitochondrial function. For this, rat primary neonatal cardiomyocytes were 
isolated and cultured in vitro, allowing mitochondrial respiration analysis in 
intact cells under various defined conditions. The data presented in this thesis 
expand the current knowledge of mitochondrial function, including new 
relations between several mitochondrial controlled processes in isolated 
cardiomyocytes and cardiac hypertrophy.  
A K I P 1  M O D U L AT E S  M I T O C H O N D R I A L  
R E S P I R AT I O N   
In a genome wide expression analysis of multiple cardiomyocyte 
hypertrophy and HF animal models, AKIP1 was identified as a differentially 
expressed gene in cardiomyocytes (3). Since AKIP1 was shown to encode a 
mitochondrial localized protein, we therefore decided to investigate the relation 
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between AKIP1 induced hypertrophic effects and potential mitochondrial and 
bioenergetics effects. In chapter 3, the effect of AKIP1 on mitochondrial function 
in isolated cardiomyocytes was described. Using a Seahorse flux analyzer the 
oxygen consumption rate (OCR) in cultured neonatal rat cardiomyocytes was 
investigated. It was shown that induction of hypertrophy by PE significantly 
stimulated the OCR. AKIP1 expression was also induced by PE and interestingly, 
AKIP1 overexpression alone was sufficient to stimulate OCR. Silencing of AKIP1 
could attenuate this PE induced increase in OCR, further corroborating the role 
of AKIP1 in PE induced OCR. This increase in OCR was independent of glycolytic 
flux and mitochondrial biogenesis was not enhanced in AKIP1 overexpressing 
cells. The increased respiration was not paralleled by an increase in 
mitochondrial ROS production. In contrast, less superoxide was observed in 
AKIP1 overexpressing cells and this was not a result of increased expression of 
scavenging systems, such as SOD2 and GPX4. These data suggest that the 
complexes of the ETC in AKIP1 overexpressing cells are working more efficient. 
This more efficient respiration machinery in AKIP1 overexpressing cells could be 
beneficial in cardiac stress conditions. Moreover, the decreased ROS production 
in AKIP1 overexpressing cells could be protective in pathological conditions with 
increased oxidative stress, like ischemia/reperfusion. Thus, in pathological 
conditions, AKIP1 expression may be protective to the heart. In agreement, using 
ex vivo experiments, AKIP1 was capable of protecting cardiomyocytes from 
ischemic injury by maintaining mitochondrial integrity (4). Recently, this was 
confirmed in vivo, using transgenic mice with cardiac specific overexpression of 
AKIP1. These AKIP1 transgenic mice displayed a significant two-fold reduction in 
myocardial infarct size and reduced cardiac apoptosis. Moreover, AKIP1 reduced 
myocardial I/R injury through stabilization of the MPT pore via a direct 
interaction with complex V (5). This suggest that AKIP1 could constitute a target 
in cardioprotection from I/R injury, by stabilizing mitochondrial function. 
Surprisingly, in vivo no effect was observed on cardiomyocyte hypertrophy upon 
overexpression of AKIP1. Thus under these conditions no direct coupling 
between hypertrophy and mitochondrial function was observed (5). It should be 
mentioned, though, that only pathological conditions were investigated in vivo. 
In vitro this link appeared to be dependent on AKT signaling, which is linked to 
physiological hypertrophy and therefore investigations of physiological stress 
conditions in AKIP-TG mice might reveal a role for AKIP1 in hypertrophy in vivo 
as well.  
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E XO G  A N D  R O S  M E D I AT E D  H Y P E R T R O P H Y  
In chapter 4 we described the role of another mitochondrial localized 
protein, termed EXOG, in mitochondrial function. EXOG is a nuclear encoded 
mitochondrial DNA/RNA exo/endonuclease, implicated in DNA repair 
mechanism (6,7). EXOG was associated with QRS duration in a GWAS study (8) 
and a loss of function study of EndoG, another homologous endonuclease in the 
mitochondria, resulted in cardiac hypertrophy in mice (9), which gained our 
interest in the function of EXOG in cardiomyocytes. In this chapter we showed 
that EXOG silencing resulted in cardiac hypertrophy, without affecting mtDNA 
damage. This hypertrophic effect was accompanied with increased 
mitochondrial respiration. Increased mitochondrial respiration can be 
accompanied with increased mitochondrial ROS production, and this also 
occurred in EXOG depleted cardiomyocytes, without affecting mitochondrial 
membrane potential. This increased ROS production could be efficiently 
scavenged by mitochondrial targeted antioxidants, including MitoTEMPO. 
Importantly, MitoTEMPO partially reversed hypertrophy in EXOG depleted cells 
without affecting the increase in mitochondrial respiration. This indicates that 
EXOG induced ROS production is at least partially responsible for the 
hypertrophic effect under these condition and that ROS scavenging in particular 
pathological conditions may prevent or delay cardiac hypertrophy. Scavenging 
ROS as a therapeutic agent against cardiac disease and many other diseases 
including ageing has, however, provided disappointing results. That simple 
cytoplasmic scavenging of ROS is not sufficient is increasingly acknowledged. Our 
results and those of others suggest that scavenging of mitochondrial ROS could 
be a more promising avenue. Mitochondrial ROS is damaging mitochondrial 
proteins and lipids and in particular oxidation of cardiolipin seems to have 
adverse effects and alters mitochondrial structure and function. Very 
encouraging results have been recently obtained with a mitochondrial targeted 
synthetic peptide SS-31 (also termed Bendavia, Elamipretide, MTP-131). This 
anti-oxidant peptide prevents amongst others the oxidation of cardiolipin by 
cytochrome C resulting in proper maintenance of mitochondrial structure, in 
particular the cristae, the main region of OXPHOS mediated respiration (10,11). 
SS-31 improved post-MI cardiac function, restored mitochondrial energy 
production and prevented infarct expansion and adverse LV remodeling in rats 
(12–14). In a mouse cardiac pressure overload (TAC) model treatment with SS-
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31and ameliorated cardiac hypertrophy, systolic failure, and myocardial fibrosis 
(15) .Recent studies with SS-31 in hypertensive swine with cardiac dysfunction 
and in a dog heart failure model restored both mitochondrial function and 
cardiac function, showing that its protective effects are not limited to small 
animals (16,17). Not surprisingly, several phase 2 clinical heart failure trials with 
SS-31 have been initiated, including IDDEA-HF, PROGRESS-HF and RESTORE-HF. 
Thus, protection from specific mitochondrial ROS and maintaining mitochondrial 
structure may provide a novel opportunity in heart failure treatment.  
The EXOG modulating effect on mitochondrial respiration and ROS 
production and the concomitant hypertrophy induction in cardiomyocytes let us 
to investigate the role of EXOG under pathological stress-like conditions. In 
chapter 5 we showed that EXOG depletion and concomitant stimulation of 
cardiomyocytes with phenylephrine, an adrenergic hypertrophy stimulating 
agent, reduced both maximal respiration and mitochondrial reserve capacity. 
Moreover, prolonged depletion of EXOG under these conditions decreased all 
mitochondrial respiration parameters. This finally culminated in cell death of 
EXOG depleted and PE stimulated cardiomyocytes. Despite the proposed role of 
EXOG in mitochondrial DNA repair mechanisms (7), we showed that cell death 
was not a consequence of increased mitochondrial DNA damage under these 
conditions. This damage repair function of EXOG has, however, only been 
reported for proliferative cells and has been implicated in mitochondrial DNA 
quality control and repair during DNA replication. This latter function may be less 
relevant for non-proliferating cardiomyocytes and our data might suggest that 
EXOG has functions beyond mitochondrial DNA repair. Although increased ROS 
production in these EXOG depleted cells, might have contributed to accelerated 
cells death it did not appear to be the main reason. Scavenging of ROS with Mito-
TEMPO could not prevent cell death. Since cleaved caspase 3, an apoptotic 
marker, was not increased in EXOG depleted cells and the caspase inhibitor, Z-
VAD, could not prevent cell death, other mechanisms, such as necrosis or 
necroptosis, are likely to be involved. Although exact cause or consequence is 
difficult to assess, the induced cell death was preceded by a decline in 
mitochondrial OCR reserve capacity. This reserve capacity is thought to be 
important to cope with situations of increased energy demands. At rest, the 
heart consumes up to 0.15 ml of oxygen/min per g of tissue, which increases 
several fold with vigorous exercise by using the mitochondrial reserve capacity 
(18). Interestingly, the diseased heart requires more oxygen to meet energy 
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needs, which has led to the hypothesis that a state of energy starvation may 
underlie myocardial pathology. In support of this concept, myocardial oxygen 
uptake is increased 2-fold in patients with left ventricular hypertrophy (19). In 
addition, there is also an increase in the myocardial uptake of oxygen in 
experimental hypertrophy, congestive heart failure and diabetes (20–22). It is 
reasonable to conclude, therefore, that bioenergetic dysfunction and the 
imbalance of oxygen supply against demand could be a basic defect in 
myocardial pathologies (23). The mechanisms underlying this increased demand 
for oxygen in the diseased heart are unknown. Here we showed that reduced 
energetic reserve capacity in EXOG depleted cells precedes cellular death. This 
suggests that this reserve capacity is of pivotal importance for cells to cope with 
increased stress induced by pathological conditions. 
 
PAT H O L O G I C A L  S T R E S S  I N D U C E D  K I F 5 B  
To further elucidate the role of mitochondrial respiration under 
hypertrophic conditions we showed in chapter 6 that induction of hypertrophy 
in cardiomyocytes with two different stimuli, namely phenylephrine (PE) and 
Insulin-like growth factor 1 (IGF1), resulted in different metabolic and 
mitochondrial changes. Interestingly, IGF1 did not stimulate OCR, despite 
induction of hypertrophy, indicating that increased OCR is not a prerequisite for 
hypertrophy development. Moreover, increase in mitochondrial respiration in 
intact cells, as in the case after PE stimulation is not per se mediated by increases 
in the respiratory capacity of the ETC complexes as was determined using 
isolated mitochondria. Our results also revealed that different hypertrophic 
stimuli had different effects on mitochondrial respiration, indicating that 
environmental factors play a major role in controlling respiratory capacity. To 
investigate the underlying pathways we analyzed changes in mitochondrial 
biogenesis and levels of OXPHOS proteins, but did not detect any changes. 
Subsequent gene expression profiles of cardiomyocytes confirmed this. More in 
depth analysis revealed, however, that PE specifically up regulated KIF5B gene 
expression, a gene encoding a motor protein of the kinesin family, that had been 
reported to control mitochondrial localization. We also confirmed Kif5B protein 
up regulation under this condition and, moreover, in PE treated cardiomyocytes 
mitochondrial localization was altered with a more peripheral localization. 
Silencing of KIF5B prevented this peripheral localization and interestingly 
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attenuated PE induced mitochondrial respiration and hypertrophy. This distinct 
pattern of mitochondrial distribution suggests a relevant functional consequence 
of mitochondrial localization in cardiomyocytes. Importantly, we could also show 
that Kif5B was up regulated in vivo in pathological cardiac hypertrophy animal 
models, indicating that this effect is not limited to the in vitro situation. How 
Kif5B contributes to mitochondrial respiration is not clear, but it has been 
suggested that Kif5B is essential for the localization of mitochondria in the close 
proximity of the endoplasmatic reticulum and required for ER-mitochondrial 
junctions (24). In the heart the close vicinity of mitochondria to the sarcoplasmic 
reticulum is essential for excitation induced contraction and for preventing Ca2+ 
overload. Localization changes could therefore have profound effect on 
respiration, but also on other cardiomyocyte functions. It is also interesting to 
note that Kif5b interacts with the adaptor protein Milton, which on its turn can 
interact with the outer mitochondrial membrane protein Miro. Miro is a Ca2+ 
binding protein and upon high Ca2+ levels Kif5B is released from the Milton–Miro 
complex and instead binds to syntaphilin (SNPH). SNPH inhibits the ATPase 
activity of kinesin, and immobilizes the mitochondria (25). Mitochondrial motility 
is also essential for renewal of stationary mitochondria and appears to be part of 
a quality control system which involves mitochondrial fusion and fission(26). 
Moreover, the Milton/Miro complex not only interacts with Kif5B, but also with 
the mitofusin Mnf2 (27). Thus, regulation of mitochondrial function by Kif5b 
might not be limited to localization, but also other dynamic processes like 
fission/fusion and quality control of mitochondria. These processes are currently 
believed to play important roles under pathological conditions. Interestingly, 
these dynamic processes have been recently targeted in vitro by cell permeable 
peptides, resulting in correction of mitochondrial pathology triggered by 
defective or imbalanced mitochondrial dynamics (28). Maybe these studies will 
finally result in targeting of the dynamic processes that control mitochondrial 
function.  
 
C O N C L U S I O N  A N D  P E R S P E C T I V E S  
In conclusion, we have shown here that mitochondria are highly dynamic 
organelles in neonatal cardiomyocytes and under pathological stress conditions 
mitochondrial localization, ROS production and oxygen consumption can change 
in cardiomyocytes. These changes are highly interdependent and will also affect 
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mitochondrial structure and other dynamics and probably generate a vicious 
cycle of further deterioration. Moreover we have shown that modulation of 
mitochondrial function may induce hypertrophy by different mechanisms. 
Whereas AKIP1 induced hypertrophy was independent of ROS formation, EXOG 
mediated modulation of mitochondrial function induced hypertrophy in a ROS 
dependent manner. This indicates that an imbalance of mitochondrial function 
can stimulate hypertrophy, but that the mechanism is context dependent. In this 
respect it is interesting to note that AKIP1, ROS-independent, hypertrophy, 
appears to be a physiological like hypertrophy, whereas EXOG modulation 
generated a pathological-like hypertrophy. The latter can be attenuated by an 
exogenous provided mitochondrial ROS scavenger, but this did not prevent cell 
death. This, also suggests that mitochondrial ROS scavenging may be beneficial 
under certain conditions, but in isolation it will probably not be sufficient to halt 
further progression. Our studies also showed that mitochondrial localization is 
an important factor. Changes in the Kif5b motor protein can result in altered 
mitochondrial localization, probably affecting its interaction with the SR and 
maybe also affecting mitochondrial dynamics (fission-fusion) and mitochondrial 
quality control. It will be important to investigate this in more detail in adult 
cardiomyocytes in which mitochondrial structure, motility and dynamics are 
restricted by sarcomeric structures.  
All together these results indicate that mitochondrial changes can induce 
cardiomyocyte hypertrophy by different mechanisms. It is therefore unlikely that 
a single mitochondrial target can be defined in the complex heart failure 
syndrome. Depending on etiology and exact mitochondrial changes involved, a 
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S U M M A R Y   
Heart failure is a major cause of morbidity and mortality in industrialized 
counties and with the increasing age of the general population the incidence of 
heart failure will increase. Heart failure is described as a complex clinical 
syndrome that results from structural and functional cardiac changes impairing 
the pump capacity of the heart. These structural and functional changes of the 
heart are termed cardiac remodeling. Cardiomyocyte growth (cardiac 
hypertrophy) is one of the main remodeling processes and is induced by both 
biomechanical stress and neurohumoral activation. Cardiomyocyte hypertrophy 
is initially adaptive in cardiomyocytes to compensate for sustained wall stress, 
but can become maladaptive during sustained pathological stress. This adaptive 
response to stress conditions is essential, but the molecular mechanisms that 
determine hypertrophy development and the progression into pathological 
hypertrophy are still poorly understood.  
This thesis describes the relation between cardiac hypertrophy and 
mitochondrial function. Mitochondria are the energy producing organelles of the 
cell and during the transition of cardiac hypertrophy to heart failure their 
function is altered rendering the heart as an engine out of fuel. Metabolic 
changes have been recognized as a mechanism in the development and 
progression of heart failure (7). Besides their well-known classical function as 
energy suppliers mitochondria gain more and more interest as target in heart 
failure based on several other functions in cardiomyocytes, such as their role in 
cell death and oxidative stress which are all essential processes in the 
development of heart failure. Besides energetic changes in hypertrophy 
development, there is strong evidence that modulation of their shape is 
implicated in cardiomyocyte function. Mitochondria are not static organelles but 
render multiple mechanism resulting in dynamic structures. Also the cellular 
localization and distribution is highly dependent on cellular state and 
environment. These dynamic features of mitochondria play a fundamental role 
in homeostasis of the heart, associated with cardiomyocyte energetics and 
mitochondrial function (7). Although the functions of mitochondria are pivotal, 
their role, the alterations and the sequential events in cardiac hypertrophy are 
still unclear. The goal of this thesis was to further elucidate these roles of 
mitochondrial function under different conditions. To explore this cultured 
primary neonatal rat cardiomyocytes were used. By modulation of specific genes 
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or by pharmacological treatments the effects on mitochondrial activity and 
cardiomyocyte hypertrophy were investigated. 
In chapter 2, we reviewed the different mitochondrial alterations in 
response to cardiomyocyte stress and the relation to hypertrophy and heart 
failure development. We described several aspects of dynamic mitochondrial 
behavior and alterations that are implicated in cardiac hypertrophy and heart 
failure. 
Since mitochondria have multiple functions and these are complex and 
dependent on the cellular environment we used an in vitro system of neonatal 
cardiomyocytes to specifically control the experimental conditions and measure 
mitochondrial function in intact cells. In chapter 3 and 4, cardiomyocyte 
hypertrophy was induced by modulating the genes AKIP1 and EXOG by 
overexpressing and silencing constructs respectively. A kinase interacting protein 
1 (AKIP1) was one of the most significantly upregulated differentially expressed 
genes in animal heart failure models (1) and was able to stimulate hypertrophy 
via the Akt survival pathway(2). AKIP1 was also shown to localize to mitochondria 
and to protect the heart against ischemia/reperfusion injury and hence appears 
to have a stress modulating function in cardiomyocytes (3). From a genome-wide 
association studies (GWAS) analysis on QRS amplitude several loci were 
identified from which we selected EndonucleaseG-like-1 (EXOG) for further 
translational investigation (4,5). EXOG is a nuclear encoded exo/endonuclease 
and is implicated in mitochondrial DNA repair. Moreover, another mitochondrial 
endonuclease with high sequence similarity with EXOG, EndonucleaseG (EndoG) 
was implicated with cardiac hypertrophy (6). In here we investigated the role of 
AKIP1 and EXOG in hypertrophy development, in relation with purported 
mitochondrial functions.  
In chapter 3 we showed that AKIP1 increased mitochondrial respiration 
without affecting mitochondrial biogenesis and OXPHOS protein levels. AKIP1 
also reduced reactive species (ROS) production. This suggest that AKIP1 induced 
hypertrophy might be related to more efficient electron transport and hence ATP 
production. AKIP1 might therefore have protective functions in cardiomyocytes. 
In chapter 4, we showed that reduced expression of EXOG induced cardiac 
hypertrophy and mitochondrial respiration, concomitant with an increase in ROS 
production. Importantly, scavenging ROS did not affect mitochondrial 
respiration, but partially reduced cellular hypertrophy. This shows the complex 
relation between hypertrophy and mitochondrial respiration and provides 
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further support for the potential therapeutic opportunities of mitochondrial ROS 
scavenging. To further elucidate the role of EXOG in mitochondrial function, in 
particular under stress conditions we stimulated neonatal cardiomyocytes with 
phenylephrine (PE), a well-known hypertrophic inducer that acts via the 
adrenergic pathway. In chapter 5 we showed a reduced mitochondrial reserve 
capacity in EXOG depleted cells under pathological conditions, which in the long 
term resulted in cellular death. This EXOG induced cellular death could not be 
reversed by pharmalogical inhibition (caspase inhibition and ROS scavenging), 
indicating that prolonged EXOG depletion in pathological stress is inducing 
necrosis as cellular death mechanism. Although the exact role of the 
mitochondrial reserve capacity is not clear, this shows that the maintenance of 
mitochondrial reserve capacity is essential in cellular stress conditions. 
To further explore the role of mitochondrial function in different stress 
conditions we induced cardiac hypertrophy by two different pharmacological 
stimuli, phenylephrine (PE) and insulin-like growth factor (IGF1). In chapter 6 we 
showed that this resulted in different mitochondrial responses. Although both 
stimuli induced cardiac hypertrophy, we show that the effects on mitochondrial 
function are distinct. These differences are related to alterations in 
mitochondrial localization in the neonatal cardiomyocytes This shows that 
mitochondrial localization and distribution in cardiomyocytes is relevant to 
mitochondrial function. In addition, we showed that PE is inducing the 
expression of a motor protein, KIF5B, which controls mitochondrial transport in 
the cell. By silencing the expression of this protein, we could show that 
alterations in mitochondrial respiration and localization could be partially 
reversed. This indicates a direct relation between mitochondrial localization and 
mitochondrial function in neonatal cardiomyocytes. 
Finally in chapter 7 we discuss the findings of mitochondrial function in 
relation to cellular hypertrophy in our in vitro system of neonatal cardiomyocytes 
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N E D E R L A N D S E  S A M E N VAT T I N G  
Hartfalen is een belangrijke oorzaak van ziekte en sterfte in de westerse landen, 
en met een toenemende leeftijdsverwachting van de populatie zal het 
voorkomen van hart falen alleen maar toenemen. Hartfalen wordt gekenmerkt 
als een complex syndroom resulterend uit structurele en functionele 
veranderingen die leiden tot een verminderde pomp functie van het hart. Deze 
veranderingen worden remodeling van het hart genoemd. De groei van de 
hartspiercellen (hypertrofie) is een van de belangrijkste processen in de 
remodeling en wordt geïnduceerd door zowel biomechanische stress als 
neurohumorale activatie. Hypertrofie van de hartspiercellen is initieel een 
adaptieve respons, om te compenseren voor de toegenomen druk op de 
hartspier maar gedurende langere pathologische stress zorgt deze respons voor 
het disfunctioneren van het hart. Deze adaptieve respons is essentieel maar de 
moleculaire mechanismen die de ontwikkeling van de hypertrofie en de 
progressie in pathologische responsen bepalen zijn nog niet volledig bekend. 
 
In dit proefschrift wordt de relatie tussen hypertrofie en mitochondriële functie 
beschreven. Mitochondria zijn de energie producerende organellen van het hart 
en gedurende de overgangsfase van hypertrofie naar hart falen is de functie 
hiervan veranderd. Dit leidt tot een verminderde energie productie in het 
falende hart. Metabole veranderingen worden erkend als een mechanisme in de 
ontwikkeling en progressie van hart falen. Naast de wel bekende rol in de energie 
productie krijgen mitochondria steeds meer aandacht als mogelijk target in het 
onderzoek naar hartfalen, gebaseerd op andere functies in de hartspiercellen, 
zoals de betrokkenheid bij celdood en oxidatieve stress welke beide essentiële 
processen zijn in het ontwikkelen van hartfalen. Naast de energetische 
veranderingen tijdens de ontwikkeling van hypertrofie zijn er aanwijzingen die 
erop wijzen dat veranderingen in de vorm van deze organellen ook betrokken 
zijn in de functie van de cardiomyocyten. Hoewel lang is gedacht dat 
mitochondria statische organellen zijn heeft recent onderzoek aangetoond dat 
er meerdere mechanismen zijn die zorgen voor een veel meer dynamische 
structuren. Ook de cellulaire lokalisatie en verdeling is afhankelijk van 
omgevingsfactoren, waaronder de hoedanigheid van de cel en de omgeving 
hiervan. Deze dynamische eigenschappen van de mitochondria spelen een 
fundamentele rol in de homeostase van het hart, wat weer geassocieerd is met 
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de energetische huishouding van de hartspiercellen en de functie van de 
mitochondria. Hoewel de functie van mitochondria dus essentieel is zijn de 
veranderingen die plaatsvinden en de opvolgende processen tijdens het 
ontstaan en de ontwikkeling van hartfalen nog grotendeels onbekend. Het doel 
van dit proefschrift was om de rol en het functioneren van de mitochondria 
onder verschillende experimentele condities die hartfalen imiteren te 
onderzoeken. Hiervoor hebben we primaire neonatale cardiomyocyten gebruikt. 
Door specifieke genen in deze cellen te moduleren of door farmacologische 
behandelingen konden de effecten op zowel mitochondriale activiteit en functie 
als op hypertrofie onderzocht worden. 
 
In hoofdstuk 2 bespreken we verschillende mitochondriële veranderingen die 
plaatsvinden als reactie op stress in de cardiomyocyten en de relatie van deze 
veranderingen op hypertrofie en de ontwikkeling van hartfalen. 
Omdat mitochondria meerdere functies hebben in de hartspiercellen en deze 
complex en afhankelijk zijn van de cellulaire omgeving hebben we een in vitro 
systeem met neonatale cardiomyocyten gebruikt om de omgevingsfactoren en 
de experimentele condities te kunnen reguleren. Ook was het hiermee mogelijk 
de mitochondriële functie in complete cellen te onderzoeken, in tegenstelling tot 
het onderzoek wat gebruik maakt van geïsoleerde mitochondria. In hoofdstuk 3 
en 4 hebben we hypertrofie geïnduceerd door de genen AKIP1 en EXOG 
verhoogd dan wel verlaagd tot expressie te brengen. A kinase interacting protein 
1 (AKIP1) was een van de genen die significant verhoogd tot expressie kwam in 
diermodellen van hartfalen. Daarnaast hebben we laten zien in eerder 
onderzoek dat AKIP1 via de Akt pathway hypertrofie kon induceren in neonatale 
cardiomyocyten. AKIP1 is een mitochondrieel gelokaliseerd eiwit welke het hart 
beschermd tegen ischemie/reperfusie schade waaruit geconcludeerd kan 
worden dat dit eiwit een stress modulerende functie heeft in hartspiercellen. 
EndonucleaseG-like-1 (EXOG) is geselecteerd uit een genome-wide association 
studies (GWAS) naar QRS complex veranderingen voor verder translationeel 
onderzoek. EXOG is een nucleair gecodeerde exo/endonuclease die betrokken is 
bij mitochondriële DNA reparatie. Daarnaast is een andere mitochondriële 
endonuclease beschreven die op DNA sequentie niveau een hoge overeenkomst 
heeft met EXOG. Dit eiwit, EndonucleaseG (EndoG), is betrokken bij hypertrofie 
van het hart. In dit proefschrift hebben we de rol van AKIP1 en EXOG onderzocht 
met betrekking om de ontwikkeling van hypertrofie en in relatie tot 
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veranderingen in mitochondriële functie. 
In hoofdstuk 3 laten we zien dat AKIP1 zorgt voor een toegenomen 
mitochondriële respiratie zonder dat de mitochondriële biogenese en de 
hoeveelheid OXPHOS eiwitten veranderd zijn. AKIP1 verminderde ook de 
reactieve zuurstof radicalen (ROS) productie. Dit suggereert dat de hypertrofie 
die geïnduceerd wordt door AKIP1 gerelateerd is aan een meer efficiënter 
elektronen transport proces en dus ATP productie. Verder onderzoek moet 
uitwijzen of deze eigenschappen zorgen voor een beschermende werking van 
AKIP1 in hartspiercellen. In hoofdstuk 4 laten we zien dat een verminderde 
expressie van EXOG zorgt voor hypertrofie in hartspiercellen en een verhoging 
van de mitochondriële respiratie die samen gaat met een verwachte verhoging 
in de ROS productie. Het wegvangen van de ROS zorgde niet voor een 
verandering in de mitochondriële respiratie maar verminderde wel gedeeltelijk 
de cellulaire hypertrofie. Dit laat zien hoe complex de relatie tussen hypertrofie 
en mitochondriële respiratie is en onderstreept de potentiele therapeutische 
mogelijkheden van ROS scavengers. Om de rol van EXOG in het functioneren van 
de mitochondria onder stress condities verder te onderzoeken hebben we de 
cardiomyocyten gestimuleerd met fenylefrine (PE). Dit is een bekende adrenerge 
activator van cellulaire hypertrofie. In hoofdstuk 5 laten we zien dat in EXOG 
gedepleteerde cellen onder stress condities een verlaging in mitochondriële 
reserve capaciteit optreedt, en dat langere blootstelling aan deze condities 
zorgde voor celdood. Deze door EXOG geïnduceerde celdood kon niet 
voorkomen worden door farmacologische interventies, zowel caspase inhibitie 
als ROS scavenging. Dit impliceert dat langere depletie van EXOG onder 
pathologische stress condities resulteert in cellulaire dood door middel van 
necrose. Hoewel de exacte rol van de mitochondriële reserve capaciteit niet 
duidelijk is laat dit onderzoek wel zien dat het behouden hiervan essentieel is 
onder cellulaire stress condities. 
Om de functionele rol van de mitochondria in verschillende stress condities 
verder te onderzoeken hebben we hypertrofie geïnduceerd door middel van 
twee verschillende farmacologische stoffen, fenylefrine (PE) en insulin-like 
growth factor (IGF1). In hoofdstuk 6 laten we zien dat deze stimulaties resulteren 
in verschillende mitochondriële responses. Hoewel beide stimuli resulteren in 
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van een goede lokalisatie en verdeling van de mitochondria in de neonatale 
cardiomyocyten en dat deze relevant is voor het functioneren van de 
mitochondria. Daarnaast laten we zien dat PE de expressie van een motor eiwit, 
KIF5B, induceert. Dit eiwit zorgt voor het mitochondriële transport in de cellen. 
Door de expressie van dit eiwit te verlagen konden we laten zien dat de 
veranderingen in de mitochondriële respiratie en lokalisatie gedeeltelijk 
teruggedraaid konden worden. Dit impliceert een directe relatie tussen 
mitochondriële lokalisatie en mitochondriële functie in neonatale 
cardiomyocyten. 
Ten slotte bediscussiëren we in hoofstuk 7 de bevindingen. We beschrijven 
hierin de mitochondriële functie in relatie tot cellulaire hypertrofie in ons in vitro 
systeem van neonatale cardiomyocyten en relateren deze bevindingen aan 
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het ontwerpen van de cover. Ik ben er heel erg blij mee, dit maakt het helemaal 
af! Lieve Carel, mijn maatje. Zonder jou had ik hier niet gestaan vandaag. Door 
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Lief broertje en zusje, wat ben ik trots op jullie. Ieder ons eigen leven op onze 
eigen manier. Ik hoop dat we, samen met Suus en Luiz, nog van vele maaltijden 
en momenten in Marsum mogen genieten met elkaar. En de allermooiste en 
liefste Nomi, bijna 3 maar jou eigenwijsheid telt voor 10. Leg de blokjes maar 
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Lieve mama en pa, bedankt voor jullie onvoorwaardelijke liefde en alle 
mogelijkheden die jullie mij hebben geboden. Ik mocht altijd mijn eigen weg 
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